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1Introduction
1.1 Motivation
In general, the synchronized contraction of the heart supplying the en-
tire body with blood results from underlying processes of cardiac electro-
physiology. Two pathologies investigated in this thesis, i.e. atrial ﬁbrillation
(AF) and acute cardiac ischemia, impair the functionality of the heart. AF is
the most common arrhythmia causing uncoordinated activation of the atria
with high beating frequencies. This atrial rhythm disorder slowly progresses
over time, i.e. AF ﬁnally becomes chronic. Due to this, the risk for throm-
boembolism is signiﬁcantly increased leading e.g. to strokes. In case of acute
cardiac ischemia, the blood supply of the myocardium is reduced. Therefore,
it is the most common cause of death in western industrialized countries. The
effects of ischemia exacerbate over a short period in the range of few hours
often leading to ventricular arrhythmias or lethal pump failure. Therefore, an
early diagnosis and effective treatment of both pathologies is essential.
However, the complex underlying mechanisms responsible for the initiation,
maintenance and also the termination of AF are not completely understood.
Furthermore, the diagnosis of acute cardiac ischemia is based on shifts of
the ST segment in the body surface electrocardiogram (ECG). The origin
of these shifts, which can not be observed in more than one fourth of the
patients with acute cardiac ischemia [1], has also not been investigated in
its entirety yet. The impact of pharmacological therapy on human cardiac
electrophysiology in general and additionally on the initiation or termination
of arrhythmias is in the focus of current research as well.
These effects of pharmacological agents and atrial and ventricular rhythm
disorders on cardiac electrophysiology can hardly be measured in human
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hearts, especially non-invasively. Therefore, reproducible in silico multiscale
simulations ranging from the ion channel level up to the body surface ECG
allow for testing a multitude of hypotheses without affecting the health of
the patients. Different electrophysiological effects can be integrated into the
models at the ion channel or single-cell level based on experimental data.
Then, the complex anti- or proarrhythmic mechanisms can be investigated
in detail at different simulation scales using quantitative measures.
In this way, the understanding of cardiac arrhythmias and the early diagnosis
of these pathologies can be improved. Furthermore, also the development of
pharmacological agents can be supported by the ﬁndings of these simula-
tions reducing the risk and costs of clinical trials. In the future, these mul-
tiscale simulations might enable patient-speciﬁc therapy with tailored phar-
macological agents for e.g. patients with mutations of ion channels causing
AF.
1.2 Focus of the Thesis
Several aspects at different levels of multiscale simulations ranging from the
ion channel up to the torso are in the focus of this thesis.
At the ion channel level:
• Implementation of a framework for the parameter adaptation of models of
cardiac ion channels to voltage or patch clamp measurement data based on
a combination of derivative-free and a trust-region-reﬂective optimization
algorithm
• Integration of voltage and patch clamp measurement data of wild type
(WT) and mutated channels known to be associated with AF into models
of IKr and IKur
At the single-cell level:
• Adaptation of models of human atrial electrophysiology to effects of
chronic AF (cAF)
• Modiﬁcation of a model of human ventricular electrophysiology to effects
of acute cardiac ischemia
• Integration of inﬂuence of three pharmacological agents on the control
and pathologic models of atrial and ventricular electrophysiology and in-
vestigation of the resulting changes of cardiac action potentials
1.3. STRUCTURE OF THE THESIS 3
At the tissue level:
• Investigation of the restitution properties of cardiac excitation propagation
of the different modiﬁed models in 1D tissue strands
• Analysis of initiation and termination of reentrant circuits simulated in a
2D tissue patch using the different atrial models
At the organ level:
• Studying the inﬂuence of acute cardiac ischemia or pharmacological treat-
ment on excitation propagation simulated in a 3D ventricular model.
At the torso level:
• Investigation of changes of the body surface ECGs due to the effects of
acute cardiac ischemia or pharmacological therapy
1.3 Structure of the Thesis
Part I outlines medical and technical background information:
• Chapter 2 gives a brief introduction to cardiac anatomy, electrophysiology
and related measurement techniques. Furthermore, the pathological changes
due to AF and acute cardiac ischemia are introduced. Then, the impact of
pharmacological therapy on cardiac electrophysiology is delineated.
• Chapter 3 describes the electrophysiological models of human cardiac
myocytes used in this thesis and previous modiﬁcations of these models.
Furthermore, mathematical descriptions of cardiac excitation propagation
and the forward calculation of body surface potentials are outlined.
Part II presents the utilized methods:
• Chapter 4 describes the parameter adaptation framework including dif-
ferent optimization algorithms. Parts of this work were created during
the supervised bachelor thesis of Niko Konrad [2], the diploma thesis of
Jochen Schmid [3] and the master thesis of Axel Loewe [4].
• Chapter 5 presents ﬁve models of human atrial electrophysiology used
for the simulation of AF and the different investigations to assess the
arrhythmic potency of the models. Parts of this work were created in
the course of the supervised bachelor thesis of Hanne Hettmann [5] and
Vanessa Lupici-Baltzer [6].
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• Chapter 6 introduces the modiﬁcations of the ventricular model to de-
scribe different stages of acute cardiac ischemia and the creation of
heterogeneous ischemic tissue. The supervised bachelor thesis of Axel
Loewe [7] and the student research project of Franziska Grimm [8] partly
contributed to this work.
• Chapter 7 describes the changes of the atrial and ventricular models to
simulate the effects of three pharmacological agents. Furthermore, meth-
ods for the assessment of the arrhythmic potency of the compounds are
shown. Parts of this work were created during the supervised student re-
search project of Stefan Ponto [9] and Lukas Holl [10].
Part III
• Chapter 8 presents the results of the parameter adaption using different
optimization algorithms. Parts of these results were shown at a scientiﬁc
conference [11] and are submitted to a scientiﬁc journal [12].
• Chapter 9 shows the benchmark of different models of human atrial
electrophysiology, especially regarding their ability to reproduce the ef-
fects of cAF, which was published in parts in a scientiﬁc journal [13].
Furthermore, the impact of ion channel mutations on the initiation of AF
was investigated.
• Chapter 10 provides the results of simulating the impact of different
stages of acute cardiac ischemia, which was presented in parts on sci-
entiﬁc conferences [14–16] and in a scientiﬁc journal [17].
• Chapter 11 presents the results of simulations of the effects of three phar-
macological agents on atrial and ventricular electrophysiology. Parts of
this work were published in a scientiﬁc journal [18].
Chapter 12 summarizes the main ﬁndings presented in this thesis and gives
an outlook on future work in this ﬁeld.
Part I
Fundamentals

2Medical Background
This chapter presents the basic medical background information useful for
the understanding of the following technical chapters. A brief introduction
to cardiac anatomy, electrophysiology and measurement techniques of the
electrical activity of the heart is given. Then, pathological changes due to
AF and acute cardiac ischemia are described. Finally, the impact of phar-
macological therapy on cardiac electrophysiology is outlined. Furthermore,
additional literature on these topics is referenced in the corresponding sec-
tions.
2.1 Cardiac Anatomy
The human heart, which has about the size of a closed ﬁst, is the most impor-
tant part of the circulatory system. It is responsible for pumping oxygen-rich
and deoxygenated blood to supply all organs with nutrients and O2, as well
as to remove CO2 and waste products, respectively. For this purpose, the
heart (compare Fig. 2.1) is divided into two halves, which are separated by
the septum. The left atrium receives the oxygen-rich blood from the lungs
through the pulmonary veins and ﬁlls the left ventricle, which in turn pumps
the blood through the aorta into the systemic circulation. The blood ﬂow is
regulated by the mitral valve between the left atrium and ventricle and the
aortic valve between the left ventricle and the aorta. The left ventricular wall
is much thicker than the right ventricular wall due to the higher pressure in
the systemic circulation compared to the pulmonary circulation. The right
atrium receives the deoxygenated blood through the superior and inferior
vena cava and ﬁlls the right ventricle, which pumps the blood through the
pulmonary artery to the lungs. The blood ﬂow between the right atrium and
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Figure 2.1. Schematic drawings of the anatomy of the human heart presenting the coronary ar-
teries (A) and the interior (B).
ventricle is regulated by the tricuspid valve and between the right ventricle
and the pulmonary artery by the pulmonary valve [19].
The heart itself is also supplied with oxygen and nutrients by the coronary
arteries. In Fig. 2.1A, the main coronary arteries descending directly from
the aorta are shown. The left coronary artery, which passes the left atrial ap-
pendage, branches into the left anterior descending (LAD) artery and the left
circumflex (LCx) artery. The anterior part of both ventricles including the in-
terventricular septum is supplied by the LAD, whereas the LCx provides the
left atrium and ventricle with oxygen-rich blood. The right coronary artery
(RCA) passes the right atrial appendage and supplies the right atrium and
ventricle, as well as the posterior part of both ventricles including the inter-
ventricular septum [20].
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Cardiac myocytes, which present a roughly cylindrical shape, are arranged
as ﬁbers in the atrial and ventricular walls. Partly due to this ﬁber orientation,
the conduction velocity (CV) of cardiac excitation propagation is anisotropic
being faster in direction of the ﬁber than in transverse direction [21]. In the
ventricles, the ﬁber orientation can be described by the helix angle α1, which
deﬁnes the inclination of the ﬁbers from apex to base, and the transverse
angle α3, which quantiﬁes the imbrication of the ﬁbers between the endo-
cardium and epicardium. According to Streeter [22], α1 increases almost
linearly from −75◦ at the epicardium to +55◦ across the ventricular wall.
Furthermore, α3 slightly varies from −3◦ at the apex to +3◦ at the base. A
detailed description of the ventricular ﬁber orientation is given in [23].
2.2 General Cardiac Electrophysiology
This section summarizes the electrophysiological basics including the initi-
ation of electrical activity of single cardiac myocytes and the propagation of
cardiac excitation waves. Furthermore, the techniques measuring the electri-
cal activity at the ion channel or single-cell level and at the body surface are
outlined.
2.2.1 Electrophysiological Basics
The intracellular space of cardiac myocytes is separated from the extra-
cellular space by a phospholipid bilayer, the cell membrane. As a conse-
quence, different ion concentrations in the intra- and extracellular spaces can
be maintained. This imbalance causes the transmembrane voltage (TMV),
which is the difference between intra- and extracellular potential. Further-
more, the membrane contains embedded proteins, which serve as selectively
permeable pathways for ions and other substances, for which the mem-
brane is impermeable otherwise. These channels consist of cylindrical pore-
forming α-subunits, which determine the diameter and selectivity of the
channel. In addition, some ion channels have auxiliary subunits, called β ,
γ , etc., which can modify the function of the channel. Cardiac ion channels
can switch between different states modifying their conductivity by changes
in the conformation of the proteins, which is called gating. The channels can
either be in a closed state blocking all currents or in an open state allowing
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Figure 2.2. Phases of cardiac action potential (A) and the underlying transmembrane currents
(B). Modiﬁed based on [26].
the passage of speciﬁc ions. Additionally, some channels exhibit a noncon-
ducting inactivated state, which is entered after the activation. Most cardiac
ion channels are voltage-gated, i.e. they change their state depending on the
transmembrane voltage. The binding of speciﬁc substances to receptors gov-
erns the gating in case of ligand-gated ion channels. An overview of cardiac
ion channels and the gating processes is given in [24]. In addition to ion
channels, which allow passive ion transport along an electrochemical gra-
dient, exchangers and ion pumps permit active transport against an electro-
chemical gradient. Energy is used for this process, e.g. by dephosphorylation
of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) [25].
Due to the imbalance between the intra- and extracellular ion concentrations
in the resting state, the ions move passively from regions with higher con-
centration to lower concentration. Since the ions are charged particles, the
electrical gradient increases with decreasing gradient. If both forces balance
each other, the equilibrium Nernst voltage can be determined for the ion type
X :
Ex =−RTzxF ln
(
[X ]i
[X ]o
)
, (2.1)
with the gas constant R, the temperature T , the valence of the ion zx, Fara-
day’s constant F and the intra- and extracellular concentrations [X ]i and [X ]o,
respectively. In the resting state, mainly potassium channels are conductive
(compare Fig. 2.2B) causing an outward current, so that the transmembrane
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voltage Vm is close to the potassium Nernst voltage. If an external stimu-
lus depolarizes the membrane above a threshold voltage, an action potential
(AP) is initiated and a fast sodium inward current further depolarizes the
membrane. As a consequence, a rapid upstroke of the transmembrane volt-
age with an overshoot to positive values can be observed (Fig. 2.2A, phase
0). The sodium channels quickly inactivate and remain in this state until
the transmembrane voltage falls below another threshold value. The inter-
val, during which no further AP can be propagated to neighboring cells, is
called effective refractory period (ERP). Inactive sodium channels prevent
the initiation of further APs in this case. Conductive potassium channels
and a decrease of the sodium channel conductivity cause a slight repolariza-
tion (phase 1). In the meantime, the potassium conductivity is reduced and
calcium channels open. The resulting calcium inﬂow triggers an additional
calcium release from the sarcoplasmic reticulum (SR), which is a special in-
tracellular calcium storage. This leads to the plateau phase of the AP (phase
2). The slow calcium channels inactivate and the potassium conductivity in-
creases again, so that the membrane is repolarized (phase 3). Finally, the
resting membrane voltage is reached (phase 4) and the imbalance of ion
concentrations is restored by exchangers and ion pumps, as e.g. the sodium
calcium exchanger (NCX), or the sodium potassium ATPase (NKA) [25].
The interval between the upstrokes of two consecutive APs is called basic
cycle length (BCL). The time between the end of a previous AP and the
upstroke of the following AP, which is called diastolic interval (DI), is cal-
culated as the difference between the BCL and the action potential duration
(APD).
Adjacent cardiac myocytes are connected to each other by a different type
of integral membrane proteins, so-called gap junctions. Connexons, which
consist of six connexins, form tubular structures between the intra- and ex-
tracellular space. The connexons of adjacent cells face each other bridging
the gap between them, so that the intracellular spaces of the myocytes are
connected. Different types of connexins with varying size of the tubes exist.
Therefore, certain types of signaling molecules or ions can be transferred
between the cells. In this way, the electrical excitation propagates from cell
to cell until the entire heart, which is a so-called syncytium, is activated. The
density and type of the gap junctions determines the CV in the tissue and is
partly responsible for the anisotropy of the CV.
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Figure 2.3. Schematic voltage clamp measurement circuit. Difference between transmembrane
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and a current source feeds the current to electrodes (a) and (d). The resulting current transmem-
brane current Im is measured. Adopted from [27].
2.2.2 Voltage Clamp and Patch Clamp Technique
In 1949, Cole [28] and Marmont [29] developed the voltage clamp tech-
nique, which allows the measurement of ion currents across the cell mem-
brane. Three years later, Hodgkin and Huxley [30] used this technique to
quantitatively analyze the underlying ion currents, on which the action po-
tentials of giant squid axons are based. The principle behind the voltage
clamp technique is sketched in Fig. 2.3. One platinum electrode injected
into the intracellular space of the cell (b) and a reference electrode in the
extracellular space (c), which is a bath surrounding the cell, are used to
measure the transmembrane voltage Vm. The difference between the deﬁned
clamp voltage Vc and Vm is ampliﬁed afterwards. A voltage-controlled cur-
rent source then supplies the electrodes (a) and (d) resulting in the trans-
membrane current Im, which is measured using a calibrated resistance Rc.
In this way, the negative feedback loop minimizes the difference between
the transmembrane voltage and the impressed clamp voltage until they are
equal. Since the clamp voltage is constant except for the instant changes at
the voltage steps, the membrane capacity can be neglected, so that only the
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ionic currents across the membrane are measured. Due to this, the response
of all cardiac ion channels of a myocyte to certain transmembrane voltages
can be determined. In order to record only one speciﬁc ion current, all other
currents have to be blocked using pharmacological agents, which might also
inﬂuence the current of interest. Another option is to use cells, which do not
express ion channels on their own. These cells are transfected with genes
encoding the ion channel of interest, which is expressed afterwards.
Neher and Sakman [31] developed the patch clamp technique in 1976, which
allows to measure ion currents of few or even a single ion channel. Instead
of two electrodes injected into the cell, a glass micropipette is attached to
the cell surface, so that a small patch of the cell is sucked into the pipette.
Then, different recording methods exist allowing to measure e.g. only one
ion channel at this patch, or the membrane of the whole cell. In case of
the whole-cell recording, the membrane patch is ruptured, so that a direct
connection between the inside of the pipette and the intracellular space of
the cell is created. Similar to the voltage clamp technique, a feedback current
ﬂowing through the pipette is used to compensate the difference between the
deﬁned clamp voltage and Vm. However, the series resistance, which is the
resistance between the membrane and the input of the ampliﬁer, has to be
compensated, as described in detail in e.g. [32]. An overview of the voltage
clamp and patch clamp technique including the different recordings is given
in [27]. The voltage clamp and whole-cell patch clamp recordings shown in
this thesis were provided by the University Hospital Heidelberg, Department
of Internal Medicine III.
2.2.3 Cardiac Conduction System and Genesis of the
Electrocardiogram
As described in section 2.2.1, cardiac myocytes are connected by gap junc-
tions allowing propagation of electrical excitation waves. These signals are
reﬂected in the electrical potential at the body surface, which is measured
by the ECG. A narrow depolarization front causes an intracellular current
in direction of the propagation from the already activated regions to the not
yet activated regions. In the meantime, a sodium inﬂux from the extracel-
lular space can be observed at the back of the front, whereas a capacitive
outﬂow at the front further depolarizes the neighboring cells. As a conse-
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resulting in the ECG at the body surface. Modiﬁed based on [33].
quence, the resulting double layer source has a positive polarity in direction
of the propagation of the front and consequently negative polarity in the op-
posite direction. The repolarization wave, which is much broader than the
depolarization front, causes an intracellular current from the still active to
the repolarized regions and a potassium outﬂow at the wave back. A capaci-
tive inﬂow as local circuit current is present at the border to still active tissue.
Consequently, a repolarization wave leads to a double layer source with neg-
ative polarity in direction of the wave and positive polarity in the opposite
direction. The effects responsible for the genesis of electrical signals at the
body surface are described in detail in [34].
In the human heart, various cell types exist in different regions of the heart
shown in Fig. 2.4, which cause the electrical excitation of the entire organ.
During normal sinus rhythm, the electrical activity is initiated at the sinus
node. There, specialized pacemaker cells without stable resting membrane
voltage automatically trigger APs. The excitation is propagated across the
entire atria resulting in the P wave. The atria are electrically isolated from
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the ventricles except for the atrioventricular (AV) node. After a short delay
at the AV node, the excitation wave propagates along the bundle of His and
the bundle branches towards the Purkinje ﬁbers, which are specialized path-
ways with high CV. In this way, rapid depolarization of the entire ventricles
occurs, which reﬂects in the QRS complex of the ECG. The more or less
homogeneous plateau phase in the ventricles leads to the ST segment of the
ECG, which is nearly a zero baseline. The heterogeneous repolarization in
the ventricles causes the subsequent T wave [20]. In the clinical practice,
a 12-lead system is commonly used to derive an ECG. It consists of three
electrodes, which are used as unipolar (Goldberger aVR, aVL and aVF) and
bipolar (Einthoven I to III) leads, close to or on both arms and the left leg,
as well as six unipolar chest leads (Wilson V1 to V6) close to the heart [34].
2.3 Atrial Fibrillation
AF is a rhythm disorder affecting more than 1% of the population [35]. Since
the prevalence increases with increasing age, even more people will suffer
from this pathology in the future as the population is getting older [36]. This
supraventricular tachyarrhythmia presents an uncoordinated activation of the
atria with very high beating frequencies between 400 to 600 bpm [37]. AF
is responsible for up to one fourth of all strokes [38]. Additionally, it is gen-
erally associated with hypertension, diabetes, heart failure and other cardio-
vascular diseases and furthermore increases the mortality [39]. However, the
underlying mechanisms responsible for AF are not completely understood
yet [40]. The focus of pharmacological and interventional therapy of AF is
on the management of heart rate and rhythm, as well as on the reduction of
the thromboembolic risk. Admittedly, current pharmacological treatment is
still not efﬁcient enough and has many side effects [41]. As a consequence,
the management of AF has to be improved starting earlier and being more
comprehensive [35]. Detailed information on AF is given in [42]. However,
only the aspects of AF investigated in this thesis, i.e. remodeling due to cAF
and genetic defects favoring AF, are described in the following.
2.3.1 Remodeling due to Chronic AF
AF is a cardiac arrhythmia, which slowly progresses over time. It starts with
few paroxysmal episodes and ﬁnally becomes permanent/chronic [43]. AF
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itself initiates mechanisms, which promote the occurrence and maintenance
of AF. This principle that “AF begets AF” was established by Wijffels et
al. [44] in 1995. Due to the rapid rates during AF, the affected tissue under-
goes electrical remodeling, which inﬂuences several ion channels and gap
junctions. This remodeling causes a shortening of the APD and ERP, as well
as a loss of the rate adaptation of the ERP [42]. Electrical remodeling due
to cAF alters the expression or phosphorylation of several cardiac ion chan-
nels. The L-type calcium current ICaL and the transient outward potassium
current Ito are both reduced by approximately 65% [45, 46]. Furthermore,
cAF-induced remodeling decreases the ultra-rapid delayed rectiﬁer potas-
sium current IKur by 49% [46]. In contrast, the inward rectiﬁer potassium
current IK1 is increased by around 110% [47]. Changes of further ion cur-
rents, which were neglected in this work, as e.g. the acetylcholine-activated
potassium channel IKACh, are summarized in [42].
In addition to ion channels, also gap junctions may be inﬂuenced by cAF.
However, the ﬁndings on gap junctional remodeling reported in literature are
inconsistent [48] showing decrease or even increase of connexin expression
and conﬂicting spatial distributions. However, a signiﬁcant decrease by 53%
of the expression of connexin 40 (Cx40), which can mainly be found in the
atria, is observed in e.g. [49].
2.3.2 Genetic Defects Favoring AF
In general, AF is associated with structural heart diseases, such as valvu-
lar heart disease, coronary artery disease, heart failure, hypertension, and
so on. However, AF is sometimes diagnosed in patients, especially if they
are young, who do not present these typical cardiovascular comorbidities.
In this case, mutations of genes encoding proteins of the cardiac cell mem-
branes are associated with AF instead [37]. This type of AF can be classiﬁed
as either familial AF, if close relatives are known to have the same form of
AF, or as sporadic AF, if no relatives are affected [50]. Mutations of genes
encoding cardiac ion channels, connexins, atrial natriuretic peptide, ryan-
odine receptors and other proteins are associated with AF [37]. An overview
of selected genetic defects of ion channels and connexins associated with
AF is given in Table 2.1. Different genes encoding cardiac ion channels are
affected by either gain-of-function or loss-of-function mutations increasing
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or decreasing the resulting currents. Mutations affecting the rapid delayed
rectiﬁer potassium current IKr, the slow delayed rectiﬁer potassium current
IKs, IKur, IK1, the fast sodium current INa, and ICaL are reported [37, 51]. In
Fig. 2.5, an exemplary mutation of KCNH2, which is also termed human
ether-a-go-go-related gene (hERG), is shown. In this case, the channel con-
sists of six transmembrane segments S1 to S6. At codon 588, the mutation
N588K, which is associated with AF and the short QT syndrome, changes
the amino acid asparagine (N) to lysine (K), explaining the nomenclature
of the mutations. Although numerous genetic defects associated with AF
have been identiﬁed already in recent years, further research is needed to
investigate the mechanisms responsible for the initiation and persistence of
AF [42].
NH3 COO
–
S1 S2 S3 S4 S5 S6
N588K
ex
tra
int
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+
Figure 2.5. Schematic visualization of the hERG channel consisting of six transmembrane seg-
ments. Mutation N588K causes a substitution of asparagine (N) by lysine (K) at codon 588 be-
tween segments S5 and S6.
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Table 2.1. Selected genetic defects associated with AF. Modiﬁed based on [37, 51].
type channel gene chromosome variants effects
potassium IKr KCNE2 21q22 R27C gain-of-function
channel IKr KCNH21 7q35-q36 N588K gain-of-function
IKs KCNQ1 11p15 S140G, V141M gain-of-function
IKs KCNE5 Xq22.3 L65F gain-of-function
IKs KCNE3 11q13-q14 R53H unknown
IKur KCNA5 12p13 E375X, T527M, A576V, E610K loss-of-function
IK1 KCNJ2 17q23-q24 V93I gain-of-function
sodium INa SCN5A 3p21 M1875T gain-of-function
channel INa SCN5A 3p21 D1275N, N1986K loss-of-function
INa SCN1B 19q13.1 R85H, D153N loss-of-function
INa SCN2B 11q23 R28Q, R28W loss-of-function
calcium ICaL CACNA1C 12p13.1 A39V, G490R loss-of-function
channel ICaL CACNB2 12p13.1 S481L loss-of-function
gap junction Cx40 GJA5 1q21.1 P88S, M163V, G38D, A96S negative effect
on gap junctions
Cx43 GJA1 6q22-q23 c.932delC negative effect
on gap junctions
1 also known as human ether-a-go-go-related gene (hERG).
2.4 Acute Cardiac Ischemia
Acute cardiac ischemia is caused by the partial or complete occlusion of a
coronary artery, which normally supplies the heart with oxygen and nutri-
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Figure 2.6. Main effects of acute cardiac ischemia. Effects of hyperkalemia measured in rat
hearts [54] (A), acidosis observed in ferret hearts [55] (B), cell-to-cell uncoupling and occurrence
of arrhythmias investigated in swine [56] (C), lack of ATP caused by hypoxia observed in ferret
hearts [55] (D) at different stages of ischemia.
ents. As a consequence of this shortage, different spatio-temporal changes
inﬂuence the electrophysiology, which can even be observed in the body
surface ECG. Only the underlying effects having a direct impact on car-
diac electrophysiology are described in the following, whereas a general
overview and further detailed information on e.g. metabolic effects of acute
cardiac ischemia can be found in [52, 53].
2.4.1 Electrophysiological Effects of Acute Cardiac Ischemia
During the ﬁrst thirty minutes of ischemia, two distinct phases, during which
arrhythmias occur most often, can be identiﬁed. These phases, which can
be seen in Fig. 2.6C, are called phase 1a between around 2− 10min and
phase 1b between 20−30min after the onset of ischemia [53]. The electro-
physiological effects of phase 1a can be subdivided into stage 1 at around
5min and stage 2 at around 10min after the onset of ischemia effects. Gen-
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erally, acute cardiac ischemia elevates the resting membrane voltage Vm,rest ,
decreases the AP amplitude, shortens the APD, but prolongs the ERP and
reduces the CV [52]. The main underlying effects of the ﬁrst thirty minutes
of ischemia are described in the following.
An accumulation of extracellular potassium is observed after the onset of
ischemia, which is shown in Fig. 2.6A. In general, this extracellular hyper-
kalemia can be explained by activation of an ATP sensitive potassium current
IK,ATP due to loss of ATP [57], as well as by altered sodium currents, which
cause an increase of the intracellular sodium concentration [Na+]i. This in-
creased [Na+]i results in passive potassium efﬂux preserving electroneutral-
ity [58]. After a rapid increase of the extracellular potassium concentration
[K+]o, a short plateau phase can be observed, during which the concentration
remains nearly constant. This can be explained by temporary reactivation of
NKA by glycolysis [59].
After the onset of ischemia, the pH falls towards more acidic values, which
can be seen in Fig. 2.6B. This acidosis can be explained by an increased
production of protons due to anaerobic glycolysis. Furthermore, less protons
are removed from the ischemic regions, due to an insufﬁcient removal of
CO2. As a consequence, several ion channels and gap junctions are inhibited
by the decreased pH, since these proteins behave as enzymes [53].
An occlusion of a coronary artery, which results in reduced availability of
O2 (hypoxia), also causes a lack of ATP (compare Fig. 2.6D), since anaero-
bic phosphorylation and local energy storages cannot supply the demand for
ATP. This reduction in ATP on the one hand increases IK,ATP, which is inhib-
ited by physiological concentrations of ATP [60], and additionally inhibits
the active transport mechanisms of the membrane, as e.g. NKA [53].
In Fig. 2.6C, the increase of the whole tissue resistance due to acute car-
diac ischemia is shown. Several factors reducing the gap junction conduc-
tivity, as e.g. increased [Na+]i and [Ca2+]i, as well as acidosis, have been
identiﬁed [61]. This cell-to-cell uncoupling, which starts to increase after
20−30min of ischemia, is associated with phase 1b arrhythmias [62].
2.4.2 Heterogeneous Ischemic Tissue
Effects of acute cardiac ischemia generally do not occur in the entire heart,
which is called global ischemia, but only regionally depending on the oc-
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Figure 2.7. Effects of acute subendocardial and transmural ischemia on the ECG. Subendocardial
ischemia (A) causes injury currents directed to the ischemic endocardium resulting in ST segment
depression. In case of transmural ischemia, the currents are directed from the less injured endo-
cardium to the epicardium causing ST segment elevation. Adopted from [69].
clusion site. Therefore, heterogeneous distribution of ischemia effects can
be observed. A border zone (BZ) (<10mm in width) is located between the
healthy tissue and the central ischemic zone (CIZ), where the effects are
most pronounced [63, 64]. The various ischemia effects develop differently
across the BZ [65].
Additionally, the effects of acute cardiac ischemia vary also transmurally.
Since the distance to the coronary arteries is greatest in the endocardium
and the blood ﬂow, contraction and therefore also the metabolic activity is
higher in the endocardium of a healthy heart [66], ischemia effects occur
in this inner layer ﬁrst. The effects of this subendocardial ischemia spread
towards the epicardium becoming transmural, if the occlusion worsens [67].
Nevertheless, ischemia effects are more pronounced in the epicardial tissue
due to a higher sensitivity of IK,ATP to loss of ATP there [68].
2.4.3 Effects of Ischemia on the ECG
The electrophysiological changes due to acute cardiac ischemia are re-
ﬂected in the body surface ECG changing e.g. the QRS complex or the T
wave [70, 71]. However, the most pronounced effects, i.e. shifts of the ST
segment of the ECG, are used as a diagnostic marker of ischemia and my-
ocardial infarction [72]. The effects, which are assumed to be responsible for
these shifts are presented in Fig. 2.7. Injury currents ﬂow from the healthy
epicardial towards the ischemic endocardial tissue in case of subendocardial
ischemia, causing ST segment depression in leads close to the ischemic re-
gion. However, transmural ischemia results in injury currents directed from
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the less injured endocardial to the more affected epicardial tissue. Due to
this, a pronounced ST segment elevation can be observed in leads close to
the ischemic region in this case [73].
2.5 Pharmacological Effects on Cardiac Electrophysiology
The effects of pharmacological therapy on cardiac electrophysiology are
outlined in this section. Initially, a short overview of pharmacodynamics,
i.e. how the binding of pharmacological agents to receptors can be mod-
eled, and the classiﬁcation of antiarrhythmics depending on their impact on
cardiac electrophysiology is given. Then, the three compounds amiodarone,
dronedarone and cisapride, which were investigated in this thesis, are de-
scribed.
2.5.1 General Mechanisms and Classiﬁcation of Antiarrhythmic
Agents
In general, the binding of a ligand L to a receptor R can be described by the
law of mass action according to following equation:
L+R
kon
ko f f
LR, (2.2)
where kon is the association rate constant, with which the receptor-ligand
complex LR is formed, and ko f f is the dissociation rate constant of the op-
posite process [75]. In case of pharmacological agents, the binding and un-
binding of the compound to receptors of ion channels is described by this
equation. However, this simple model does not consider the effects of more
Table 2.2. Classiﬁcation of antiarrhythmics according to Vaughan Williams [74].
class action effect
I inhibition of sodium decrease of upstroke
channel (phase 0 of AP)
II beta-blocking decrease of heart rate
III inhibition of outward prolongation of APD and
potassium channel refractory period
IV inhibition of inward reduction of plateau phase
calcium channel (phase 2 of AP)
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Figure 2.8. Hill curves with different IC50 and nH describing fractional inhibition of ion currents
depending on the concentration of the pharmacological compound.
complex binding mechanisms, such as cooperativity, i.e. the binding afﬁn-
ity of a receptor is increased or decreased, if a ligand is already bound to a
receptor. Hill [76] described this behavior in case of the binding of oxygen
to hemoglobin in 1910. Accordingly, the equation describing the fractional
inhibition of ion channels by a pharmacological agent L is named Hill equa-
tion. This fractional inhibition corresponds to the reduction of the maximal
ion channel conductivity:
fractional inhibition =
1
1+
(
IC50
[L]
)nH , (2.3)
with IC50 being the half maximal inhibitory concentration, at which the re-
sulting ion currents are inhibited by 50%, [L] being the concentration of the
pharmacological agent and nH being the Hill slope. nH > 1 indicates posi-
tive cooperativity, i.e. the afﬁnity of the the receptor is increased upon bind-
ing of the ligand, whereas nH < 1 indicates negative cooperativity, i.e. the
afﬁnity of the receptor is reduced upon binding of the ligand [75]. In this
way, the values of IC50 and nH describe the sigmoidal binding curve and
therefore the dose-dependent inhibition of ion channels by pharmacological
agents.
Antiarrhythmic agents can be classiﬁed according to their effect on cardiac
electrophysiology. The different classes and corresponding effects are sum-
marized in Table 2.2. The effects range from inhibition of cardiac ion chan-
nels, which can immediately be seen in the APs of the affected myocytes,
to inhibition of the sympathetic nervous system. Sodium channel blocker
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Table 2.3. Inhibition of cardiac ion currents due to the antiarrhythmic agent amiodarone.
current IC50 (μM) nH source
INa 1.4 1.0 [77]
INKA 15.6 1.0 [78]
IKr 0.8/0.07 1.3/1.1 [79]/[80]
IKs 3.84 0.63 [81]
ICaL 5.8/0.55 1.0/0.26 [82]/[83]
INCX 3.3 1.0 [84]
are grouped in class I, potassium channel blocker in class III and calcium
channel blocker in class IV. β -blocker inhibiting β -adrenergic receptors,
which mainly inﬂuence the heart rate and blood pressure, are assigned to
class II [74].
2.5.2 Antiarrhythmic Agent Amiodarone
Amiodarone is a class III antiarrhythmic agent, which is used for the man-
agement of ventricular tachycardia or ventricular ﬁbrillation due to myocar-
dial ischemia and infarction [85], as well as for the treatment of AF [86].
Although amiodarone is classiﬁed as class III antiarrhythmic agent due to its
effective inhibition of potassium channels, it furthermore exhibits properties
of the other classes, since it is a multichannel blocker. An overview of the
affected ion currents is given in Table 2.3. The therapeutic concentrations
of amiodarone range between 1 and 3 μM [87]. Therefore, effects on other
channels with IC50 values far above the therapeutic concentrations, as e.g.
IK1 with an IC50 of 92.14 μM [88], are neglected in this thesis. In general, the
values describing the inhibition of the ion channels reported in literature vary
signiﬁcantly depending on the species and temperature of the cells that were
used for the measurements. In case of IKr and ICaL, these differences are most
pronounced. Additionally, the effects of acute and chronic administration of
amiodarone vary also [87]. As a consequence, either an increase of the APD,
no change, or even a shortening is reported depending on the study and the
species investigated [87]. Furthermore, no signiﬁcant changes of the QT in-
terval are visible after acute administration [89], whereas chronic treatment
leads to a signiﬁcant prolongation of the QT interval and the ERP [90, 91].
Nevertheless, the occurrence of torsade de pointes arrhythmias is rare [92].
However, corneal micro-deposits can be observed in most of the patients
chronically treated with amiodarone [92]. Furthermore, amiodarone can in-
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duce severe thyroid dysfunction, which is the most common reason for dis-
continuation of chronic administration of amiodarone, due to its structural
similarity to the thyroid hormone thyroxine [93]. Additional experimental
data of the inhibition of cardiac ion channels are listed in [9, 94]. Further
general information on amiodarone is given in e.g. [87, 95] and the different
effects on atrial and ventricular electrophysiology, which are reﬂected in a
prolongation of the APD predominantly in the atria, are described in [96].
2.5.3 Antiarrhythmic Agent Dronedarone
Dronedarone, which is a derivative of amiodarone, has been approved in
the USA in 2009 [101]. The structure of amiodarone was systematically
changed in order to reduce adverse side effects. On the one hand, iodine was
removed to eliminate thyroid toxicity and on the other hand, the lipophilic-
ity was decreased to reduce the accumulation in tissue [101]. Dronedarone
is advised for the treatment of non-permanent AF, since recent studies
showed that dronedarone is not as effective as amiodarone in the treatment of
cAF [102]. Nevertheless, dronedarone, which is also a class III antiarrhyth-
mic agent [103], presents similar effects on various cardiac ion channels as
amiodarone [104]. The main cardiac ion channels inhibited by dronedarone
are listed in Table 2.4. The steady state plasma concentrations are reported
to be between 84 and 147 ng/ml [105], which corresponds to around 150
to 270 nM. Therefore, the impact on ion channels, which presented much
higher IC50 values, as e.g. IK1 with an IC50 > 30 μM [98], was neglected in
the present work. Chronic treatment of rabbit atrial tissue with dronedarone
increased the APD and ERP [106]. Additional experimental values describ-
ing the inhibition of cardiac ion channels are listed in [10]. Further general
information on dronedarone is given in [100, 104].
Table 2.4. Inhibition of cardiac ion channels due to the antiarrhythmic agent dronedarone.
current IC50 (μM) nH source
INa 0.54 2.03 [97]
IKr 0.0591 0.8 [80]
IKs 5.6 0.51 [98]
IKur 1.0 1.0 [99]
ICaL 0.83 2.75 [100]
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Table 2.5. Inhibition of cardiac ion channel due to the gastroprokinetic agent cisapride.
current IC50 (μM) nH source
IKr 0.023 0.8 [107]
2.5.4 Gastroprokinetic Agent Cisapride
Cisapride, which is a gastroprokinetic agent, was administered for the fa-
cilitation and restoration of gastrointestinal motility [108] until its with-
drawal from market in the USA in 1999. In many patients, prolongation
of the QT interval, torsades de pointes and ventricular ﬁbrillation could be
observed, which led to discontinuation despite the beneﬁt of this pharma-
cological agent [109]. At the ion channel level, inhibition of IKr (Table 2.5)
is visible at therapeutic concentrations. The peak plasma concentration is in
the range of 150 to 300 nM [110]. However, more than 95% of cisapride
is bound to plasma proteins. The effective concentration inhibiting cardiac
ion channels is therefore much lower [107]. Inhibition of ion channels with
IC50 values much higher than the effective concentration was neglected in
the present work, e.g. ICaL presented an IC50 of 46.9 μM [111]. Prolongation
of the APD and the QT interval was also observed in different species, as
e.g. guinea pig, rabbit and dog [112, 113]. More information on the electro-
physiological effects of cisapride is given in e.g. [94, 107].
3Computational Cardiac Modeling
The background information on modeling cardiac electrophysiology is out-
lined in this chapter. Mathematical descriptions used for multiscale sim-
ulations, which range from the cell membrane of single myocytes up to
models of cardiac tissue, are introduced. In this thesis, ﬁve models of hu-
man atrial electrophysiology and one model of ventricular electrophysiology
were used. Furthermore, the anatomical model of the ventricles used in this
thesis and the forward calculation of body surface ECGs is summarized.
Further reading is referenced in the corresponding sections.
3.1 Modeling Electrophysiology of Cardiac Myocytes
The mathematical descriptions of the membranes of cardiac myocytes are
mostly based on the ﬁndings of Hodgkin and Huxley [30]. In 1952, they
investigated the membranes of giant squid axons and developed an electri-
cal circuit representing these membranes, which is shown in Fig. 3.1. The
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Figure 3.1. Electrical circuit representing the membrane of a giant squid axon according to
Hodgkin and Huxley [30].
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transmembrane voltage Vm, which is the difference between the intracellu-
lar potential Φi and the extracellular potential Φe, depends on the sum of
ion currents Iion and a capacitive current Ic, which results from the dielectric
properties of the membrane. This can be described by the following ordinary
differential equation (ODE):
dVm
dt
=−Iion+ Istim
Cm
, (3.1)
where Istim is a stimulus current andCm the membrane capacity. This formu-
lation is still used in current models of cardiac electrophysiology. Hodgkin
and Huxley identiﬁed three currents contributing to Iion in the giant squid
axon: a sodium current INa, a potassium current IK and a leakage current
IL [30]. The different ion currents Ix each depend on the maximal conductiv-
ity gx, the product of gating variables γi describing the open probability of
the channels, as well as the difference between the transmembrane voltage
and the Nernst potential Ex of the type of ions:
Ix = gx
(
∏
i
γi
)
[Vm−Ex] . (3.2)
The gating variable γi, whose values range between 0 (closed) and 1 (open),
is calculated using following ODE:
dγi
dt
= αγi(1− γi)−βγiγi, (3.3)
where αγi is the forward rate constant describing the transition from closed
to open state and βγi is the backward rate constant describing the transition
in the opposite direction. The rate constants depend on the transmembrane
voltage Vm. Depending on the protein structure of the ion channel, one or
more gating variables govern the opening, closing and inactivation of the
channel. Further information on the mathematical description of myocyte
membranes is given in e.g. [27, 114].
3.1.1 Models of Human Atrial Electrophysiology
One part of this thesis is the benchmark of models of human atrial electro-
physiology. In the recent years, ﬁve models with diverse current formula-
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Figure 3.2. Models of human atrial myocyte according to Courtemanche et al. [115], Nygren et
al. [116], Maleckar et al. [117], Koivumäki et al. [118] and Grandi et al. [119]. A: Schematic of
the myocyte membrane including the different ion channels, transporters and pumps of the ﬁve
models. B: Schematic description of the calcium handling in the different compartments of the
ﬁve models. Modiﬁed from [13].
tions and therefore different resulting characteristics have been published. A
schematic illustration of the membrane including the ion currents described
by the different models is presented in Fig. 3.2A. Furthermore, the calcium
handling of the models including the different compartments is shown in
Fig. 3.2B. Short descriptions of the origins, similarities and differences of
the models are given in the following, as well as in [13, 120].
3.1.1.1 Courtemanche et al. 1998
The model of Courtemanche et al. [115], which is termed Courtemanche
model in the following, was published in 1998 as one of the ﬁrst models
of human atrial electrophysiology. This model was intended for the inves-
tigation of the inhibition of ICaL and INCX , as well as the adaptation of the
human atrial AP to changes of the heart rate. The Courtemanche model for-
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mulations of INa, IKur, Ito, ICaL, IKr, IKs and IK1 are based on human experi-
mental data. In contrast, INCX , INKA, the plasma membrane calcium ATPase
current IPMCA, the background calcium and sodium currents IbCa and IbNa,
as well as the intracellular calcium handling build on the model of guinea
pig ventricular myocytes of Luo and Rudy [121]. The Courtemanche model
comprises intra- and extracellular compartments for the different ions. The
intracellular ion concentrations are computed dynamically, whereas the ex-
tracellular concentrations are constant. The calcium uptake into the network
SR is maintained by the uptake calcium current Iup, whereas a calcium leak
current Ileak decreases the amount of calcium in the network SR. The junc-
tional SR and network SR are connected by the calcium transfer current Itr.
The calcium release current Irel supplies the intracellular space with calcium
stored in the SR. Mathematical descriptions of calsequestrin, calmodulin and
troponin allow for buffering of [Ca2+]i.
3.1.1.2 Nygren et al. 1998
The model of Nygren et al. [116] was also published in 1998. The main
purpose of the Nygren model was to compare the differences between rab-
bit and human atrial electrophysiology, especially regarding the repolarizing
currents. The Nygren model, which is mostly based on the rabbit atrial model
of Lindblad et al. [122], reﬂects nearly the same human experimental data
as in case of the Courtemanche model. In general, the Nygren and Courte-
manche model present the same transmembrane ion currents; only the ultra-
rapid delayed rectiﬁer potassium current IKur is termed sustained outward
potassium current Isus in the Nygren model. Long term stability of the ion
concentrations is achieved by an electroneutral sodium inﬂux. Furthermore,
the ions can accumulate or deplete in a cleft space between the intra- and
extracellular space around the cell membrane. In case of calcium ions, an
additional dyadic space between the L-type calcium channels and the junc-
tional SR is included. At this dyadic space, the calcium concentration can
be signiﬁcantly increased compared to the concentration in the remaining
intracellular space. A calcium diffusion current Idi ﬂows from the dyadic to
the intracellular space. In contrast to the Courtemanche model, which offers
a phenomenological voltage-dependent calcium release, a calcium-induced
calcium release is described in the Nygren model.
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3.1.1.3 Maleckar et al. 2008
Ten years after the publication of the ﬁrst models of human atrial electro-
physiology, Maleckar et al. [117] presented a re-implementation of the Ny-
gren model. The model was used to study the coupling between myocytes
and ﬁbroblasts and to improve the description of the rate-dependent repo-
larization of human atrial APs. For this purpose, more recent human atrial
experimental data of the repolarizing currents IKur and Ito are included. The
effects of cholinergic stimulation on human atrial electrophysiology are con-
sidered by adding a mathematical description of IKACh according to Kneller
et al. [123].
3.1.1.4 Koivumäki et al. 2011
In 2011, the model of Koivumäki et al. [118] was published. As the Maleckar
model, it is based on the Nygren model. The Koivumäki model aimed at im-
proving the description of the intracellular calcium handling and to inves-
tigate the impact of the calcium dynamics on the shape of the AP. For this
purpose, three intracellular and one subspace calcium, as well as four SR
compartments were deﬁned to model spatially heterogeneous intracellular
calcium dynamics. Calcium ﬂows between the SR compartment closest to
the membrane and the subspace, as well as between the three other SR com-
partments and the corresponding intracellular compartments. In this way,
calcium diffusion due to the lack of a transverse tubular system is mathe-
matically described. The calcium release to the intracellular compartments
is modeled by a Hodgkin-Huxley type current formulation. In addition, a
hyperpolarization-activated inward potassium current I f is included accord-
ing to [124].
3.1.1.5 Grandi et al. 2011
The model of human atrial electrophysiology of Grandi et al. [119] was pub-
lished in the same year as the Koivumäki model. The Grandi model is based
on neither the Courtemanche nor the Nygren model, but on a model of hu-
man ventricular electrophysiology published by the same group [125]. A
rabbit ventricular model [126] in turn forms the basis of the human ventric-
ular model. The focus of the human atrial model is on the investigation of
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Figure 3.3. Schematic of human ventricular myocyte membrane based on the model of ten Tuss-
cher and Panﬁlov [127]. Shown are the different ion channels, transporters and pumps of the
membrane, as well as the calcium handling including cytosolic, SR and subspace (SS) buffers
(Buf).
the differences between human atrial and ventricular electrophysiology, es-
pecially regarding the intracellular calcium handling. For this purpose, the
detailed descriptions of the intracellular calcium dynamics of the rabbit ven-
tricular model [126] were adopted. A junctional cleft between the membrane
and the release unit of the SR is considered to allow for local accumulation
of calcium. Furthermore, a subsarcolemmal space adjacent to the membrane
is included. The concentration of chloride and therefore a calcium-activated
and a background chloride current ICl(Ca) and IbCl are considered in addition,
as well as a plateau potassium current IKp.
3.1.2 Model of Human Ventricular Electrophysiology
For the simulation of human ventricular electrophysiology, the model of ten
Tusscher and Panﬁlov [127] published in 2006, which is called ten Tusscher
model in the following, was used in this thesis. A schematic of the ventricu-
lar myocyte described by this model including the ion currents, ion compart-
ments and the SR, is shown in Fig. 3.3. This model, which is an extension of
the previous model published by the same group [128], is based on mostly
human experimental data. The original purpose of the ten Tusscher model is
to investigate dynamic instabilities in the APD resulting in steep restitution
curves and reentrant circuits in 2D patches. The ten Tusscher model has an
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improved description of intracellular calcium dynamics including a Markov
model of the ryanodine receptor based on [126, 129] to simulate calcium-
induced calcium release. Furthermore, different buffers in the intracellular
space, the SR and the subspace (SS) regulate the calcium concentrations
in the different compartments of the model. Transmural heterogeneities in
the human ventricles are considered by different maximal ion channel con-
ductivities and current formulations of Ito and IKs for endocardial, M and
epicardial myocytes.
3.1.3 Adaptation of Models of Cardiac Electrophysiology
The models of human cardiac electrophysiology introduced so far, gener-
ally describe normal physiological conditions. However, current research fo-
cuses on the investigation of other conditions, i.e. the inﬂuence of patholog-
ical changes or pharmacological treatment. In this thesis, the impact of AF,
acute cardiac ischemia and pharmacological treatment on cardiac electro-
physiology was investigated. Therefore, exemplary adaptations of models of
cardiac physiology to these conditions are outlined in the following.
3.1.3.1 Models of Atrial Fibrillation
The Courtemanche model was adapted to cAF-induced electrical remodel-
ing in e.g. [130, 131], where the conductivities of Ito, IKur and ICaL were
reduced to investigate the resulting effects, as e.g. AP shortening at differ-
ent rates. Furthermore, the inﬂuence of pharmacological treatment on single
cells, which was modeled by additional reduction of ion channel conductiv-
ities, was investigated in [130]. In [132], electrical remodeling was repro-
duced by reduction of the maximal channel conductivities of Ito, IKur, ICaL
and IK1. In this case, the inhibition of IKur by modiﬁcation of the channel
kinetics was simulated to analyze the effects of this pharmacological ther-
apy in atrial myocytes. Two descriptions of cAF-induced remodeling were
investigated in [133], where reductions of maximal channel conductivities,
as well as shifts of the voltage-dependent activation of Ito, ICaL, INa and IK1
were considered. The impact of the different changes on human atrial APs
was investigated in single myocytes. In a more recent work [134], a stretch-
activated channel was included in the Courtemanche model. Under these
conditions, atrial dilation facilitated the initiation and increased the stability
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of AF in a 3D model of the atria. The Nygren model was also adapted to re-
produce cAF-induced remodeling in [131, 133], where the same changes as
in the Courtemanche model were investigated. The Grandi model presents an
own model of cAF-induced remodeling [119], in which the maximal channel
conductivities of IK1, Ito, IKur, IKs, ICaL, INa and INCX were altered. Addition-
ally, the intracellular calcium handling was modiﬁed by an increase of Ileak
and an increase of the sensitivity of Irel to changes of the calcium concen-
tration in the SR. In this way, the effects of cAF on the simulated AP and
the intracellular calcium dynamics were investigated. An overview of elec-
trophysiological models of AF is given in [135].
The impact of mutations of cardiac ion channels associated with AF was
investigated in e.g. [136]. In this case, the maximal channel conductivity of
IKur of the Courtemanche model was reduced to describe the E375X loss-of-
function mutation in KCNA5. As a consequence, early afterdepolarizations
could be observed in single cells, which was assumed to be the underlying
mechanism responsible for AF in case of this mutation. In [137], a voltage-
dependent change of the maximal channel conductivity of IK1 adapted to
measured I-V curves was used to simulate the effects of the V93I gain-in-
function mutation in KCNJ2. The mutation caused an increased stability of
reentrant circuits in 2D and 3D atrial models.
3.1.3.2 Models of Acute Cardiac Ischemia
The main effects of acute cardiac ischemia on ventricular electrophysiology
were investigated in e.g. [138]. There, the impact of the transmural hetero-
geneity of an ATP sensitive potassium current IK,ATP was studied in a model
of rabbit ventricular myocytes [139] after 20min of ischemia. The focus
of this study was on the metabolic effects. These effects were also investi-
gated in detail in [140] in a model of guinea pig ventricular myocytes [121]
after 15min of ischemia. In e.g. [141–143], the focus was on phase 1b of
ischemia, which was investigated in a model of guinea pig ventricular my-
ocytes [144]. In [145], the effects of different stages of acute cardiac is-
chemia were analyzed in a tissue patch using a model of rabbit ventricular
myocytes [146].
In [147], the effects of acute cardiac ischemia were integrated into a model of
human ventricular myocytes [128]. However, only exemplary changes were
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included, as e.g. an additional IK,ATP and modiﬁcations of IK1, ICaL, Irel and
Iup. The effects of phase 1a of acute cardiac ischemia were integrated into the
ten Tusscher model [127] of human ventricular electrophysiology in [148].
For this purpose, a current formulation of IK,ATP according to [149] was
integrated into the model and several model parameters were adapted to dy-
namically model the effects at different stages of ischemia. Furthermore, the
effects of ischemia, which were modeled heterogeneously, were investigated
in body surface ECGs.
3.1.3.3 Models of Pharmacological Therapy
The impact of pharmacological treatment on cardiac electrophysiology was
studied in e.g. [132], where the inhibition of IKur was investigated in the
Courtemanche model. The effects of dofetilide, which inhibits hERG chan-
nels, on the dispersion of ventricular repolarization were analyzed in [150].
For this purpose, the inhibition was simulated using a model of guinea
pig ventricular myocytes [144]. The inﬂuence of the same pharmacologi-
cal agent on the ECG was observed in [151]. In this study, a model of human
ventricular myocytes [125] and a 3D model of the body including the heart,
which was stimulated apically, were used to simulate QT prolongation due
to dofetilide. In [152], dose-dependent effects of pinacidil on IK,ATP and ar-
rhythmogenesis were investigated in an ischemic 2D tissue patch using a
model of guinea pig ventricular myocytes based on [121].
Transmurally varying effects of amiodarone and d-sotalol were studied in
a 3D ventricular wedge in [153] using a model of canine ventricular my-
ocytes [154]. In case of amiodarone, only the inhibition of INaL, ICaL and
IKs was considered by reduction of the maximal ion channel conductivities.
In [155], the inﬂuence of dronedarone on human atrial electrophysiology
was simulated using the Courtemanche model. For this purpose, the ion
channel conductivities of INa, IKr, IKs and ICaL were reduced. Due to this,
bifurcation of the single-cell APD restitution curve was prevented and the
APD was increased. General information on modeling the impact of phar-
macological therapy on cardiac electrophysiology is given in e.g. [156].
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3.2 Modeling Cardiac Excitation Propagation
In the previous section, modeling of cardiac electrophysiology was described
at the single-cell level only. However, cardiac myocytes are connected by gap
junctions forming a syncytium, as described in section 2.2.1. Due to this, a
mathematical description of the coupling between the cells is needed. De-
pending on the focus of the simulation, either microscopic models describ-
ing each single myocyte in detail or macroscopic models spatially averaging
small parts of the tissue, can be used. In this thesis, the tissue simulations
ranged up to the organ level. Therefore, a macroscopic approach was used,
since the number of cardiac myocytes of only the left ventricle is in the order
of 109 [157].
Bidomain Model
The bidomain model is a mathematical description of electrical excitation
propagation and was ﬁrst applied to cardiac tissue in 1978 [158, 159]. This
model spatially averages the tissue, which is represented by two continuous
domains: the intra- and extracellular spaces, which are both deﬁned at every
point in space. Conductivity tensors deﬁned at each of these points give in-
formation on the ﬁber orientation and coupling of the averaged tissue. Except
for external stimuli, currents ﬂowing out of one domain enter the other do-
main through the membrane [160]. As a consequence, the electric potential
in each domain can be determined using the following Poisson equations:
∇ · (σi∇Φi) = β Im− Isi (3.4)
∇ · (σe∇Φe) =−β Im− Ise, (3.5)
where σi and σe are the volume-averaged conductivity tensors of the intra-
and extracellular spaces, β is the membrane surface to cell volume ratio, Im
the transmembrane current density and Isi, as well as Ise are external stimulus
current sources [161]. Since cardiac myocytes have approximately cylindri-
cal shapes, the conductivity tensors can be transformed into longitudinal and
transversal components, which reﬂect the main axes of the cells. The bido-
main equations can be derived from equations (3.4) and (3.5):
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∇ · ((σi+σe)∇Φe) =−∇ · (σi∇Vm) (3.6)
∇ · (σi∇Vm)+∇ · (σi∇Φe) = β (CmdVmdt + Iion)− Isi. (3.7)
To obtain equation (3.6), which is an elliptic partial differential equation,
equations (3.4) and (3.5) are added and the deﬁnition of Vm is applied. Fur-
thermore, the assumption that no external stimulus currents are applied, is
necessary. The deﬁnition of the transmembrane current Im = CmdVmdt + Iion
has to be used to derive the parabolic differential equation (3.7) from equa-
tion (3.4). Dirichlet and Neumann boundary conditions are applied to deﬁne
the reference potential and the interface between the tissue and the surround-
ing medium. More detailed information on the bidomain model is given in
e.g. [161, 162].
Monodomain Model
The monodomain model is described by the reaction-diffusion equation (3.8)
consisting of a parabolic partial differential equation coupled to a system of
ODEs. The monodomain equation can be derived from the bidomain model
assuming equal anisotropy, i.e. a scalar constant κ satisﬁes the following
equation σi = κσe:
∇ · (σi∇Vm) = Iinter = (κ +1)β
(
Cm
dVm
dt
+ Iion
)
. (3.8)
Depending on the transmembrane voltage distribution, the intercellular stim-
ulus current Iinter is described. If no external electrical ﬁelds are applied, the
monodomain model is sufﬁcient to investigate cardiac excitation propaga-
tion [135]. The monodomain model was used for all tissue simulations pre-
sented in this thesis, since this model is much less computationally expensive
than the bidomain model.
3.3 Anatomical Models and the Forward Problem of
Electrocardiography
An anatomical voxel model (cubic voxel size 0.4mm) of the ventricles,
which was derived from magnetic resonance images of a healthy volunteer
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Figure 3.4. Anatomical models for whole organ and body modeling. Heterogeneous ventricular
(A) and torso model (B) of healthy volunteer used for forward calculation of body surface po-
tential maps (BSPMs). A: transmural and apico-basal heterogeneity of gKs. B: torso model with
virtual ECG electrodes (I–III: Einthoven leads, V1–V5: Wilson chest leads, V6 on the back) and
the internal organs.
in a previous work [163], was used in this thesis for whole organ model-
ing. As described in [163], the transmurally varying tissue conductivity was
scaled to ﬁt canine ventricular wedge experiments [164] resulting in a lon-
gitudinal CV of approximately 650mm/s. The same endocardial stimula-
tion proﬁle mimicking the His-Purkinje network and the ﬁber orientation
described in [163] were used. For the simulation of ventricular excitation
propagation using the ten Tusscher model described in section 3.1.2, differ-
ent heterogeneities were considered. For this purpose, the transmural tissue
layers were distributed as follows: 40% endocardial, 40% midmyocardial
and 20% epicardial tissue. Consequently, the transmural heterogeneities of
IKs and Ito suggested in [127] were applied. Furthermore, the values of the
maximal channel conductivity gKs were linearly increased from the base to
the apex to the twofold value according to [165]. The resulting ventricular
model including the different heterogeneities of gKs is shown in Fig. 3.4A.
For the forward calculation of body surface potentials, a high resolution
tetrahedral model of the torso consisting of approximately 0.75 million
nodes, which was also derived from magnetic resonance images of the same
healthy volunteer [163], was used. As outlined in [163], the transmem-
brane voltage distributions resulting from simulations of ventricular exci-
tation propagation were interpolated on the tetrahedral mesh ﬁrst. Then, the
body surface potentials were computed at each simulated millisecond using
equation (3.6). This equation was transformed into a linear system of equa-
tions using the ﬁnite element method and afterwards solved with the help
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of the Cholesky decomposition and a conjugate gradient method. The torso
including the internal organs, as well as the virtual electrodes of the 12-lead
ECG are presented in Fig. 3.4B. More information on the forward calcula-
tion of body surface potentials is given in e.g. [166].

Part II
Methods

4Parameter Adaptation of Electrophysiological
Models
This chapter describes the methods necessary for the adaptation of models
of cardiac electrophysiology to voltage or patch clamp measurement data,
which were introduced in section 2.2.2. In this study, different optimization
algorithms for the adjustment of a model of IKr to voltage clamp measure-
ment data of the hERG channel, which is the α-subunit of IKr, were investi-
gated. At ﬁrst, the experimentally measured and synthetic data used for the
test of the optimization algorithms are described. Then, the necessary pre-
processing of the noisy measurement data of single myocytes is presented.
Furthermore, two methods to solve ODEs modeling the gating processes of
cardiac ion channels are compared. Three algorithms, which pursue different
strategies to minimize the difference between measured and simulated cur-
rent traces, were analyzed in this work. Finally, a local sensitivity analysis of
the inﬂuence of the adjustable parameters on the function to be minimized
was carried out. The corresponding results can be found in chapter 8.
4.1 Measured hERG and Synthetic Voltage Clamp Data
In this study, exemplary hERG double microelectrode voltage clamp data
were used for the test of optimization algorithms. However, patch clamp
measurement data or data of other currents can be used instead, as shown e.g.
in section 5.3. For the test of the optimization algorithms, currents of wild
type (WT) hERG and two mutations of hERG, namely K897T and N588K,
were provided by the University Hospital Heidelberg. The QuickChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to
introduce both mutations into the hERG cDNA. 46 nl cRNA solution were
injected in each Xenopus oocyte to heterologously express hERG channels
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there. The oocytes were incubated at 16◦C for three to four days. Then, the
voltage clamp recordings were performed using a Warner OC-725A ampli-
ﬁer (Warner Instruments, Hamden, CT, USA) at 23 to 25◦C. The microelec-
trodes had tip resistances in the range of 1 to 5MΩ . The currents were low-
pass ﬁltered at 1 to 2 kHz and digitized at 5 to 10 kHz (Digidata 1322A,
Axon Instruments, Union City, CA, USA). The bathing solution contained
5mM KCl, 100mM NaCl, 1.5mM CaCl2, 2mM MgCl2, and 10mM of the
buffering agent HEPES. The pH was adjusted to 7.4 with NaOH. The pipette
solution contained 3M KCl. The data of the WT channels were used to adapt
and compare the optimization algorithms. The algorithms were furthermore
tested with the voltage clamp data of the mutated channels.
In addition to the experimentally measured hERG currents, synthetic cur-
rent traces were used to assess the ability of the optimization algorithms
to reconstruct known parameter values. For this purpose, current traces
were obtained from simulation of the same voltage clamp protocol as used
for the measured data. The IKr current formulation of the Courtemanche
model [115] with the 12 adjustable parameters (grey) is:
IKr =
gKrxr(Vm−EK)
1+ exp
(
Vm+gKr1
gKr2
) (4.1)
αx(r) = Xra1
Vm+Xra2
1− exp
(
Vm+Xra2
Xra3
) (4.2)
βx(r) = 7.3898e−5
Vm+Xrb1
exp
(
Vm+Xrb1
Xrb2
)
−1
(4.3)
τx(r) = [XrKQ10(αx(r) +βx)]−1 (4.4)
xr(∞) =
[
1+ exp
(
−Vm+Xrm1
Xrm2
)]−1
(4.5)
EK =
RT
F
log
[K+]o
[K+]i
, (4.6)
where gKr was the maximum conductivity and XrKQ10 the temperature cor-
rection factor. The Nernst voltage EK based on the gas constant R (8.3143J/(K ·
mol)), the temperature T (297.15K) and Faraday’s constant F (96.4867C/mmol)
was computed with constant intracellular potassium concentration [K+]i.
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The gating variable xr was determined using the ODE described in equa-
tion (4.7). The original values of the adjustable parameters (compare Ta-
ble 8.1) of the model were used for the generation of synthetic clamp data.
Then, the optimization algorithms, which received random initial parame-
ter values as an input, were supposed to reconstruct the original parameters
again.
All current traces, i.e. the measured and synthetic data, and the correspond-
ing voltage clamp protocol are depicted in Fig. 8.7.
4.2 Preprocessing of Measured Ion Current Recordings
As the currents recorded during voltage or patch clamp protocols are noisy
and relatively small (e.g. in the range of μA) and vary from cell to cell, the
measurements of several cells were averaged ﬁrst. Furthermore, the aim of
the adaptation of ion current models to measurement data was not to model
the properties of a speciﬁc single cell, but rather to reproduce the characteris-
tics of a cohort of certain cells. For this purpose, the current traces of all cells
were normalized to their maximal peaks (positive or negative) ﬁrst, since the
amplitudes varied from cell to cell depending on the size and expression of
the ion channels. Then, the normalized current traces of different cells corre-
sponding to the same voltage step were averaged. Afterwards, each of these
averaged current traces was multiplied by the average of the maximal peaks
of the different cells. In this way, information on the amplitude of the cur-
rent traces corresponding to different voltage steps was included again. In
addition, the averaging reduced the remaining high-frequency noise.
The cells, which were used for voltage clamp or patch clamp measurements
in this work, were injected with the cRNA encoding the ion channel that
should be investigated. In this way, the cells mainly expressed the channel
of interest. Nevertheless, background and leak currents of the cells also con-
tributed to the measured currents. As a consequence, the measured current
traces were slightly shifted, which could be identiﬁed in parts of the volt-
age clamp protocol, during which the current of interest was supposed to
be zero. If available, the current recordings were corrected with measure-
ments of the background currents using cells without injected cRNA. These
measurements, which were also averaged as described above, were scaled,
so that the difference between the current of interest and the background
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current was zero at clamp voltages, at which the channels of interest were
supposed to be closed, e.g. at −80mV. If these additional recordings were
not available, the shifts of the current traces were corrected manually, so that
the current traces were zero on average, if the channels were supposed to be
closed.
Finally, the number of measurement points was decreased to reduce comput-
ing time of the optimization process, which depended on the number of func-
tion evaluations calculating the difference between simulated and measured
data. Additionally, points immediately after instant changes of the clamp
voltage were discarded, as the measured current could be inﬂuenced by the
capacitive properties of the cell membrane.
4.3 Methods for the Solution of ODEs
ODE (3.3) describing the gating process of cardiac ion channels can be
rewritten as follows:
dγ
dt
=
γ∞− γ
τγ
, (4.7)
where γ∞ is the steady state value and τγ the time constant of the gating pro-
cess. Both, γ∞ and τγ depend on the transmembrane voltage Vm. In general,
two possible methods to solve these ODEs in Matlab (R2012b, The Math-
Works, Natick, MA, USA) were compared in this work.
Analytical Solution
As the transmembrane voltage was a piecewise constant function during the
voltage clamp protocols used in this work, the values of γ∞ and τγ were
also constant during deﬁned intervals, except for the instant changes in Vm.
Consequently, an analytical solution of equation (4.7) existed, as shown in
e.g. [167]:
γ(t− t0) = γ∞+(γ0− γ∞)exp
(
−(t− t0)
τγ
)
, (4.8)
with t0 being the time of a voltage step and γ0 the corresponding initial value
at t0.
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Numerical Solution
In computational cardiology, ODE (4.7) is not solved directly, but approxi-
mated numerically, since the transmembrane voltage and therefore γ∞ and τγ
generally change over time during the cardiac cycle. The predeﬁned solver
ode15s, which numerically approximates stiff ODEs with a variable time
step, was used for the optimizations. In order to obtain an approximation
with sufﬁcient accuracy, the error tolerance was set to 1e−9.
4.4 Optimization Algorithms
In this work, the parameters of the models of cardiac ion currents were
adapted to reproduce the properties of measured ion currents. For this pur-
pose, the difference between simulated and measured ion currents was min-
imized. The quality of the adaptation was quantiﬁed using the least squares:
min
p
(
∑
j
∑
i
(
IKr,meas(ti,Vj)− IKr,sim(ti,Vj,p)
)2)
, (4.9)
with p being the set of adjustable parameters, ti discrete evaluation times
and Vj the clamp voltages. Vj was described by a piecewise constant func-
tion reproducing the voltage clamp protocol of the measurements. The re-
sulting optimization problem was nonlinear, multi-dimensional and non-
convex. Therefore, different optimization algorithms were investigated re-
garding their suitability for this task.
4.4.1 Trust-Region-Reﬂective Algorithm
The trust-region-reﬂective (TRR) algorithm used in this work is imple-
mented in the Matlab function lsqnonlin. Instead of minimizing the nonlin-
ear function directly, a quadratic approximation qk(x) of the function f (xk),
which is deﬁned in a trust region with radius rΔ around the parameter vector
xk, is minimized [168]:
qk(x) = f (xk)+∇ f (xk)T (x− xk)+ 12(x− xk)T∇2 f (xk)(x− xk) (4.10)
min
‖s‖≤rΔ
qk(xk+ s), (4.11)
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with s being the difference between xk and x. In the course of the optimiza-
tion, the trust region radius Δ and the parameter vector xk are adapted. In this
work, the maximum number of iterations was set to 1e5 and the number of
maximal function evaluations to 2.5e6 to restrict the maximum computing
time of this algorithm. As a further stopping criterion of the algorithm, the
minimal changes of the parameter and function values were set to 1e− 11.
However, the results of the TRR algorithm can depend on the initial param-
eter vector, if it is applied to problems with several local minima [168].
4.4.2 Derivative-Free Optimization Algorithms
In addition to the TRR algorithm, which was based on information about
the derivatives, a different class of heuristics exists, which does not consider
this information. Instead, stochastic optimization algorithms randomize the
search process to avoid running into local minima, trying to ﬁnd a global
minimum. Both derivative-free algorithms implemented in Matlab in this
study use a population of parameter vectors instead of only one. The compu-
tation of the iterations of individuals of these populations was parallelized.
4.4.2.1 Particle Swarm Optimization
The particle swarm optimization (PSO) algorithm is based on swarming the-
ory of animals, such as ﬂocking birds [169]. The algorithm describes the
behavior of a population of particles starting from random initial positions,
which correspond to the parameter vectors, within certain boundaries. The
entire population tries to move towards the global best position. For each par-
ticle, the velocity vi depending on the current global best postion pg and the
own best position pi is computed in every iteration as described e.g. in [170]:
vi ← χ(vi+U(0,φ1)⊗ (pi−xi)+U(0,φ2)⊗ (pg−xi)), (4.12)
xi ← xi+vi, (4.13)
with U(0,φ1) and U(0,φ2) being vectors of uniformly distributed random
numbers between 0 and φ1 or φ2. ⊗ is a component-wise multiplication.
The values of pg and pi are updated, as soon as better positions are found
in an iteration. The constriction coefﬁcient χ was deﬁned by Clerc and
Kennedy [171] as:
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χ =
2
φ −2+
√
φ 2−4φ , with φ = φ1+φ2 = 4.1 ⇒ χ ≈ 0.7298. (4.14)
The weighting factors φ1 and φ2 were equal in this case. Furthermore, the
resulting parameter values were set to values within the boundaries, if they
were determined to be out of the deﬁned range. For this purpose, the cor-
rected parameter value was placed within 25% of the deﬁned range starting
from the boundary. If the number of particles N was sufﬁciently large, the
swarm was supposed to move to the global best position avoiding local min-
ima. In contrast to the previous algorithms, a ﬁxed number of iterations was
used.
4.4.2.2 Genetic Algorithm
Genetic algorithms (GA) are a further class of derivative-free optimization
heuristics using a population of N parameter sets. As in case of the PSO
algorithm, the GA implemented in this work had a ﬁxed number of iterations.
The heuristic was based on three steps inspired by biological evolution:
1. Selection: The function to be minimized was evaluated for all parame-
ter sets in parallel. The nalpha best parameter sets of a generation, which
were called alphas as in [172], were selected ﬁrst. Then, the N− nalpha
other parameter sets were divided into groups of nalpha/N−1 remaining
parameter sets, which were assigned to one alpha each.
2. Crossover: In this step, the parameter values of the remaining parameter
sets were crossed over with the values of their corresponding alpha. The
probability pcrossover of each parameter value of the remaining parameter
sets to inherit the value of the alpha was independent of those of the other
parameters.
3. Mutation: Finally, all parameter values of the alphas and remaining pa-
rameter sets were mutated with a probability pmutation. The range of the
perturbation of the parameter value was decreased with increasing num-
ber of iterations as described in [173]. In the ﬁrst iteration, the pertur-
bations ranged from ±50% of the maximum difference between the up-
per and lower boundaries and the current value. In the last iterations, the
range centered around the current value was decreased to ±2.5%, so that
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the minimum search was focused on more local parameter ranges towards
late iterations.
4.5 Local Sensitivity Analysis
The aim of a sensitivity analysis is to quantify, how sensitive an obtained so-
lution is to variations of one or more input parameters. In this work, the local
sensitivity S based on the partial derivatives, i.e. the inﬂuence of changes of
one parameter at a time on the solution, was analyzed:
Si =
d f (xi)
dxi
. (4.15)
As shown in equation (4.8), an analytical solution of the ODEs of the models
of cardiac ion currents existed in case of piecewise constant transmembrane
voltages during voltage clamp experiments. Due to this, the partial deriva-
tives of the function to be minimized in equation (4.9) with respect to the
adjustable parameters could be computed directly using Maple (v. 15, 2011,
Maplesoft, Waterloo, ON, Canada). Therefore, the sensitivity of the mini-
mum, which was found using the optimization algorithms, to changes of the
adjustable parameters was investigated.
In contrast to local sensitivity, global sensitivity, which is based on e.g. the
variance, analyzes how changes of combinations of parameters affect the
solution. An overview of the topic sensitivity analysis is given e.g. in [174].
5Modeling Atrial Fibrillation
The methods used for multiscale simulations of AF effects, which are sum-
marized in section 2.3, are described in this chapter. Five models of human
atrial electrophysiology were benchmarked regarding general model proper-
ties and their ability to reproduce effects of cAF-induced remodeling. Fur-
thermore, the impact of mutations of the ultra-rapid delayed rectiﬁer potas-
sium current integrated into a model of human atrial electrophysiology with
methods described in chapter 4 were investigated. The scale of the simula-
tions ranged from single myocytes up to 2D tissue patches. The initiation
of reentrant circuits was analyzed in these patches. For this purpose, the ro-
tor centers were detected automatically and pseudo-ECGs were computed
in order to determine the dominant frequency. The corresponding results are
presented in chapter 9.
5.1 General Properties of Models of Atrial Electrophysiology
The principal properties of the ﬁve models of human atrial electrophysiology
presented in section 3.1.1 (Courtemanche, Nygren, Maleckar, Koivumäki
and Grandi) were investigated ﬁrst in order to determine, which of them was
most suitable for the simulation of effects of AF. For this purpose, some as-
pects that are important for the simulation of human atrial electrophysiology
were benchmarked using the models as they were published:
Long Term Stability
In order to assess the numerical long term stability of the models, some AP
parameters of interest were observed over long simulation times. For this
purpose, the resting membrane voltage Vm,rest was recorded during a period
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of 20min without external stimulation, so that Vm,rest did not change signif-
icantly. After this quiescent phase, the myocytes were paced with a BCL of
1 s and Vm,rest was measured for each cycle. In this way, the reaction of the
models to onset of external stimulation was examined. Furthermore, the AP
amplitude, APD50 and APD90 (AP durations at 50% and 90% repolarization)
of each cycle were analyzed during 20min pacing with a BCL of 1 s.
Alternans
Alternans is a physiological phenomenon, which occurs if the BCL is only
slightly higher than the APD, so that the myocytes are not able to recover
completely from the previous beat. Consequently, a smaller AP with shorter
duration is initiated in the following causing a longer DI than before. Due
to this, a longer AP is initiated again, which results in an alternating pattern
of short and long APs. This behavior was investigated in the ﬁve models of
atrial electrophysiology by pacing the myocytes for 30 s with BCLs ranging
from 0.2 to 1 s. The APD50 of different numbers of stimuli was measured to
investigate alternating behavior of the APD. Furthermore, the resulting APs
and the calcium transient were observed during 30 s pacing with a BCL of
0.25 s.
Computing Time
Another aspect important for the simulation of human atrial electrophysiology,
e.g. ﬁbrillation in a complex geometry, is the computing time. The more
complex the models are, the more time is needed for the solution of the
underlying mathematical equations. The single-cell computing times of the
different models were determined by simulation of 1000 s with a BCL of 1 s
on Mac OSX 10.7 (Apple Inc., Cupertino, CA) with a 2.7GHz Intel Core i7
and 8GB RAM. In this case, no results were written to hard disk to avoid
unwanted delays.
5.2 Model of Electrical Remodeling due to Chronic AF
As described in section 2.3.1, processes changing the expression and func-
tionality of ion channels and gap junctions occur during cAF. This is called
electrical remodeling. Table 5.1 summarizes the changes of ion channel con-
ductivities, which were considered in this work. These changes were inte-
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Table 5.1. Change of ion channel conductivities (% of original value) describing electrical re-
modeling due to cAF.
conductivity gto gKur gCaL gK1
change −65% −49% −65% +110%
source [46] [46] [45] [47]
grated into the ﬁve models of human atrial electrophysiology in order to
assess, which of them is most suitable for the simulation of cAF. Further-
more, gap junctional remodeling was considered by reduction of the intra-
cellular tissue conductivity by 30% in tissue simulations of cAF as presented
in [175].
In order to investigate the effects of cAF, various electrophysiological prop-
erties were analyzed. After 50 s paced with a BCL of 1 s, the AP amplitude
and durations (APD50 and APD90), maximum upstroke velocity dV/dtmax,
as well as the resting membrane voltage Vm,rest of the control and cAF mod-
els were compared. The stimulus amplitudes were adapted model speciﬁc,
so that they were twice the threshold amplitude, which was needed to ini-
tiate APs. Additionally, the restitution curves of the APD90, ERP, CV and
wave length (WL, see also section 7.4.2 for further explanation) of the con-
trol and cAF models were determined in a 1D tissue strand of 200× 1× 1
cubic voxels (size 0.1mm). The models were paced for 50 beats in a single-
cell environment with varying BCL between 0.2 and 1 s. After this phase of
initialization, all single-cell variables were transferred to a tissue simulation
environment. Then, ﬁve beats were computed in tissue with stimulus ampli-
tudes 20% above threshold amplitude. Furthermore, model-speciﬁc values
for the isotropic tissue conductivity were deﬁned, so that a CV of approx-
imately 750mm/s was obtained in the control case at a BCL of 1 s. The
restitution properties were evaluated at the last beat in tissue and only, if all
previous beats initiated APs [13].
5.3 Modeling Genetic Defects Favoring AF
Section 2.3.2 described that genetic defects of cardiac ion channels are
known to favor AF. In this work, the impact of mutations of the KCNA5
gene, which encodes IKur, was investigated. The whole-cell patch clamp
recordings of WT and three mutations of this channel (A576V, E610K and
T527M) known to be associated with AF [176] were provided by the Uni-
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versity Hospital Heidelberg. The chinese hamster ovary (CHO) cells used
for this purpose were cultured in minimum essential medium α in an atmo-
sphere of 95% humidiﬁed air and 5% CO2 at a temperature of 37◦C. This
medium was supplemented with 100 μg/ml streptomycin sulphate, 10% fe-
tal bovine serum and 100U/ml penicillin G sodium. Prior to treatment, the
CHO cells were passaged regularly and subcultured. Fugene (PROMEGA,
Madison, USA) transfection reagent was used for transient transfections
of the CHO cells according to the manufacturer’s instructions. The same
amount of DNA (3 μg per bowl) was used for this purpose. The patch clamp
recordings were performed at a temperature of 37◦C. The pipette solution
contained 100mM K aspartate, 20mM KCl, 2mM MgCl2∗6H2O, 1mM
CaCl2∗2H2O, 10mM HEPES, 10mM EGTA and 2mM Na2ATP. The pH
value of the pipette solution was adjusted to 7.2 using KOH. The bathing so-
lution consisted of 140mM NaCl, 5mM KCl, 1mM MgCl2∗6H2O, 1.8mM
CaCl2∗2H2O, 10mM HEPES and 10mM glucose monohydrate. NaOH was
used to adjust the pH of the bathing solution to 7.4.
The current traces of the WT and mutated channels and the corresponding
clamp protocol are shown in Fig. 9.6. The adaptation of the model of IKur
to the patch clamp data was carried out using the methods introduced in
chapter 4.
The current formulation of the Courtemanche model with the 24 adjustable
parameters (blue, red) was:
IKur = gKuru3aui(V −EK) (5.1)
gKur = gKur1+
gKur2
1+ exp
(
V+gKur3
gKur4
) (5.2)
EK =
RT
F
log
[K+]o
[K+]i
(5.3)
αua = uaa1
[
exp
(
V +uaa2
uaa3
)
+ exp
(
V +uaa4
uaa5
)]−1
(5.4)
βua = 0.65
[
uab1+ exp
(
V +uab2
uab3
)]−1
(5.5)
τua = [uaKQ10(αua+βua)]−1 (5.6)
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ua∞ =
[
1+ exp
(
V +uam1
uam2
)]−1
(5.7)
αui =
uia1
uia2+ exp
(
V+uia3
uia4
) (5.8)
βui =
[
exp
(
V +uib1
uib2
)]−1
(5.9)
τui = [uiKQ10(αui+βui)]−1 (5.10)
ui∞ =
[
1+ exp
(
V +uim1
uim2
)]−1
(5.11)
uaKQ10 and uiKQ10 were the temperature correction factors, the temperature
T was 310K and the intracellular potassium concentration [K+]i was con-
stant. The gating variables ua and ui were determined using the analytical
solution of the ODE described in equation (4.8). After the adjustment of the
parameters within deﬁned ranges as speciﬁed in Table 5.2, the resulting pa-
rameter sets were used to calculate relative changes between the data of mu-
tated and WT channels. For this purpose, the relative changes of the parame-
ters pmod, which appeared in a sum (blue) or which were multiplied/divided
(red), were determined as follows:
pmod,sum = (pmutation− pWT )+ pcontrol (5.12)
pmod,mult =
pmutation
pWT
· pcontrol (5.13)
In this way, parameter changes due to the experimental settings during the
patch clamp measurements were canceled out and only the changes due to
the mutations remained. Consequently, three parameter sets reﬂecting the
relative changes due to the mutations A576V, E610K and T527M were com-
pared to the control model in multiscale simulations. As described in sec-
tion 5.2, the effects of the mutations on the APs were investigated in the
single cell and on the restitution properties in the 1D tissue patch.
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Table 5.2. Ranges of the adjustable parameters of the ultra-rapid delayed rectiﬁer current for the
adaptation to patch clamp recordings of WT and mutated channels. For the adaptation to data
of the mutated channels, the boundaries of the temperature correction factors uaKQ10 and uiKQ10
were ﬁxed to the values resulting from the adaptation to the data of WT channels, as the same
measurement conditions were assumed. The lower boundaries of gKur1 and gKur2 were set to
the values of the WT adaptation to prevent negative conductivity values after the calculation of
relative changes.
parameter original WT mutations
lower upper lower upper
uaa1 0.65 6.5E-3 65 6.5E-3 65
uaa2 10 −100 80 −100 80
uaa3 −8.5 −100 −1 −100 −1
uaa4 −30 −100 80 −100 80
uaa5 −59 −100 −1 −100 −1
uab1 2.5 0.25 25 0.25 25
uab2 82 −60 140 −60 140
uab3 17 1 100 1 100
uam1 30.3 −100 80 −100 80
uam2 −9.6 −100 −1 −100 −1
uaKQ10 3 0.01 100 29.65 29.66
uia1 1 0.01 100 0.01 100
uia2 21 0.21 2100 0.21 2100
uia3 −185 −230 −50 −230 −50
uia4 −28 −100 −1 −100 −1
uib1 −158 −200 −20 −200 −20
uib2 −16 −100 −1 −100 −1
uim1 −99.45 −150 30 −150 30
uim2 27.48 1 100 1 100
uiKQ10 3 0.01 100 0.0111 0.0112
gKur1 0.005 5e-5 5E2 68.9702 5E2
gKur2 0.05 5e-4 5E3 119.757 5E3
gKur3 −15 −100 80 −100 80
gKur4 −13 −100 −1 −100 −1
5.4 Initiation of Functional Reentries in 2D Atrial Tissue
Patch
For the investigation of AF in atrial tissue simulations, reentrant circuits were
initiated in 2D tissue patches of 1000×1000×1 cubic voxels (size 0.1mm).
For this purpose, the models were initialized for 50 beats in a single-cell en-
vironment paced at a short BCL (0.4 s). In this way, the APs and underlying
processes of the models could adapt to the high pacing frequency. Then, one
side of the patch was stimulated ﬁve times at the same BCL of 0.4 s. After
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10 ms 210 ms 310 ms 370 ms
Figure 5.1. Exemplary initiation of rotor in a 2D atrial tissue patch using the electrically re-
modeled Courtemanche model. At ﬁrst, regular stimulus lines were placed at one side of the
patch with a high BCL (e.g. 0.4 s) to create planar wave fronts. A following cross-ﬁeld stimulus
perpendicular to the original excitation wave was placed at the wave back (t = 210ms). After
310ms, the excitation wave followed the re-excitable tissue around the stimulated area, which
was excited again in the following (t = 370ms). Stimulus sites are highlighted by dashed lines.
TMV: transmembrane voltage.
the initiation of the last regular excitation wave, a cross-ﬁeld stimulus was
placed (compare Fig. 5.1), when the wave back reached the center of the
patch. In this case, the stimulated area was a rectangle reaching from the
previous stimulation site to the transition of still refractory and re-excitable
tissue in direction of the regular excitation wave. Perpendicular to the di-
rection of the regular excitation wave, the stimulus was smaller than half of
the width of the tissue patch, so that the new excitation wave could move
in direction of the re-excitable tissue. In the exemplary cross-ﬁeld (S1–S2)
protocol shown in Fig. 5.1, the new excitation wave had entered the area of
the cross-ﬁeld stimulus after 370ms creating a rotor.
5.5 Detection of Rotor Centers
For the analysis of reentrant circuits, an algorithm for the automatic detec-
tion of rotor centers in a 2D tissue patch was implemented. It was based
on the algorithm of Bray et al. [177] from 2001. This algorithm, which can
also be extended to determine ﬁlaments in 3D tissue [178], is based on the
calculation of the topological charge nt :
nt =
∮
c
∇Θ ·dc. (5.14)
This is the line integral of the gradient of the phase Θ along a closed path
c, as comprehensively described in e.g. [179]. If the transmembrane voltage
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Figure 5.2. Detection of rotor centers in a 2D tissue patch. The phase Θ (B) was calculated
using two consecutive transmembrane voltage Vm distributions (A). The topological charge nt
(D), which was nearly zero except for the phase singularity, was then computed as the curl of the
gradient of Θ (C).
distributions are transformed into the phase space, a rotor center can be inter-
preted as a point, in which all phases meet, a so-called phase singularity. In
this case, the phase was computed using two consecutive TMV distributions,
as also exemplarily shown in Fig. 5.2:
Θ(x,y, t) = atan2[Vm(x,y, t+ τ)−V ∗m, Vm(x,y, t)−V ∗m], (5.15)
with τ being the time increment between two consecutive TMV distributions
(typically τ = 1ms) and V ∗m = −40mV the origin of the phase. Since the
algorithm was based on the phase, it was independent of e.g. the amplitude of
the APs, which can vary depending on the model used. Then, the gradient of
the discretized phase Θ [m,n, t] was approximated using forward differences
kx[m,n, t] and ky[m,n, t]:
kx[m,n, t] =Θ [m+1,n, t]−Θ [m,n, t] (5.16)
ky[m,n, t] =Θ [m,n+1, t]−Θ [m,n, t]. (5.17)
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However, since the values of the phase gradually increased from −π to π ,
phase jumps at the transition to −π occurred, which would have been in-
terpreted as a discontinuity in phase. Therefore, phase jumps greater than
π were compensated by conversion to the 2π complement as described
in [178]. Afterwards, the line integral was determined by calculation of the
curl of the gradient, which was nearly zero except for the phase singularity,
i.e. the rotor center. However, post-processing as mentioned in [180] was
necessary, e.g. due to the discretization of the TMV distributions. This dis-
cretization was responsible for blurring of the phase singularity, i.e. the value
of nt deﬁned by equation (5.14) gradually decreased around the phase sin-
gularity to nearly zero. Consequently, a threshold of the absolute vale of nt
was deﬁned. The rotor center was then determined as the local maximum of
the values above the threshold.
5.6 Pseudo-ECG and Dominant Frequency
As the dominant frequency (DF) is correlated with the persistency of AF,
i.e. high DFs indicate more persistent forms of AF [181], this measure was
determined to quantify the arrhythmic potency of the models of AF. For this
purpose, pseudo-ECGs of the 2D rotor simulations were computed ﬁrst. The
electric potential Φ within an inﬁnite medium with homogeneous conduc-
tivity was used as described in e.g. [182]:
Φ(x′,y′,z′, t) =
1
4πσ
∫ Iv(x,y,z, t)
r(x,y,z,x′,y′,z′)
dxdydz, (5.18)
where σ is the electrical conductivity, Iv is the intercellular current density
and r is the distance between the current source and a virtual measurement
electrode. To obtain a pseudo-ECG, the difference between the potentials at
two virtual electrodes was determined for a series of time steps t:
pECG= Φ(x1,y1,z1, t)−Φ(x2,y2,z2, t). (5.19)
The electrodes were placed 5mm above the center of the 2D patch with a
distance of 10mm between each other. Afterwards, the power spectral den-
sity of the derived signal was computed using the fast Fourier transform for
spectral analysis. The frequency with the highest peak is called DF [181].

6Modeling Effects of Acute Cardiac Ischemia
This chapter describes the methods necessary for multiscale simulations of
the effects of acute cardiac ischemia introduced in section 2.4 ranging from
single cells up to the body surface ECG. The main effects of different stages
of acute cardiac ischemia were integrated into an electrophysiological model
of a healthy ventricular myocyte. Furthermore, regional heterogeneities de-
pending on the occlusion site and transmurally varying ischemia effects were
considered during tissue simulations. Cellular uncoupling during phase 1b
was considered in the forward calculation of ECGs. The corresponding re-
sults are presented in chapter 10.
6.1 Model of a Cardiac Myocyte at Different Ischemia Stages
The effects of the ﬁrst thirty minutes of acute ischemia were integrated into
the electrophysiological model of ventricular myocytes of ten Tusscher and
Table 6.1. Parameter values of the model of ventricular myocytes at different stages of acute
cardiac ischemia as shown in [16, 17].
model parameter control stage 1 stage 2 phase 1b
0 min 5 min 10 min 20–30 min
[K+]o (mmol/l) 5.4 8.7 12.5 15.0
gNa, gCaL (%) 100 87.5 75 50
dVm,Na (mV) 0 1.7 3.4 3.4
[ATP]i (mmol/l) 6.8 5.7 4.6 3.8
[ADP]i (μmol/l) 15 87.5 99 101.5
kNaCa (%) 100 100 100 20
PNaK (%) 100 100 100 30
Vrel (%) 100 100 100 5
Vmaxup (%) 100 100 100 90
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Panﬁlov [127] with modiﬁcations of Weiss et al. [148]. This altered model
had e.g. an additional ATP sensitive potassium channel IK,ATP and repro-
duced the main effects of phase 1a ischemia – hypoxia, hyperkalemia and
acidosis – dynamically depending on the time elapsed since the occlusion
of the coronary vessel. The parameters that changed over time were set to
certain values according to table 6.1 at different stages shown in Fig. 2.6.
A linear interpolation of the values in between allowed for a dynamic com-
putation of the temporal changes. For the representation of hyperkalemia,
the extracellular potassium concentration [K+]o was increased. Acidosis was
considered in the simulations by a reduction of the conductivities gNa and
gCaL and a shift of the voltage dependence of the sodium channels dVm,Na.
The reduction of the intracellular ATP concentration [ATP]i and the increase
of [ADP]i reﬂected the effects of hypoxia.
In this work, the formulation of IK,ATP was modiﬁed, since this current is
inhibited by physiological concentrations of ATP [60]. For this purpose, the
half maximum inhibition constant Km was adjusted:
Km = (−151.0919+75.5379 · [ADP]0.256i ) ·Km, f actor (6.1)
As in [148], the value of Km, f actor varied in endocardial, M and epicar-
dial myocytes reﬂecting the different sensitivities of these cell types to a
lack of ATP and an increase of ADP [68]. The existing model was ex-
tended by adding parameter sets of the altered model parameters for phase
1b (20− 30min after occlusion) according to Pollard et al. [141]. Further-
more, the values of kNaCa, PNaK , Vrel and Vmaxup were reduced in this later
stage of ischemia [141]. Acidosis was responsible for the reduction of kNaCa,
whereas hypoxia led to decrease of PNaK , Vrel and Vmaxup after 20− 30min
of ischemia [142]. In this way, the impact of ischemia on ionic pumps and
exchangers, as well as the intracellular calcium handling was considered. In
contrast to [141], modiﬁcations of IbCa and the nonselective calcium sensi-
tive cation current Ins,Ca were not implemented, since the effects could be
neglected and the latter current was not part of the ten Tusscher model, re-
spectively. All parameter changes due to acute cardiac ischemia are summa-
rized in table 6.1.
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6.2 Modeling Ischemic Tissue
As already described in section 3.3, an anatomical model of the ventricles
was derived from magnetic resonance images of a healthy volunteer in a pre-
vious work [163]. In order to model the effects of acute cardiac ischemia in
the ventricles, the main coronary arteries were segmented. For this purpose,
a seed point was set in the aorta, which had the same intensity in the MR
image as the coronary arteries, since they were ﬁlled with blood. The region
growing method, which iteratively looks for values with similar intensity
within deﬁned thresholds in a neighborhood, was then used for the segmen-
tation of the LCx and the LAD (see also Fig. 6.2). However, the RCA could
not be identiﬁed in the MR images due to the limited resolution. Based on
these ﬁndings, models of heterogeneous ischemia effects could be created
and occlusion of these vessels could be reproduced.
6.2.1 Heterogeneous Ischemic Tissue
In order to simulate transmurally varying ischemia effects, the ventricular
wall was divided into 20% epicardial, 40% midmyocardial and 40% endo-
cardial tissue, as presented in section 3.3. Consequently, the sensitivity of
IK,ATP to changes of [ATP]i and [ADP]i was increased from endocardial to-
wards epicardial tissue.
As presented in [148], the ischemic regions and the inﬂuence of the distance
to the occluded coronary artery on the effects of ischemia were modeled us-
ing a so-called zone factor (ZF). It varied between 0 indicating healthy tissue
in the normal zone (NZ) and 1, which represented the CIZ, where ischemia
effects were most severe. A BZ was located between both zones with a grad-
ual increase of the severity of ischemia effects towards the CIZ. Furthermore,
the course of the different ischemia effects hypoxia, hyperkalemia and acido-
sis varied across the BZ (see Fig. 6.2). After only 10% of the BZ, the effects
of hypoxia were fully present, whereas the effects of hyperkalemia linearly
increased across the entire BZ. The effects of acidosis started at 50% of the
BZ and then underwent a linear course towards the CIZ [148].
In case of phase 1b ischemia 20− 30min after the occlusion of a coronary
artery, the tissue conductivity was linearly reduced to 12.5% of the normal
value towards the CIZ [143]. In this way, cellular uncoupling due to reduced
gap junctional conductance was modeled.
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Figure 6.1. Creation of ellipsoidal ischemic regions in the concave ventricular wall. Two points
P1 and P2 are set manually (A). On a plane perpendicular to the vector
−−→
P1P2, the point E on the
endocardial surface with the shortest distance to the midpoint M of this vector is searched (B).
The radius r1 of the ellipsoid, which is placed afterwards, deﬁnes the transmural extent of the
ischemic region. Iterative erosion of the ellipsoid leads to the incremental course of the ZF across
the BZ (C). Only the overlapping parts of the ellipsoids with the ventricles remain (D).
6.2.2 Creation of Ellipsoidal Ischemic Regions
The ischemic regions modeled in this work were shaped as ellipsoids, so that
the main axis of the ellipsoid reﬂected the course of the coronary artery that
should be occluded. Furthermore, two radii deﬁned the transmural extent
and the size of the ischemic region.
For the creation of the ellipsoidal ischemic region, which had to be ro-
tated in the coordinate system and aligned to the endocardial surface, a
semi-automatic algorithm was implemented. Two points P1(x1,y1,z1) and
P2(x2,y2,z2) were manually set at the endocardial surface deﬁning the main
axis
−−→
P1P2 of the ellipsoid (compare Fig. 6.1). The algorithm creating the el-
lipsoidal ischemic region required a concave ventricular wall between both
points. The midpoint M(xm,ym,zm) of
−−→
P1P2 was computed deﬁning the center
of the ellipsoid. Then, a plane perpendicular to
−−→
P1P2 with M(xm,ym,zm) be-
ing on the plane was deﬁned. The intersection point E(xe,ye,ze) of this plane
with the endocardial surface, which had the shortest distance toM(xm,ym,zm),
was determined afterwards. The vector
−−→
ME deﬁned the second axis of the
ellipsoid and the radius r1 determined the transmural extent. The radius r2
deﬁned the length of the third axis of the ellipsoid perpendicular to
−−→
P1P2
and
−−→
ME. An ellipsoid speciﬁed by the center and the three perpendicular
axes was set in the ventricular model describing the maximal extent of the
ischemic region. Afterwards, iterative erosion of the ellipsoid was used to
create the gradual increase of the ZF towards the CIZ. The number of ero-
sion steps deﬁned the width of the BZ and also the increments of the ZF
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Figure 6.2. Ischemic zones in a model of the human ventricles describing an occlusion of the dis-
tal LAD. The transmural extent of the ischemic region was gradually increased from subendocar-
dial (1) to completely transmural (10). The course of the ischemia effects hypoxia, hyperkalemia
and acidosis varied across the BZ. Modiﬁed according to [17].
across the BZ. Finally, the parts of the ellipsoids, which did not overlap with
the ventricular wall, were removed. In this way, ischemic regions describing
the inﬂuence of the distance to the occlusion on the ischemia effects could
be modeled.
In this work, the severity of the occlusion of the distal LAD was investigated.
In Fig. 6.2, ten setups with varying transmural extent and radius r1 of the
ischemic regions, respectively, are presented. The radius r2 was set to 12mm
in all cases. In the different setups, the endocardial surface of the ischemic
regions was the same in all cases, only the volume of the affected tissue
increased from subendocardial (1.36%) to transmural ischemia (3.83% of
the volume of the left ventricle). The width of the BZ was set to 4mm in
all cases. The different stages of acute cardiac ischemia were initialized in
a single-cell environment ﬁrst. Afterwards, the excitation propagation in the
ventricles was simulated during one cardiac cycle with a duration of 450ms.
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6.2.3 Forward Calculation of ECGs under the Inﬂuence of Ischemia
In case of phase 1a ischemia, the BSPMs and ECGs resulting from simula-
tions of ischemia in the ventricles were forward calculated as described in
section 3.3. However, the intracellular conductivities in the ischemic regions
were reduced in case of phase 1b ischemia, as in the simulations of cardiac
excitation propagation. For this purpose, high resolution tetrahedral torso
models for each of the ischemia regions were created, since the intracellular
conductivities in these regions differed from the healthy ones.
7Modeling the Impact of Pharmacological Therapy
on Cardiac Electrophysiology
The methods used for the investigation of the effects of three different phar-
macological agents on cardiac electrophysiology are described in this chap-
ter. The inhibition of certain ion channels due to the three compounds amio-
darone, dronedarone and cisapride is delineated ﬁrst. The effects of these
drugs were investigated in multiscale simulations of control and electrically
remodeled atrial, as well as in control and ischemic ventricular myocytes
and tissue. Then, different markers used for the quantitative assessment of
the antiarrhythmic potency of the drugs, as e.g. the vulnerable window, are
presented. The corresponding results can be found in chapter 11.
7.1 Modeling Effects of Amiodarone
In section 2.5.2, an introduction to the effects of the class III multichannel
blocker amiodarone was already given. The cardiac ion channels, which are
affected by this drug, are summarized in Table 2.3. As noted in [87], the
range of therapeutic concentrations of amiodarone is between 1 and 3 μM.
Therefore, these two concentrations were used as low and high concentra-
Table 7.1. Reduction of ion channel conductivity (% of original value) due to antiarrhythmic
agent amiodarone. Low concentration: 1 μM, high concentration: 3 μM.
conductivity (%) setup 1 setup 2
low high low high
gNa 58.33 31.82 58.33 31.82
PNaK 93.98 83.87 93.98 83.87
gKr 42.80 15.21 5.09 1.58
gKs 80.20 69.50 80.20 69.50
gCaL 85.29 65.91 46.12 39.15
kNaCa 76.74 52.38 76.74 52.38
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tions for the simulation of the effects of amiodarone. With the help of the
IC50 and nH values given in Table 2.3, the reduction of the maximal ion
channel conductivities resulting from both concentrations could be com-
puted using equation (2.3). Since the reported values of IKr and ICal var-
ied in literature [79, 80, 82, 83], two setups representing different inhibition
of the channels were generated. The resulting reductions of the maximal
ion channel conductivities are summarized in Table 7.1. PNaK and kNaCa are
the maximal NKA and NCX currents, respectively. Since amiodarone is rec-
ommended as a treatment option in case of myocardial ischemia [85] and
AF [86], the inﬂuence on both pathologies was simulated in this work. For
the simulation of the impact of amiodarone on atrial electrophysiology, the
control and electrically remodeled Courtemanche model described in sec-
tion 5.2 was adapted accordingly. The modiﬁed ten Tusscher model de-
scribed in section 6.1 was adapted to simulate the drug effects in control
and ischemic ventricular myocytes and tissue. The inﬂuence of amiodarone
on ischemia was investigated only at 5min after the onset of effects, since
no excitation could be initiated in epicardial ischemic tissue after this stage.
Ischemia effects were initialized in a single-cell environment ﬁrst. In or-
der to investigate the impact of amiodarone on the simulated body surface
ECGs, only the control ventricular model was used, since the heterogeneous
ischemia effects, which vary spatially and also temporally (compare chap-
ter 10), would superimpose the drug effects.
7.2 Modeling Effects of Dronedarone
As described in section 2.5.3, dronedarone is also a multichannel blocker
similar to amiodarone mainly used for the treatment of AF [104]. The ion
currents, which are inhibited by dronedarone, are summarized in Table 2.4.
Table 7.2. Reduction of ion channel conductivity (% of original value) due to antiarrhythmic
agent dronedarone. Low concentration: 150 nM, high concentration: 270 nM.
conductivity (%) low high
gNa 93.12 80.37
gKr 32.19 22.88
gKs 86.31 82.38
gKur 86.96 78.74
gCaL 99.10 95.61
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As no information on the peak plasma concentration of dronedarone was
available, the reported steady state plasma concentration between 150 and
270 nM [105] was used instead. With the low and high concentrations and
the reported IC50 and nH values given in Table 2.4, the inhibitions of the
maximal ion channel conductivities could be computed using equation (2.3).
The resulting changes of the conductivities affected by dronedarone are
listed in Table 7.2. These changes were integrated into the control and elec-
trically remodeled Courtemanche model (compare section 5.2). In this way,
the impact of dronedarone on cAF could be investigated in multiscale simu-
lations ranging from the single cell up to 2D tissue patches.
7.3 Modeling Effects of Cisapride
Although cisapride was used as a gastroprokinetic agent (compare sec-
tion 2.5.4), it also has an impact on cardiac IKr as shown in Table 2.4. The
peak plasma concentration of cisapride ranged between 150 and 300 nM [110].
However, the effective concentration of cisapride inhibiting the ion channels
was much lower, since more than 95% was bound to plasma proteins [107].
Consequently, the determined effective concentrations as well as the IC50
and nH values presented in Table 2.4 were used for the computation of the
reduction of the maximal ion channel conductivities. Since cisapride pro-
longed the QT interval and caused torsades de pointes [109], its impact on
ventricular electrophysiology was investigated in this work. For this pur-
pose, the reductions of gKr were integrated into the modiﬁed ten Tusscher
model described in section 6.1. As it exhibited similar QT prolongation as
amiodarone, cisapride was compared to this antiarrhythmic drug.
Table 7.3. Reduction of ion channel conductivity (% of original value) due to gastroprokinetic
agent cisapride. Low concentration: 150 nM, high concentration: 300 nM.
conductivity (%) low high
gKr 71.44 58.97
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Figure 7.1. Detection of the vulnerable window, during which a unidirectional block can be initi-
ated, using a 1D tissue strand. Depending on the stimulus time of the premature stimulus 2, three
different effects could be observed: bidirectional block if the stimulus was applied too early, bidi-
rectional conduction if the stimulus was too late, and unidirectional block during the vulnerable
window.
7.4 Markers of Antiarrhythmic Potency of Pharmacological
Agents
For the assessment of the antiarrhythmic potency of pharmacological agents,
several markers, which try to quantify the ability of a compound to prevent
or terminate rhythm disorders or to even promote them, exist. Some of the
markers introduced in this section, as e.g. the vulnerable window (VW) or
the WL, are of rather theoretical nature and are determined in computational
studies mainly, whereas other markers are also used in clinical trials, as e.g.
the QT interval.
7.4.1 Automatic Detection of the Vulnerable Window
Unidirectional blocks, which cause retrograde excitation propagation due to
a premature stimulus at a wave back, are a necessary condition for reen-
trant circuits. The VW describes the spatio-temporal window, during which
a uni-directional block can be initiated. The width of the VW indicates, how
probable the initiation of a reentrant circuit is [183]. On the one hand, the
site of the premature stimulus can be varied within a certain range and on
the other hand, the time of stimulation causing a unidirectional block also
varies within a speciﬁc interval. The VW can either be determined in a 2D
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tissue patch as e.g. in [184], in which reentrant circuits were initiated, or
more simplistic in a 1D tissue strand, as introduced in [183].
In this study, the VW was determined in a 1D tissue strand consisting of
400× 1× 1 voxels with a side length of 0.1mm in case of atrial tissue and
0.2mm in case of ventricular tissue, as shown in Fig. 7.1. At ﬁrst, the mod-
els were initialized in a single-cell environment and then, four regular beats
were initiated at the ﬁrst three voxels of the 1D ﬁber (stimulus 1). Then,
a premature stimulus was applied at the center of the tissue strand (stimu-
lus 2), i.e. only the stimulus time was varied in this work, so that the VW
described the time interval, during which unidirectional blocks could be ini-
tiated. Depending on the stimulus time, three different effects could be ob-
served at two sensor sites. If the stimulus was applied too early, i.e. the tissue
was completely refractory at the stimulus site, the premature stimulus was
blocked in both retrograde and antegrade direction causing a bidirectional
block. However, a second activation could be seen in both sensors, if the
stimulus was applied too late, so that the stimulus site was completely ex-
citable again (bidirectional conduction). In between both cases, the prema-
ture stimulus caused a retrograde excitation propagation only. The algorithm
implemented in this work for the detection of the VW iteratively increased or
decreased the stimulus time depending on the result of the previous prema-
ture stimulation. In this way, an upper limit of the stimulus time, after which
bidirectional conduction occurred, and a lower limit, before which bidirec-
tional block was observed, could be determined. The VW was deﬁned as the
interval in between, during which unidirectional blocks could be initiated.
7.4.2 Other Markers of Antiarrhythmic Potency
In addition to the VW, further markers, which indicate if a pharmacological
agent has anti- or proarrhythmic properties, were investigated in this study.
Slope of the APD Restitution Curve
The slope of the APD or CV restitution is assumed to contain information on
the probability of the initiation of ﬁbrillation in tissue. This so-called resti-
tution hypothesis states that steep slopes of the restitution curves (>1) cause
oscillations of the WL. Due to this, wave breaks occur leading to chaotic
excitation propagation patterns [185]. Consequently, ﬂattening of the APD
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restitution is assumed to be antiarrhythmic [186]. In this study, the slope of
the APD90 restitution was investigated at different diastolic intervals.
Wave Length
The wave length reﬂects the distance, which an excitation wave propagates
during the refractory period, i.e. the WL determines the minimal distance
between two consecutive wave fronts. Therefore, also the shortest possible
path of a reentrant circuit is described by this measure of length. If the dis-
tance traveled by the excitation wave is smaller than the WL, the wave front
collides with still refractory tissue and is eliminated afterwards. Since the
WL inﬂuences the area occupied by a rotor, it is an indicator of the mainte-
nance of rotors and gives an estimate of the maximal number of rotors in a
deﬁned area. Unphysiological changes of the WL promote the maintenance
of reentrant circuits. The WL was calculated as the product of ERP and CV,
which were determined as described in section 5.2, at different DIs.
Termination of AF
In case of simulations of cAF, the reaction of rotors to administration of
drugs was tested in a 2D tissue patch. For this purpose, a stimulation proto-
col as described in section 5.4 was used to initiate four stable rotors in the
electrically remodeled Courtemanche model. After the cross-ﬁeld stimulus,
two further stimuli at the wave backs of the reentrant circuits were applied
to initiate additional rotors. Then, the resulting excitation propagation and
the rotor trajectories (see section 5.5) were observed for 5 s. Furthermore,
the dominant frequency was determined using pseudo-ECGs as described in
section 5.6. This procedure was repeated, but after the initiation of the ro-
tors, the effects of the pharmacological agents were included. In this way,
the changes of the rotor trajectories, as well as the DFs could be compared
between the different compounds and the cAF model alone.
QT Interval
The impact of pharmacological agents on ventricular electrophysiology
could not only be investigated in the heart, but also on the body surface by
forward calculation of ECGs, as described in section 3.3. Since some non-
antiarrhythmic drugs were known to cause torsades de pointes, which was
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accompanied by a prolongation of the QT interval, this interval was intro-
duced as a marker of cardiotoxicity [187]. The QT interval was determined
as the time between the onset of the QRS complex and the end of the T
wave. In this study, the onset of the QRS complex was deﬁned by the endo-
cardial stimulation proﬁle, which initiated ventricular excitation propagation
at t = Qonset = 0ms. Since the simulated ECG signals did not contain any
measurement noise, a simple threshold voltage (Vthresh = 0.01mV) could be
used for the detection of Tend.

Part III
Results

8Results: Parameter Adaptation of
Electrophysiological Models
In this chapter, the results of the parameter adaptation of models of cardiac
ion currents as described in chapter 4 are presented. At ﬁrst, two methods
for the solution of ODEs describing the gating of cardiac ion channels were
investigated. Then, three different optimization algorithms for the minimiza-
tion of the difference between simulated and measured ion currents were
tested and compared alone as well as in combination. The ability of the al-
gorithms to reconstruct known parameter values was assessed with synthetic
ion current data and they were tested with different data of mutated ion chan-
nels. Finally, the sensitivity of the function to be minimized to changes of the
adjustable parameters was analyzed.
8.1 Computing Times of Analytical and Numerical Solution of
ODEs
The ODE (4.7) could be solved either analytically, since the transmembrane
voltage was a piecewise constant function during the voltage clamp pro-
tocols used in this work, or numerically, which is the standard method in
computational cardiology. The accuracy of the numerical approximation de-
pends on the time step and error tolerances of the underlying ODE solver,
which are speciﬁed in section 4.3. Therefore, only the computing times of
both solution methods were compared in this work. They were measured
with a 2.4GHz Intel Xeon E5645 and 64GB RAM under Mac OSX 10.7
(Apple Inc., Cupertino, CA, USA). The computing times of 1000 evaluations
of the function to be minimized in equation (4.9) using the analytical or nu-
merical solution were averaged and compared. One function evaluation took
on average 0.35ms in case of the analytical solution and 1.11 s in case of
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Figure 8.1. Box plots of the least squares before (A) and after the optimization using the TRR
algorithm (B) resulting from 50 experiments with random initial parameter values. The corre-
sponding computing times are shown in (C). The horizontal lines in the boxes, which surround
the ﬁrst and third quartiles, indicate the medians of the plotted data sets. The whiskers mark the
most distant points within a range of 1.5 times the interquartile range. Plus signs indicate outliers.
the numerical approximation. As a consequence, only the analytical solution
was used for the following optimizations due to the more than 3000 times
smaller computing time of this method.
8.2 Test of Single Optimization Algorithms
Initially, each of the three optimization algorithms introduced in section 4.4
was investigated alone using the WT hERG measurement data described in
section 4.1. Since the derivative-free PSO and GA, which were implemented
in this work, had several parameters to be adapted, as e.g. the number of
particles or iterations, different settings were tested ﬁrst before comparing
the algorithms.
8.2.1 Trust-Region-Reﬂective Algorithm
The results of 50 optimization experiments using the TRR algorithm with
random initial parameter sets within the ranges deﬁned in Table 8.1 are
presented in Fig. 8.1. Before optimizing the parameters, the median least
squares of the initial parameter sets was 1.497e12 and the outliers lay in
a range from 1719.9 up to 6.636e13 (compare Fig. 8.1A). After the opti-
mization using the TRR algorithm, the median least squares was reduced
to 1256.6 and the variation of the resulting least squares was also reduced,
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Figure 8.2. Least squares of the PSO algorithm with varying number of iterations (A) and par-
ticles (B) resulting from 50 experiments with random initial parameter values. The number of
particles was set to N = 1536 in (A) and the number of iterations to 2000 in (B). Deﬁnition of
box plots as in Fig. 8.1. Modiﬁed according to [12].
as shown in Fig. 8.1B. The computing time presented in Fig. 8.1C exhib-
ited great variations depending on the initial parameter set with a median
of 2.3 s. In all cases, the TRR algorithm stopped before the maximum num-
ber of iterations or function evaluations was reached, since the value of the
function to be minimized ﬁnally changed by less than 1e−11, as deﬁned in
section 4.4.1. Therefore, the maximum number of iterations was sufﬁcient
allowing convergence of the optimization algorithm.
8.2.2 Adaptation of the Particle Swarm Optimization Algorithm
In case of the PSO algorithm, the number of iterations and particles N was
varied in 50 experiments with random initial parameter values each to adapt
the algorithm to the optimization problem (Fig. 8.2). The purpose of this
adaptation was to ﬁnd a combination, which on the one hand led to satisfac-
tory adjustment of the parameters of the ion current model by minimizing
the difference between simulated and measured current traces. On the other
hand, a computing time as small as possible should be reached. In Fig. 8.2A,
the number of iterations was increased from 10 to 10000, while the num-
ber of particles N was set to 1536. After 10 iterations, the median least
squares was 1290.3, whereas it was reduced to 18.1 after 10000 iterations.
The largest variance of the least squares could be observed around 100 iter-
ations. Since the computer used for the analysis of computing times had 12
cores, the number of particles was increased in multiples of 24 in Fig. 8.2B
to facilitate parallelizing the computation of the different particles per iter-
ation. The number of iterations was set to 2000. Starting with 24 particles,
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minimum (B) of the GA resulting from 10 experiments with random initial parameter values.
The probabilities pmutation and pcrossover, as well as the relation of alphas to remaining parameter
sets were varied. The number of parameter sets was set to N = 1026 and the number of iterations
to 2000. Modiﬁed according to [12].
a median least squares of 1030.3 with greatest variance was obtained. The
median, as well as the variance, were reduced towards increasing number of
particles. The median least squares was 18.7 in case of 12288 particles.
For the further use of the PSO algorithm, the number of particles was set to
1536 and the number of iterations to 2000, which was a compromise between
the quality of the adaptation and the resulting computing time. A higher
number of particles or iterations caused only a negligible improvement of
the resulting least squares, whereas the computing time was increased by the
factor of the increase of the number of particles and iterations.
8.2.3 Adaptation of the Genetic Algorithm
In case of the GA, the probabilities pmutation and pcrossover, as well as the rela-
tion of alphas to the number of remaining parameter sets were adjusted ﬁrst.
Then, the number of iterations and parameter sets N was determined. Fig. 8.3
presents the median least squares and median number of iterations to reach
105% of the current minimum resulting from 10 experiments with random
initial parameter values with N = 1026 parameter sets and 2000 iterations.
On the x and y axes, pmutation and pcrossover were varied and the different
grids correspond to different relations of alphas to remaining parameter sets.
In most of the cases, the resulting median least squares shown in Fig. 8.3A
increased with increasing pcrossover and furthermore with decreasing relation
of alphas to remaining parameter sets, i.e. if an alpha had the chance to pass
its parameter values on to more remaining parameter sets. However, varia-
tion of pmutation caused no general trend of the resulting least squares. The
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minimal median least squares of 39.4 was reached using pcrossover = 0.1 and
pmutation = 0.5 with a 1 to 1 relation between alphas and remaining parameter
sets. The median number of iterations to reach 105% of the current minimum
(shown in Fig. 8.3B) increased with decreasing pcrossover and increasing re-
lation of alphas to remaining parameter sets. However, variation of pmutation
again depended on the other settings and presented no general trend. Using
pcrossover = pmutation = 0.9 with a relation of alphas to remaining parameter
sets of 1 to 17, the convergence of the GA was fastest. In this case, 105% of
the current minimum was reached after a median number of iterations of 4.
As a compromise between the speed of convergence and the quality of the
adaptation, a pcrossover of 0.3, a pmutation of 0.5 and a 1 to 6 relation of alphas
to remaining parameter sets were used. Compared to the setting causing the
minimal median least squares, this conﬁguration caused a 2.7 times higher
least squares, but converged 7.6 times faster.
As in case of the PSO algorithm, the number of iterations and parameter sets
N was varied in 50 experiments each with random initial parameter values to
adapt the algorithm to the optimization problem (Fig. 8.4). In Fig. 8.4A, the
number of iterations was increased from 10 causing a median least squares
of 1368.6 to 10000 resulting in a median least squares of 102.4. The num-
ber of parameter sets N was ﬁxed at a value of 1536. However, the median
least squares remained in a similar range, if the number of iterations was
increased starting from 200 iterations. In this case, the median least squares
was already 101.2. Furthermore, the deviations from the median value also
remained similar. The number of parameter sets N was varied in Fig. 8.4B
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from 24 causing a median least squares of 1721.9 to 12288 resulting in a me-
dian least squares of 69.9. The number of iterations was set to 2000. In case
of 24 parameter sets, six outliers with values up to 1.44e7 were obtained,
but the deviations from the median were reduced towards higher numbers of
parameter sets.
On the one hand, the number of iterations was set to 500 in the following,
since the GA showed faster convergence behavior than the PSO algorithm.
On the other hand, the number of parameter sets N was set to 12288, which
caused the best median least squares. The number of iterations was set to 500
to allow for convergence of the algorithm, since the number of parameter
sets was higher and therefore the convergence behavior slower than in case
of the 1536 parameter sets in Fig. 8.4A. As a consequence, this combination
of number of iterations and parameter sets resulted in twice as many function
evaluations as in case of the PSO algorithm.
8.3 Combination of Optimization Algorithms
In addition to the comparison of the three optimization algorithms alone, the
combinations of the derivative-free PSO and GA with the TRR algorithm
were evaluated using the WT hERG voltage clamp data, since the TRR al-
gorithm alone was prone to end in local minima, as already mentioned in sec-
tion 4.4.1. The algorithms were furthermore assessed regarding their ability
to reconstruct synthetic data with known parameters. Finally, the algorithms
were used to adapt the model parameters to two further voltage clamp current
recordings of mutated ion channels. The twelve best parameter sets result-
ing from optimizations using the derivative-free algorithms were selected as
an input for the subsequent TRR algorithm in case of combinations of the
optimization algorithms.
8.3.1 Comparison of the Optimization Algorithms
Fig. 8.5 presents a direct comparison of the least squares, computing times
and exemplary parameter values of gKr and Xrm1 resulting from 50 experi-
ments with random initial parameter values using the different optimization
algorithms alone and in combination. The median least squares (Fig. 8.1A)
of the TRR algorithm alone was highest with 1256.6 compared to the GA
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Figure 8.5. Comparison of the optimization algorithms alone and in combination. The least
squares (A), computing times (B) and exemplary parameter values of gKr (C) and Xrm1 (D)
resulted from 50 experiments with random initial parameter values. Deﬁnition of box plots as in
Fig. 8.1. Modiﬁed according to [12].
with 73.7 and the PSO algorithm with 19.5. The deviation from the median
value was also highest in case of the TRR algorithm, again followed by the
GA. If the derivative-free algorithms were combined with the subsequent
TRR algorithm, the median least squares and the deviations from this value
were further reduced. The PSO combined with the TRR algorithm caused
a median least squares of 17.7 and in addition, the smallest least squares
reached by all algorithms (16.2) was obtained in three of the 50 experiments.
However, the GA combined with the TRR algorithm showed almost no de-
viations around the median least squares of 17.5 being almost independent
of the random initial parameter vectors.
The computing times of the different algorithms are depicted in Fig. 8.1B.
In general, the TRR algorithm caused the greatest variance of the comput-
ing times. The computing times of the TRR varied depending on the ini-
tial parameter vector, whereas the derivative-free algorithms showed nearly
constant computing times due to the ﬁxed number of iterations. The TRR
algorithm alone caused a median computing time of 2.3 s, the PSO algo-
rithm needed 213.4 s and the GA 260.9 s. The evaluation of the function to
be minimized in equation (4.9) contributed to on average 90.9% of the to-
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tal computing time in case of the GA and even 96.2% in case of the PSO
algorithm. The combination of the derivative-free algorithms with the TRR
algorithm increased the median computing time of the PSO and TRR algo-
rithm to 267.3 s and to 292.3 s in case of the GA and TRR algorithm.
The exemplary adjustable parameters gKr and Xrm1 are presented in Fig. 8.1C
and D. The TRR algorithm alone caused various parameter values span-
ning nearly the entire range, which was deﬁned for the parameter adapta-
tion (compare Table 8.1). The median value of gKr was 2046.6 nS/pF in case
of the TRR algorithm, whereas the PSO and GA algorithms found values
of 551.7 nS/pF and 742.9 nS/pF, respectively. After use of the subsequent
TRR algorithm, the median gKr values were reduced to 426.6 nS/pF in case
of the PSO and TRR algorithm and to 0.149 nS/pF in case of the GA and
TRR algorithm. However, the combination of the PSO and TRR algorithm
increased the resulting variance, whereas the GA and TRR algorithm de-
creased the variance. The median value of Xrm1 (Fig. 8.1D) was 85.1 in case
of the TRR algorithm and −46.2 in case of the GA, which presented also
great variations of the values. In contrast, the PSO, PSO and TRR, as well
as the GA and TRR algorithms caused similar median values of around −10
with almost no outliers.
The parameter values of the adaptation to the WT data using the PSO and
TRR algorithm, which caused the smallest least squares, are summarized in
Table 8.1. The corresponding current traces of the measured WT hERG data
and the simulated IKr current can be seen in Fig. 8.7A. The simulated cur-
rents ﬁt the measured curves well except for the fast upstroke of the current
after the step to −120mV. This part of the protocol could not be reproduced
well by the Courtemanche model IKr formulation, which caused a slower
upstroke.
8.3.2 Reconstruction of Synthetic Data
In order to assess the ability of the algorithms to reconstruct known pa-
rameters, synthetic voltage clamp data was generated as described in sec-
tion 4.1. Then, each algorithm should reproduce the simulated synthetic data
and adapt the parameters, so that the original parameter values were recon-
structed. The resulting least squares of 50 experiments with random initial
parameter values of the different algorithms are shown in Fig. 8.6A. In gen-
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Figure 8.6. Reconstruction of simulated synthetic data set. Least squares of the different op-
timization algorithms resulting from 50 experiments with random initial parameter values (A).
Deﬁnition of box plots as in Fig. 8.1. Relative deviation of reconstructed from original param-
eter values of the best optimizations using the PSO or GA combined with the TRR algorithm.
Modiﬁed according to [12].
eral, qualitatively similar results as in case of the adaptation to the WT data
could be observed. The TRR algorithm caused the greatest variations around
the median value of 117.7. The PSO algorithm alone and combined with the
TRR algorithm showed the same median value, however, the values of the
outliers were reduced in case of the combination of the algorithms. The PSO
combined with the TRR algorithm caused the two best least squares of all ex-
periments (0.0005 and 0.0006). The smallest median least squares could be
observed using the GA algorithm alone (39.6) and in combination with the
TRR algorithm (0.95). Furthermore, the results of the GA combined with the
TRR algorithm, which exhibited the third smallest least squares of 0.0009,
was almost independent of the initial parameter vectors.
In Fig. 8.6B, the relative deviations between the original and reconstructed
parameter values resulting from the best optimizations using the PSO and
TRR, as well as the GA and TRR are presented. Most reconstructed param-
eters match the original values nearly perfectly except for the parameters
Xra1, Xra2, Xra3, Xrb1 and Xrb2. These parameters, which inﬂuence the time
constant τxr of the gating variable, showed larger deviations up to +144.9%
and down to −99.8%. The parameter values giving the best reconstruction
of the synthetic clamp data using the PSO and TRR algorithm are listed in
Table 8.1. The corresponding current traces of the reconstructed simulation,
which perfectly matches the original synthetic data, is depicted in Fig. 8.7B.
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Table 8.1. Adjustable parameters of IKr with original values and their ranges. The parameter
values presented in the last four columns are the result of 50 adaptations each with random ini-
tial parameter sets. Shown are only those resulting parameter sets, which caused the minimal
least squares. The reconstructed parameters were obtained after adaptation to the synthetic clamp
data. The WT, K897T and N588K parameter sets resulted from adaptation to the experimentally
measured clamp recordings. Modiﬁed according to [12].
parameter range original reconstructed WT K897T N588K
gKr 0 5000 0.029411765 0.030068 0.1663 2615.9664 1427.7935
gKr1 −100 400 15 15.5909 11.2557 337.4943 323.2364
gKr2 −200 200 22.4 23.5206 21.8706 26.6261 28.1195
Xrm1 −150 150 14.1 14.0285 −9.0557 −2.3033 −4.1286
Xrm2 −150 150 6.5 6.4019 −11.9409 −22.8260 −21.6105
Xra1 0 2000 0.0003 0.00036 1970.4759 0.00003 0.00018
Xra2 −500 500 14.1 11.7296 260.1914 −19.1977 −35.1890
Xra3 −150 150 −5 −5.1760 7.5102 −8.5063 −9.7988
Xrb1 −500 500 −3.3328 −3.5805 −23.0389 92.2019 78.3990
Xrb2 −150 150 5.1237 0.0092 −16.4636 0.2711 0.000003
XrKQ10 −20 300 1.0 0.9976 −8.9526 16.0140 7.3604
[K+]i 0 3300 3000 2893.4584 35.9483 356.978 380.3644
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Figure 8.7. Measured hERG or synthetic IKr voltage clamp data (×) and adapted simulated cur-
rent traces (solid lines) with the corresponding clamp protocol. Voltage clamp recordings of WT
(A), K897T (C) and N588K (D) mutations. Synthetic data (B) was generated by simulation of the
same voltage clamp protocol using the original parameter values listed in Table 8.1.
8.3.3 Assessment of Algorithms Using Data of Mutated Ion Channels
The algorithms were furthermore tested with voltage clamp data of the
K897T and N588K mutations of the hERG channel to investigate if the op-
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timization algorithms and their settings were also suitable for the adapta-
tion of other measurement data. In general, similar behavior of the different
optimization algorithms as in case of the WT data could be observed. The
resulting least squares were different, since the current amplitudes differed
signiﬁcantly. As in case of the WT data, the PSO combined with the TRR
algorithm led to the minimal least squares, which was 1.82 for the K897T
data and 4.28 for the N588K data. However, the GA combined with the
TRR algorithm presented nearly constant least squares almost independent
of the initial parameter vector with median values slightly above the best
least squares. In Table 8.1, the adjustable parameters of IKr and their ranges,
as well as the resulting parameter sets of the best adaptations are summa-
rized. The corresponding current traces of the K897T and N588K mutations
are shown in Fig. 8.7C and D. As in case of the WT data, the ﬁrst part of
the curve could be adjusted well, whereas the recovery from the second volt-
age step to −120mV was too fast for the model. In case of both mutations,
this recovery was even faster than in the WT data. Nevertheless, the peak
current amplitudes, which were reduced compared to the WT case, could be
reproduced well.
8.4 Sensitivity Analysis
Finally, the local sensitivity of the function to be minimized in equation (4.9)
was analyzed around the minimum of the adaptation of the model of IKr
to WT voltage clamp data obtained by optimization using the PSO com-
bined with the TRR algorithm. In this way, the sensitivity of the minimum to
changes of one parameter at a time was investigated. The parameter values
corresponding to the minimal least squares are given in Table 8.1. The func-
tion values and partial derivatives with respect to four exemplary parameters
are presented in Fig. 8.8 to get an overview of how different the inﬂuences
of the parameters on the minimum were. In Fig. 8.8A and B, the impact of
variations of gKr on equation (4.9) could be observed. Since the function
value depended quadratically on gKr, the resulting sensitivity was a linear
function. The minimum, which was marked by × was close to zero and
the function value increased quadratically towards higher values of gKr. In
Fig. 8.8C and D, the inﬂuence of variations of the factor Xra1 on the function
to be minimized could be seen. Except for Xra1 = 0, which caused extreme
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Figure 8.8. Sensitivity analysis of exemplary adjustable parameters. Shown are the function val-
ues and partial derivatives with respect to gKr (A, B), Xra1 (C, D), Xrm1 (E, F) and Xrm2 (G, H)
within the deﬁned ranges speciﬁed in Table 8.1. The minimum, which was found by the opti-
mization algorithm, was marked by ×.
changes and also a discontinuity of the function value, the sensitivity of this
parameter was negligibly small, since the function value was nearly con-
stant otherwise. The parameter Xrm1, which was varied in Fig. 8.8E and F,
showed also small sensitivity around the minimum. However, the function
value increased towards the upper boundary of the parameter range caus-
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ing a signiﬁcant sensitivity there. The last exemplary parameter Xrm2 shown
in Fig. 8.8G and H presented an almost constant function value immedi-
ately around the minimum resulting in a sensitivity of nearly zero. Towards
more negative values, the function values slowly increased causing a small
sensitivity there. However, a discontinuity could be observed at zero, since
the values in equation (4.6) exponentially increased if Xrm2 became posi-
tive. Due to the discretization of the output of the sensitivity analysis, the
expected peak of the sensitivity at zero could not be reproduced. Towards
more positive values, a signiﬁcant sensitivity was visible.
8.5 Discussion
In this study, the adaptation of parameters of a model of the rapid delayed
rectiﬁer current IKr to measured hERG and synthetic voltage clamp data
was investigated. For this purpose, two methods for the solution of ODEs
and three optimization algorithms were compared and evaluated regarding
accuracy and computing time. Furthermore, the sensitivity of the detected
minimum to variation of the parameter values was analyzed.
Since the transmembrane voltage was a piecewise constant function during
the voltage clamp protocol used in this work, the ODEs describing the gat-
ing behavior of cardiac ion channels could be solved analytically. Compared
to the numerical approximation, the computing time of this solution method
was drastically decreased. In this way, use of complex population-based op-
timization algorithms, which are computationally expensive in general, was
possible in an adequate amount of time. However, the computing times of the
numerical and analytical solution of the ODEs also depend on the duration
of the applied voltage clamp protocol, the number of samples and voltage
steps. Due to this, the relative difference in computing times between both
methods may vary depending on the data used.
The PSO and GA implemented in this work were adapted to the investigated
optimization problem at ﬁrst. In case of the PSO, the number of iterations
and particles were varied for this purpose. The number of iterations was set
to 2000 and the number of particles to 1536 as a trade-off between the quality
of the adaptation and the computing time. In case of the GA, more settings
were tested: the probabilities pmutation and pcrossover, the relation of alphas
to remaining parameter sets and the number of iterations and parameter sets
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were varied. As a trade-off between speed of convergence and quality of the
adaptation, pmutation was set to 0.5 and pcrossover to 0.3 with a 1 to 6 relation
of alphas to remaining parameter sets as in [172]. Compared to the PSO
algorithm, the number of iterations could be decreased to 500 due to the
faster convergence of the GA. However, the number of parameter sets was
set to 12288 to obtain acceptable resulting least squares. Consequently, the
product of number of parameter sets and iterations of the GA was two times
higher than in case of the PSO. Nevertheless, the computing time of the GA
was only 22% higher indicating that the parallelized computation of multiple
parameter sets per iteration scaled differently than the serial calculation of
iterations.
The results of the single optimization algorithms TRR, PSO and GA showed
great differences depending on the initial parameter vectors. Due to this, the
combination of the derivative-free PSO or GA with the TRR algorithm was
tested using the WT hERG data ﬁrst. In comparison to the derivative-free
algorithms alone, the subsequent TRR algorithm generally improved the re-
sulting least squares, but furthermore increased the computing time. As the
median least squares was already small in case of the PSO algorithm alone,
the improvement due to the TRR algorithm was relatively small. In contrast,
the least squares resulting from the combination of the GA and TRR algo-
rithm caused signiﬁcant reduction of the median least squares. Additionally,
the variance of the resulting least squares was smallest using the GA and
TRR algorithm, i.e. the same minimum was found in almost all cases inde-
pendent of the initial values. This effect can be explained by the high number
of parameter sets covering great parts of the parameter ranges. Despite this,
the PSO combined with the TRR algorithm found the best least squares in
case of all data sets. The corresponding simulated current traces reproduced
the measured WT current well, at least the ﬁrst part of the voltage clamp pro-
tocol. The rapid recovery of the current after the voltage step to −120mV
was too fast for the model of IKr of Courtemanche.
Both derivative-free algorithms successfully reconstructed most parameters
of synthetic voltage clamp data with known parameter values. The PSO com-
bined with the TRR algorithm caused the smallest least squares again. Only
some parameters, which had an inﬂuence on the time constant τxr, showed
greater deviations from the original values. Since these parameters depend
on each other, they could not be uniquely identiﬁed using this voltage clamp
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protocol. Nevertheless, the resulting current traces of the reconstruction per-
fectly matched the original synthetic data. In case of the mutations, the re-
sults were qualitatively similar as in case of the WT data, i.e. the combination
of PSO and TRR algorithm caused the smallest least squares, but the GA and
TRR algorithm had a median least squares close to the smallest value with
almost no deviations. The current traces were also reproduced well except
for the fast recovery from the voltage step to −120mV.
If the resulting parameter values of Table 8.1 are compared, some param-
eters as e.g. Xra1 show large differences between the current recordings of
WT and mutated ion channels. This discrepancy can be explained by the
low sensitivity of this parameter over nearly the entire range used for the
optimization. In general, some of the parameters presented low sensitivity
or even discontinuities complicating the adaptation of the models of cardiac
ion currents to measured voltage clamp recordings. Due to this, the combi-
nation of a derivative-free optimization algorithm for the selection of good
initial parameter vectors for the subsequent minimum search using the TRR
algorithm was better than the algorithms alone. Nevertheless, either a high
number of particles have to be used to ﬁnd the best parameter sets, or the best
result of many random experiments as in case of the PSO combined with the
TRR algorithm has to be considered.
In previous studies, different optimization algorithms were used to adapt the
parameters of entire models of cardiac electrophysiology to reproduce AP or
restitution curves of cardiac myocytes [188–191]. For this purpose, different
optimization strategies with population-based or less complex algorithms
were used. However, the amount of available information within the data
used for the parametrization determines the maximal number of adjustable
parameters that can be uniquely identiﬁed [167]. As a consequence, either
the model that should be parametrized has to be simple with few adjustable
parameters as in e.g. [190], or only some of the parameters as e.g. the max-
imal conductivities can be identiﬁed [188]. Derivative-free algorithms for
the parameter adaptation of cardiac ion currents as the PSO algorithm were
already used in [192], wheras a GA was investigated in [172]. In [2], the
TRR algorithm was compared to other algorithms implemented in Matlab,
whereas in [3], the inﬂuence of the analytic solution of the ODEs on the op-
timization using the TRR algorithm was investigated. In [4], the derivative-
free GA and PSO were compared. However, this is the ﬁrst comprehensive
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comparison of both derivative-free algorithms alone and in combination with
the TRR algorithm used for the adaptation of cardiac ion currents to mea-
sured clamp recordings.
In this study, the IKr formulation of the Courtemanche model was used, al-
though it is a Hodgkin-Huxley type model with only one activating gating
variable. Due to this, the fast recovery from the voltage step to −120mV
could not be reproduced well by the model. However, the effects of muta-
tions of cardiac ion channels should be investigated in multiscale simulations
as described in section 9.3. Due to this, usage of the Courtemanche model,
which is a well-established model applied for the simulation of e.g. effects of
AF as shown in [13], was reasonable, since the K897T and N588K mutations
analyzed in this work are known to favor AF [193, 194]. Despite this, a more
sophisticated ion current model as e.g. a Markov model would probably im-
prove the results of the adaptation to measured currents. Another limitation
of this work is the use of hERG measurement data for the parametrization of
a model of IKr, since hERG is only the pore-forming α-subunit of the chan-
nel. In addition, the oocyte voltage clamp measurements were performed at
room temperature, which might probably not reﬂect the behavior of human
IKr well.
9Results: Modeling Atrial Fibrillation
The results of multiscale simulations of AF as described in chapter 5 and
in [13, 120] are presented in this chapter. Initially, the general properties of
ﬁve models of human atrial electrophysiology introduced in section 3.1.1
were benchmarked. Then, the ability of the different models to reproduce
cAF-induced remodeling was investigated in multiscale simulations ranging
from the single cell up to 2D tissue patches, in which a reentrant circuit
was initiated. Finally, the effects of genetic defects of the ultra-rapid delayed
rectiﬁer potassium channel IKur were studied in multiscale simulations using
the modiﬁed Courtemanche model of human atrial electrophysiology.
9.1 General Properties of Models of Atrial Electrophysiology
The ﬁve models of human atrial electrophysiology (Courtemanche, Nygren,
Maleckar, Koivumäki and Grandi) were benchmarked regarding general
model properties, which were also important for the simulation of AF.
9.1.1 Long Term Stability
Initially, the ﬁve models of human atrial electrophysiology were bench-
marked regarding the numerical stability of model parameters over long sim-
ulation times. For this purpose, relative changes of AP parameters compared
to published initial values were observed. Fig. 9.1A shows how the resting
membrane voltage Vm,rest of the different models reacted to sudden onset of
pacing with a BCL of 1 s after a quiescent period of 20min, during which no
external stimuli were applied. In this way, the models could reach a nearly
stable state of Vm,rest ﬁrst. The Courtemanche model presented almost no
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Figure 9.1. Long term stability of Vm,rest (A), AP amplitude (B), APD50 (C) and APD90 (D) of
models of human atrial electrophysiology.Vm,rest was observed during 20min without pacing and
following 10min of pacing at a BCL of 1 s. Amplitude, APD50 and APD90 were obtained during
20min paced at a BCL of 1 s. All values were normalized to the ﬁrst beat. Modiﬁed according
to [13].
change during the ﬁrst 20min, whereas a slight decrease followed by an in-
crease of Vm,rest could be observed after the onset of pacing. The Nygren
and Maleckar models showed an increase of Vm,rest during the ﬁrst minute
and then a decrease. Then, the Nygren model presented a slight increase
after 10min, whereas the Maleckar model reached a stable Vm,rest below
the initial value. After the onset of external stimulation, Vm,rest of the Ny-
gren and Maleckar models decreased and then increased again. Within the
ﬁrst second, Vm,rest of the Koivumäki model was reduced by nearly 1.2%.
10min later, a stable Vm,rest was reached. The ﬁrst stimulus caused an ele-
vation slightly above the initial value and then continuously increased until
the end of the investigated period. Vm,rest of the Grandi model gradually de-
creased to around 92% of the initial value after 10min and remained stable
until the onset of pacing. A rapid decline to 36% could be observed after the
twelfth beat followed by a rapid and then a gradual increase up to the initial
value 5min later.
The AP amplitude, APD50 and APD90 were investigated during 20min of
pacing with a BCL of 1 s. Fig. 9.1B presents the amplitudes of the differ-
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ent models. The amplitude of the Courtemanche model gradually decreased
to 97.5% of the initial value after 20min. The Nygren and Grandi models
showed an abrupt change of the amplitude after the ﬁrst beat: the amplitude
of the Nygren model increased by less than 0.5% and then gradually de-
creased below the initial value after 20min, whereas the Grandi model pre-
sented a reduction of nearly 1% followed by a slow increase to 99.7% after
8min. Then, the amplitude of the Grandi model remained constant until the
end of the investigated period. The Maleckar model caused a slight reduc-
tion of the amplitude to 99.8% during the ﬁrst 10min, after which the results
were stable. The amplitude of the Koivumäki model decreased marginally
below the initial value during the ﬁrst beats and remained constant.
The APD50 of the models over 20min pacing with a BCL of 1 s can be found
in Fig. 9.1C. The values of the Courtemanche and the Nygren model grad-
ually decreased to 58% and 97.3%, respectively. The Maleckar, Koivumäki
and Grandi models reached steady states close to the initial values after small
adaptations of the APD50 during the ﬁrst minutes.
In Fig. 9.1D, the APD90 of the ﬁve atrial models is presented during 20min
of stimulation with a BCL of 1 s. The APD90 of the Courtemanche model
decreased by 17% during the ﬁrst 16min and then slightly increased until
20min without reaching a steady state. The Nygren and Maleckar models
caused a slight reduction of the APD90 during the ﬁrst minute followed by an
increase of approximately 2% until 10min, after which the values remained
stable. The Grandi model showed similar behavior with opposite sign: slight
increase of the APD90 during the ﬁrst beats followed by a reduction to 98.7%
of the initial value. The APD90 of the Koivumäki model gradually decreased
to 97% after 20min.
9.1.2 AP and Calcium Transient Alternans
The phenomenon of alternans was investigated by stimulating the different
models for 30 s at different BCLs (compare Fig. 9.2). The single cell APD50
restitution curves of the ﬁve atrial model are shown in Fig. 9.2A. The bifur-
cations of the traces of the Courtemanche, Koivumäki and Grandi models re-
sulted from different numbers of stimuli, indicating an alternans of the APD
depending on the number of stimuli. The Grandi model showed this bifur-
cation at a BCL of 0.5 s, whereas the Courtemanche and Koivumäki models
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Figure 9.2. AP and calcium transient alternans of models of human atrial electrophysiology.
Single cell APD50 restitution curves over BCLs between 0.2 and 1 s (A). APs (B) and resulting
calcium transients (C) over the last two seconds of 30 s pacing with a BCL of 0.25 s. Calcium
transient curves of Nygren and Maleckar models overlap.
presented it at around 0.25 s. Consequently, the APs and calcium transients
of the models were investigated during the last two seconds of 30 s pacing
with a BCL of 0.25 s (see also Fig. 9.2B and C). A beat-to-beat alternans of
the APs was observed in case of the Courtemanche model, as a peak of the
calcium transient was initiated only every second beat. In this case, the intra-
cellular calcium concentration [Ca2+]i with a diastolic value of 0.2 μM and
a peak value of 0.8 μM slowly decreased. The Nygren and Maleckar models
did not show any alternans of the APs and the calcium transient, as already
indicated by the APD50 restitution curves. The calcium transients had a low
diastolic value of 0.13 μM and a sharp peak with an amplitude of 0.75 μM.
The Koivumäki model presented a reduced AP amplitude every third beat,
which corresponded to an increased calcium transient peak (0.54 μM) in
the previous beat. The diastolic [Ca2+]i was slightly higher than that of the
Courtemanche model. The most pronounced alternans could be observed
using the Grandi model, which produced two APs with low amplitude and
short duration after a longer beat. In this case, a peak of the calcium transient
was initiated only every third beat with amplitudes in a similar range as the
Koivumäki model.
9.1. GENERAL PROPERTIES OF MODELS OF ATRIAL ELECTROPHYSIOLOGY 97
Table 9.1. Computing times of the models of human atrial electrophysiology needed for the
simulation of 1000 s with a BCL of 1 s without writing results to hard disk.
model Courtemanche Nygren Maleckar Koivumäki Grandi
et al. et al. et al. et al. et al.
time (s) 35.9 37.4 55.9 123.0 161.3
9.1.3 Computing Time
For the benchmark of models of atrial electrophysiology, the computing time
plays a crucial role, since the simulation of AF on complex geometries can be
a time-consuming process even with current computers. Table 9.1 summa-
rizes the computing times of the ﬁve atrial models resulting from the single-
cell simulations of 1000 s paced with a BCL of 1 s. To avoid delays during
the simulation, no results were written to hard disk. The Courtemanche and
Nygren models show similar computing times, as the number of underly-
ing currents was the same. Compared to the Courtemanche model, which
was the fastest, the computing time of the Maleckar model was increased
1.56-fold. The Koivumäki and Grandi models, which had a more complex
description of the calcium handling, had 3.43 and 4.49 times longer comput-
ing times.
9.1.4 Discussion
Although the major goal of this work was to investigate which model of hu-
man atrial electrophysiology was suited best for the simulation of AF, an
analysis of general properties of the models, as e.g. the long term stability
of AP properties, was essential. However, these aspects were not analyzed
in previous benchmarks of models of human atrial electrophysiology. In
e.g. [131], only the ion concentrations were observed during 10min of sim-
ulation. Depending on the requirements of the simulation, the AP properties
should be stable over long periods for a robust usage, be able to reproduce the
phenomenon of alternans to investigate its connection to rhythm disorders, or
have small computing times for complex simulations using high-resolution
geometries with a large number of elements.
The resting membrane voltageVm,rest of the Courtemanche, Grandi, Maleckar
and Koivumäki model reached a steady state during 20min without pac-
ing, only the Nygren model showed a drift of Vm,rest . After the onset of
stimulation, the Grandi model presented the most prominent changes of
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Vm,rest within the ﬁrst minute. However, only the Koivumäki model showed
a small drift of Vm,rest after 10min stimulation, the other models reached a
steady state close to the initial value. The amplitudes of the Courtemanche
and Nygren models still changed after 20min pacing, whereas those of the
Maleckar, Koivumäki and Grandi models reached a steady state close to the
initial value. Only the Maleckar, Koivumäki and Grandi models presented
a stable APD50 after 20min pacing close to the initial value, whereas the
Courtemanche model produced signiﬁcant changes of the APD50 and did
not result in a stable value after 20min, which was also the case for the
Nygren model. The APD90 of the Nygren, Maleckar and Grandi models
reached a steady state during 20min, in contrast to the Courtemanche and
Koivumäki models. Consequently, only the Maleckar and Grandi models
offered stability of all investigated AP parameters over longer periods and
should therefore be used for long term simulations. However, slight modiﬁ-
cations of the Courtemanche model published in 2009 [195] allow for long
term stability of this model. Furthermore, other models were suited better
for short term simulations and experiments, in which the model state was
changed abruptly, since the Grandi model reacted sensitive to sudden onset
of external stimulation after quiescence.
The Nygren and Maleckar models were not able to cause alternans in the sin-
gle cell, whereas the Courtemanche, Koivumäki and Grandi models showed
different alternans patterns of the APs and the calcium transients. Further-
more, the underlying mechanisms responsible for the alternans of the cal-
cium transients differed, since the Courtemanche model has a phenomeno-
logical description of the SR calcium release depending on the transmem-
brane voltage. In contrast, the calcium handling of the Koivumäki and
Grandi models is based on more recent ﬁndings enabling calcium-induced
calcium release.
The aforementioned complex descriptions of the calcium handling of the
Koivumäki and Grandi models cause a signiﬁcantly higher computing time
compared to the Courtemanche and Nygren models. Therefore, the Courte-
manche and Nygren models were suited better for tissue simulations with a
large number of elements.
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Figure 9.3. Single-cell APs of control and electrically remodeled myocytes. APs of control mod-
els of human atrial electrophysiology (A). Relative deviations between cAF and control AP pa-
rameters compared to experimental data of Bosch et al. [45], Workman et al. [196] (BCL= 0.8 s)
and Christ et al. [197] (B). ∗: Relative change of dVm/dtmax of Grandi model reached a peak of
nearly 290%. APs resulting from model of cAF-induced remodeling (C).
9.2 Modeling Electrical Remodeling due to Chronic AF
The ﬁve models of human atrial electrophysiology were adapted as described
in section 5.2 to reproduce effects of cAF-induced remodeling. The proper-
ties of the models of cAF were compared to the control models in multiscale
simulations ranging from the single cell up to 2D tissue patches.
9.2.1 Single-Cell APs of Control and Electrically Remodeled Myocytes
The control APs of the ﬁve models of human atrial electrophysiology are
presented in Fig. 9.3A. The AP of the Courtemanche model presented a pro-
nounced spike-and-dome morphology, whereas the other four models pro-
duced triangular shaped APs. The Nygren and Maleckar models caused very
similar APs. The AP of the Koivumäki model had a plateau phase with a
signiﬁcantly lower amplitude. The APs resulting from simulations using the
Grandi model had a less pronounced overshoot than the other models and
the myocyte repolarized in two phases causing a longer APD than the other
models. In Fig. 9.3C, the APs of the cAF models are shown. All APs were
shortened due to electrical remodeling and even the shape of the Courte-
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manche model was triangular. The relative changes of the AP parameters
are visualized in Fig. 9.3B together with experimental values of Bosch et
al. [45], Workman et al. [196] and Christ et al. [197]. The AP amplitude
increased due to cAF. The relative changes of the amplitude of all mod-
els, especially the Grandi model, were above the experimental data. Fur-
thermore, cAF-induced remodeling caused a shift of the resting membrane
voltage Vm,rest towards more negative values. The change of Vm,rest of the
Courtemanche model was in the range of experimentally observed values,
whereas the other models were above the values. The APD90 was reduced
due to cAF. The APs of the Koivumäki and Grandi models were shorter than
the experimental data. In contrast, the APD90 of the Courtemanche, Nygren
and Maleckar models were in the range of experimental values. As a con-
sequence of cAF, the maximum upstroke velocity dVm/dtmax was increased.
Except for the Grandi model, all models lay in the range of experimental
values. dVm/dtmax of the Grandi model was increased by almost 290%.
The absolute values of the control and cAF AP parameters of the ﬁve atrial
models are summarized in Table 9.2, which were compared to experimen-
tally determined values of human atrial myocytes in Table 9.3. In the con-
trol case, the amplitudes of all models except for the Grandi model were
in the range of experimental data. The amplitude of the Grandi model was
approximately 30− 40mV smaller than those of the other models. In case
of cAF, only the Courtemanche model reproduced the experimentally deter-
mined amplitude. The other atrial models caused 10− 15mV higher val-
ues. The resting membrane voltages Vm,rest of the control and cAF Ny-
gren, Maleckar, Koivumäki and Grandi models were similar to the exper-
imental values. A more negative Vm,rest could be observed using the con-
trol and cAF Courtemanche model. Compared to the Nygren, Maleckar and
Table 9.2. AP properties of control and electrically remodeled myocytes (BCL = 1s).
AP parameter Courtemanche Nygren Maleckar Koivumäki Grandi
control cAF control cAF control cAF control cAF control cAF
amplitude (mV) 110.11 121.58 116.14 134.92 119.14 137.10 120.77 138.08 81.38 133.28
Vm,rest (mV) −81.0 −84.3 −74.2 −80.3 −73.8 −79.7 −76.1 −81.3 −73.5 −81.9
APD50 (ms) 165.16 74.99 29.55 30.14 29.77 35.33 20.98 29.17 125.30 39.54
APD90 (ms) 294.83 143.87 220.34 115.13 197.09 115.59 259.58 109.21 330.13 85.70
dVm/dtmax (V/s) 186.58 211.38 149.77 174.96 160.66 182.47 168.54 179.26 92.50 359.53
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Table 9.3. Experimentally determined control and cAF AP properties of human atrial myocytes.
Values (where available) taken from Bosch et al. [45], Workman et al. [196] (BCL = 0.8 s) and
Christ et al. [197].
AP parameter Bosch et al. Workman et al. Christ et al.
control cAF control cAF control cAF
amplitude (mV) 116±3 120±2
Vm,rest (mV) −76.3±2.2 −78.9±2.9 −76.9±2.1 ≈−77 −75.0±0.4 −78.9±1.1
APD90 (ms) 255±45 104±9 209±22 95±12 ≈ 344 287±16
dVm/dtmax (V/s) 203±11 231±16
Koivumäki models, which exhibited similar APD50, the Grandi and Courte-
manche models presented much longer APD50. The Courtemanche model
had the longest APD50 due to the spike-and-dome morphology of the AP,
whereas the Koivumäki model showed the shortest duration caused by the
low amplitude plateau phase. In case of the Grandi and Courtemanche mod-
els, the APD50 was reduced due to cAF, but the values of the other models
were increased. The APD90 of the control Grandi model, which was longest
among all models, best matched the measurements of Christ et al. [197], but
the APD90 was shortest in case of cAF reproducing the values of Workman et
al. [196]. The APD90 of the control Courtemanche model was closest to the
measured values of Bosch et al. [45]. However, the Courtemanche model did
not reproduce experimentally determined APD90 in case of cAF. The con-
trol and cAF Koivumäki model caused APD90 in the range of measurements
of Bosch et al. [45], whereas the control and cAF Nygren and Maleckar
models caused similar APD90 reﬂecting the experimental values of Work-
man et al. [196]. The experimentally measured maximum upstroke veloc-
ity dVm/dtmax [196] was reproduced best by the Courtemanche model, the
values of the Nygren, Maleckar and Koivumäki models were signiﬁcantly
smaller. The Grandi model, however, showed a two times smaller dVm/dtmax
in the control case compared to the measured value, but had a more than
150V/s faster upstroke than the other models in case of cAF.
9.2.2 Restitution Properties of Control and Electrically Remodeled
Tissue
The restitution properties of the ﬁve models of human atrial electrophysiology
were determined in simulations using the 1D tissue strand as described in
section 5.2. The restitution curves of the APD90, ERP, CV and WL of the
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Figure 9.4. Restitution properties of control (left) and electrically remodeled (right) tissue simu-
lated in a 1D ﬁber. APD90 restitution curves in comparison to experimental data of Franz [198]
(A, B). ERP restitution curves compared to experimental data from the right atrial appendage
(exp1) and the distal coronary sinus (exp2) of Yu et al. [199] (C, D). CV restitution curves com-
pared to experimental data from the right atrial free wall (exp1) and the septum (exp2) of Feld et
al. [200] (E, F). Restitution curves of the WL (G, H). Modiﬁed according to [13, 120].
control and cAF models compared to experimental data where available are
shown in Fig. 9.4. In the control case, the Grandi model could not excite the
tissue at every beat at BCLs of 0.54 s and lower. The Courtemanche model
presented a limiting BCL of 0.31 s, whereas the other three models could be
evaluated at BCLs of 0.3 s in the control case. In case of cAF, all models ex-
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cept for the Grandi model initiated APs down to BCLs of 0.2 s. The Grandi
model was limited to a BCL of 0.25 s.
The APD90 restitution curves of the control and cAF models were compared
to experimental data of Franz [198] (see Fig. 9.4A and B). The Courte-
manche and Grandi models lay in the range of experimental values in the
control case at high BCLs. However, the Nygren, Maleckar and Koivumäki
models, which generally had a shorter APD90, showed similar values as the
experiments at a BCL of 0.3 s. The APD90 restitution curves of the Courte-
manche and Koivumäki models had slightly ﬂatter slopes than the exper-
iments, whereas the Nygren, Maleckar and Grandi models showed an in-
crease of the APD90 towards shorter BCLs. In case of cAF, the APD90 and
also the slopes of the restitution curves of all models were smaller than in the
experiments. The APD90 of the Grandi model was constant over the different
BCLs.
In Fig. 9.4C and D, the ERPs of the atrial models are compared to exper-
imental data of Yu et al. [199] originating from the right atrial appendage
(exp1) and the distal coronary sinus (exp2). In the control case, the values of
the Nygren, Maleckar and Koivumäki models were in the range of the exper-
iments. Nevertheless, the ERP of the Nygren and Maleckar models increased
towards shorter BCLs, whereas the Koivumäki model presented a decrease
similar to the experimental data. The ERP of the Courtemanche model was
around 50ms longer than the experimentally measured values, but the slopes
of the restitution curves were similar. The Grandi model produced an ERP,
which was around 200ms longer than the measured values and increased to-
wards shorter BCLs. In case of cAF, the ERP of all models was more than
50ms shorter than the experimental data. Again, the Courtemanche model
reproduced the slopes of the measured restitution curves best. The slopes of
the other models were signiﬁcantly smaller.
Experimental data of Feld et al. [200] from the right atrial free wall (exp1)
and the septum (exp2) was used for the comparison with simulated CV resti-
tution curves of the control and cAF models (compare Fig. 9.4E and F). In
the control case, the CV restitution curves of the Courtemanche, Nygren,
Maleckar and Koivumäki models lay approximately within the standard de-
viation above the mean of the experimentally measured values, since the
tissue conductivity of each model was adjusted to obtain a CV of around
750mm/s at a BCL of 1 s. The measured CV slightly reduced towards
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short BCLs, whereas the simulated curves of the Nygren, Maleckar and
Koivumäki models slightly decreased ﬁrst and rapidly declined between
BCLs of 0.4 and 0.3 s. The Courtemanche model presented a slight increase
of the CV around a BCL of 0.5 s, which is called supernormal conduc-
tion [201], and also a rapid decline between 0.4 and 0.3 s. However, the CV
of the Grandi model signiﬁcantly decreased between BCLs of 1 and 0.54 s
showing no stable CV values around a BCL of 1 s. In case of cAF-induced re-
modeling, the CVs of the Courtemanche, Nygren, Maleckar and Koivumäki
models were in the range of experimental data, whereas the Grandi model
caused more than 300mm/s higher CVs than the other cAF models, which
was higher than in the control case. The cAF Courtemanche model presented
an increase of the CV towards short BCLs, whereas the other models repro-
duced the slopes of the measured restitution curves well.
As no experimental data of the WL was available, only the simulated values
of the control and cAF models were compared to each other in Fig. 9.4G
and H. The Grandi model caused the longest WLs followed by the Courte-
manche model in the control and cAF cases. However, the control Grandi
model caused a signiﬁcant decrease of the WL between BCLs of 1 and
0.54 s, whereas the other models showed only a slight decrease of the WL
towards short BCLs. The control Nygren, Maleckar and Koivumäki models
caused similar WLs of around 150mm, which was almost 100mm shorter
than the WL of the Courtemanche model and more than 200mm less than
the Grandi model at a BCL of 1 s. At a BCL of 0.4 s, which was the BCL
used for the 2D rotor simulations, the Courtemanche model caused a WL
of 227mm, the Nygren model 154mm, the Maleckar model 141mm, the
Koivumäki model 137mm and the Grandi model did not initiate APs at ev-
ery beat at this BCL. In case of cAF, the WLs of the Nygren and Maleckar
models were similar and the Koivumäki model caused the shortest WL. All
models presented a similar slope of the WL restitution curve in case of cAF.
The WLs of the cAF models at a BCL of 0.4 s, which was used as pac-
ing rate for the 2D rotor simulations, were: Courtemanche (92mm), Nygren
(81mm), Maleckar (79mm), Koivumäki (71mm) and Grandi (105mm).
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Figure 9.5. Rotor trajectories of the models of control and electrically remodeled tissue. The
dominant frequencies derived from the pseudo-ECGs are speciﬁed below the trajectories in paren-
theses. Using the control Courtemanche and Grandi models, no reentrant circuit could be initi-
ated. Modiﬁed according to [13].
9.2.3 Initiation of Rotors in Control and Remodeled 2D Tissue Patches
The possibility to initiate a single rotor in a 2D tissue patch using the control
and cAF models of atrial electrophysiology was investigated as described in
section 5.4. For this purpose, a cross-ﬁeld (S1–S2) protocol should initiate
a reentrant circuit. The control Courtemanche and Grandi models failed to
produce a rotor in the 2D tissue patch due to their long WL. Using the con-
trol Nygren, Maleckar and Koivumäki models, as well as all cAF models, a
reentrant circuit each could be initiated. In this case, the trajectories of the
rotor centers were tracked as described in section 5.5. Furthermore, pseudo-
ECGs were derived using two virtual electrodes and the corresponding DF
was computed (compare section 5.6). The trajectories of the centers of all
successfully initiated rotors are depicted in Fig. 9.5. The courses of the ro-
tor centers were tracked between the second and fourth simulated second.
The control Nygren, Maleckar and Koivumäki models caused elliptical ro-
tor center trajectories with nearly the same size of less than 1 cm2. The three
models also caused similar DFs: the Nygren model presented the smallest
value with 3.4Hz and the two other models had a slightly increased DF of
3.9Hz. In case of cAF, the Nygren and Maleckar models showed similar
star-shaped trajectories occupying larger areas than in the control case. The
DFs of both models were increased (+3.1Hz). The cAF Koivumäki model
produced a stable circular rotor trajectory, which was signiﬁcantly smaller
than in the control case. The DF of the Koivumäki model was increased
(+3.4Hz) in case of cAF. The Courtemanche and Grandi models caused
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curved star-shaped rotor center trajectories. The rotor center trajectory of the
Grandi model occupied the largest area. Furthermore, the DF of the Grandi
model was highest (8.3Hz), but was only slightly higher than the DF of the
Courtemanche model.
9.2.4 Discussion
In this study, the ability of the ﬁve models of human atrial electrophysiology
to reproduce cAF-induced remodeling was investigated in multiscale simula-
tions. For this purpose, the control and remodeled models were compared to
each other and to experimental data. The resulting single cell APs of the dif-
ferent models were shortened due to cAF and showed a triangular shape. The
AP of the Courtemanche model, which had a spike-and-dome morphology in
the control case, was more triangular. The control and cAF AP amplitude of
the Courtemanche model reproduced experimental data best, which showed
an increase of amplitude due to cAF. The Nygren, Maleckar, Koivumäki and
Grandi models closely matched control and cAF Vm,rest , however, the rela-
tive change due to cAF, i.e. a shift towards more negative values, was also
reproduced by the Courtemanche model. Except for the Grandi model, the
reduced APD90 of the electrically remodeled models reﬂected well the ex-
perimental values. The Grandi model appeared to be sensitive to changes of
the amplitude of the external stimulus amplitude and Vm,rest , as the max-
imum upstroke velocity dVm/dtmax was almost four times higher in case
of cAF. Only the Courtemanche model closely matched the experimentally
measured dVm/dtmax.
The restitution properties of the models were investigated in a 1D tissue
strand. The measured control APD90 restitution curves were reproduced
best by the Courtemanche and Koivumäki model, although the slopes of
the curves were too ﬂat. In case of cAF, all models caused too short APD90
compared to the experiments. However, the slopes of the curves were similar
to those of the experimental data. The ERP of the control Nygren, Maleckar
and Koivumäki models were in the range of experimental values. Only the
control and cAF Courtemanche model showed similar slopes of the ERP
curves as compared to experiments. In case of cAF, the ERP of all mod-
els was below experimental values. All models except for the Grandi model
lay in the range of experimentally measured CV, although the curves of the
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control models were too steep towards short BCLs. The cAF Grandi model
caused a signiﬁcantly increased CV compared to the control case, although
the tissue conductivity was decreased as in the other models. Again, this was
due to the lower Vm,rest , which caused an increased dVm/dtmax. In all mod-
els, the WL was reduced due to cAF being shortest in the Koivumäki model
and longest in the Grandi model, which was followed by the Courtemanche
model. Consequently, no reentrant circuit could be initiated using the control
Courtemanche and Grandi models, which was assumed to be more realistic
than the ability of the control Nygren, Maleckar and Koivumäki models to
initiate a rotor. The elliptical trajectories of the rotor centers and DFs were
similar among the successful control models. The cAF models, which were
all able to initiate a rotor, showed greater diversity regarding shape (from
circular to star-shaped) and size of the rotor center trajectory and the DF.
Not all models considered in this work were published yet in previous bench-
marks of models of human atrial electrophysiology. In [202], the Courte-
manche and Nygren models have been compared regarding the difference
in AP shape of the models, which was based on the different magnitude of
the underlying currents, although the models relied on almost the same data.
An analysis of the ionic currents was out of the scope of this work, which
aimed at investigating the ability of the models to reproduce cAF-induced
electrical remodeling. Cherry et al. [131, 203] investigated the differences
of the Courtemanche and Nygren models regarding the ability to adapt to
different pacing rates, coming to the same conclusion as in the present work
that the APD of the Courtemanche model changed most with varying BCL
(compare Fig. 9.4A). Furthermore, the initiation of rotors was also inves-
tigated in [203]. In case of electrical remodeling, stable reentrant circuits
could be observed in both models. However, transient wave breaks could
also be observed using the control Courtemanche model, which might be
due to the use of tissue patches up to 30×30cm in contrast to 10×10cm in
the present work. Furthermore, the CV used in the present work might have
been higher resulting in a longer WL. These values were not stated in [203].
Therefore, no reentrant circuit could be initiated using the control Courte-
manche model in this study in contrast to [203]. In [5], properties of the
Courtemanche, Nygren, Maleckar and Koivumäki models were compared to
each other. Furthermore, the minimal model published by Bueno-Orovio et
al. [190], which was adapted by Weber [204] to reproduce the AP and resti-
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tution curve of the Courtemanche model, was also compared to the other
models. However, the benchmark did not investigate rotor trajectories and
DF in 2D simulations and did not include the Grandi model.
The benchmark of the models of human atrial electrophysiology showed that
relatively small changes of the current formulations and variations of con-
sidered ion currents have a signiﬁcant impact on the output of multiscale
simulations. The results of the Courtemanche model were in good agree-
ment with measured single-cell AP properties, as well as experimental data
of the APD90 and CV. Nevertheless, the other models showed similar results
as observed in some of the experiments, too, but none of the models could
reproduce all experimentally investigated properties. The measured restitu-
tion properties were based on only one data set each. Therefore, more ex-
perimental data for the validation of the models of cAF-induced remodeling
would be necessary. Depending on the purpose of the simulation, different
models could be used. Regarding the initiation of rotors in a 2D tissue patch,
the Courtemanche or Grandi model should be preferred, as only these cAF
models were able to initiate rotors and not the control models, which is as-
sumed to be the physiological case. Furthermore, the Courtemanche model
was able to produce stable beat-to-beat alternans, which is linked to atrial
rhythm disorders. In many simulation studies of AF, as e.g. [130–133], the
Courtemanche model was already used. As already discussed in section 9.1,
the computing time of the Courtemanche model was the shortest reducing
costs of tissue simulations with large amount of elements. Besides, long term
stability was not necessary during simulations shorter than a minute. Conse-
quently, the Courtemanche model was used for the following simulations of
effects of AF.
9.3 Modeling Genetic Defects Favoring AF
In this study, mutations of KCNA5 encoding the ultra-rapid delayed recti-
ﬁer potassium channel introduced in section 5.3 were investigated in multi-
scale simulations. At ﬁrst, the effects of the mutations were integrated into
a mathematical description of the current at the ion channel level. Then, the
resulting changes were investigated in the single cell, a 1D tissue strand and
a 2D tissue patch.
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Figure 9.6. Patch clamp recordings (dashed lines) of WT and mutated IKur and adapted simulated
current traces (solid lines) with the corresponding clamp protocol.
9.3.1 Adaptation of Model of Ultra-Rapid Delayed Rectiﬁer Current to
Mutations
The model of the ultra-rapid delayed rectiﬁer current IKur of the Courte-
manche model was adapted to the patch clamp data described in section 5.3
using the parameter adaptation framework introduced in chapter 4. The com-
bination of the PSO and TRR algorithm was used to ﬁnd the parameter val-
ues within the ranges deﬁned in Table 5.2 resulting in the minimal difference
between the simulated and measured current traces shown in Fig. 9.6. For the
adaptation to data of WT and mutated channels, different ranges were de-
ﬁned: uaKQ10 and uiKQ10 were set to the values found after the adjustment to
the WT data, since the same measurement conditions were assumed. Further-
more, the values of gKur1 and gKur2 of the adjustment to the WT data served
as lower boundaries in case of the adaptation to data of mutated channels to
prevent negative conductivities after the calculation of the relative changes
due to the mutations using equations (5.13) and (5.13). All simulated cur-
rent traces depicted in Fig. 9.6 matched the measured traces well (minimal
least squares: 6.2 (WT), 1.9 (A576V), 2.8 (E610K) and 3.2 (T527M)). The
WT currents shown in Fig. 9.6A presented the largest amplitudes and a slow
exponential decrease during the voltage steps to 40 and 60mV, respectively.
However, the mutation A576V (compare Fig. 9.6B) caused nearly linearly
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Table 9.4. Parameter values of the control model and resulting from adaptation to WT and mu-
tated IKur and following calculation of relative changes due to mutations.
parameter control A576V E610K T527M
uaa1 0.65 4.7228 198.9204 147.1922
uaa2 10 −12.5983 107.4018 −28.0843
uaa3 −8.5 −3.5609 −7.5221 −98.0457
uaa4 −30 −2.4678 24.3074 127.6908
uaa5 −59 −14.1038 −109.3183 −19.9413
uab1 2.5 2.5014 25.6124 21.3226
uab2 82 17.8828 34.7356 −23.3846
uab3 17 9.7316 74.7051 26.7549
uam1 30.3 −53.8125 −17.8970 −42.1249
uam2 −9.6 −9.6000 −9.6000 −9.6000
uaKQ10 3 3 3 3
uia1 1 0.5408 0.9936 0.3239
uia2 21 1002.3652 −767.6070 1006.4243
uia3 −185 −184.9999 −185.0000 −185.0001
uia4 −28 −1066.5728 −17.4074 −85.0142
uib1 −158 −23.6979 −158.0000 −56.8848
uib2 −16 −0.3267 −21.9186 −0.2772
uim1 −99.45 −31.6312 −78.6915 −18.7487
uim2 27.48 0.2748 27.48 27.4799
uiKQ10 3 3 3 3
gKur1 0.005 0.00504 0.00503 20.2543
gKur2 0.05 0.07845 0.0549 0.0500
gKur3 −15 −35.5380 −14.7700 −15.5589
gKur4 −13 −13.0469 −12.9319 −12.9121
decreasing currents with the maximal amplitude being more than 2.5 times
smaller than the maximal WT current at the voltage step to 60mV. However,
this maximal current amplitude of the mutated channels was more than two
times higher than that of the voltage step to 40mV. In case of the mutation
E610K shown in Fig. 9.6C, a fast exponential decrease could be observed
at voltage steps to 40 and 60mV. This part of the protocol could not be
reproduced as well as the other parts of the protocol by the adapted simula-
tions. Furthermore, the maximal current amplitude was reduced by less than
two times compared to the WT currents. The T527M currents, which are
depicted in Fig. 9.6D, were in a similar range than those of the A576V mu-
tation. However, the currents resulting from the steps to 20 and 40mV were
increased compared to those of the A576V mutation. The currents decreased
only slightly during the variable voltage steps.
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Table 9.5. AP parameters of the control Courtemanche model and the model adapted to mutations
of IKur (BCL = 1s).
AP parameter control A576V E610K T527M
amplitude (mV) 105.6 105.4 105.0 104.3
Vm,rest (mV) −81.0 −80.4 −80.4 −80.4
APD50 (ms) 172.4 225.5 224.8 225.7
APD90 (ms) 298.4 290.9 293.1 293.9
dVm/dtmax (V/s) 190.9 197.7 198.2 198.2
The resulting parameter values describing the relative changes due to the
mutations A576V, E610K and T527M are compared to the original control
values of the Courtemanche model in Table 9.4. The temperature correction
factors uaKQ10 and uiKQ10 had the same values as in the original model, since
they were the same in the measurements of both WT and mutated channels.
Further parameters as e.g. uam2, uim2 or gKur4 showed similar or the same
values as in the control original model. In general, the parameter values of
all mutations were in similar ranges, if they were close to the original model
parameters. In case of some of the parameters as e.g. uia4 or gKur1, very large
differences between the mutations could be observed.
9.3.2 Effects of Ion Channel Mutations on Single Cell APs
The APs of the original control model and the models adapted to the IKur
mutations A576V, E610K and T527M are presented in Fig. 9.7A and the AP
parameters are summarized in Table 9.5. The APs of the myocytes with mu-
tated channels looked similar in general. These APs furthermore exhibited an
increased TMV after the overshoot causing a more pronounced spike-and-
dome morphology compared to the control AP. This effect was strongest in
case of the A576V mutation, whereas the two other mutations showed simi-
lar changes. The TMV returned to approximately 15mV causing an elevated
plateau phase and an APD50 prolonged by more than 50ms. However, the
repolarization phase was faster than in case of the control model, so that the
APs of the mutated channels showed a slightly shortened APD90 compared
to the control model. The upstroke velocities dVm/dtmax were increased by
around 4% in case of the mutations. Nevertheless, the AP amplitudes were
similar.
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Figure 9.7. APs (A) and corresponding IKur current (B) resulting from mutations of KCNA5.
The underlying currents responsible for the differences are depicted in
Fig. 9.7B. The course of the control IKur qualitatively followed the ﬁrst part
of the AP showing a fast upstroke and a short peak followed by a small dome
with low amplitude going back to zero at around 200ms. The mutations also
presented a short current peak during the AP upstroke. The amplitude of this
peak was increased in case of the T527M mutation, whereas the other mu-
tations caused a reduction of the amplitude. During the plateau phase of the
AP, the second rise of the currents of the mutated channels was signiﬁcantly
smaller in amplitude compared to the control current. After the initial peak,
the current was nearly zero in case of the A576V mutation causing almost
no rise of the current.
9.3.3 Restitution Properties of Tissue with Ion Channel Mutations
The restitution properties of the mutations of IKur presented in Fig. 9.8 were
investigated in a 1D atrial tissue strand between BCLs of 0.3 to 1 s as de-
scribed in section 5.2. In general, the mutations caused very similar restitu-
tion curves, which were hard to distinguish. Therefore, the changes of the
restitution properties resulting from the mutations were described in general
and not separately for each mutation. The mutations caused APs at every
stimulus at BCLs down to 0.31 s, whereas the control model could be inves-
tigated at BCLs down to 0.3 s.
The APD90 restitution curve (Fig. 9.8A) of the control model started at
around 0.32 s at a BCL of 1 s and slowly decreased to 0.25 and 0.27 s, re-
spectively, at a BCL of 0.3 s. The APD restitution curve bifurcated at around
0.5 s due to negligible AP alternans, which slightly increased towards a BCL
of 0.3 s. The APD90 of the mutations was around 20ms shorter than that of
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Figure 9.8. Restitution curves of APD90 (A), ERP (B), CV (C) and WL (D) resulting from mu-
tations of IKur. Bifurcations of the restitution curves reﬂect alternans at short BCLs.
the control model at a BCL of 1 s. The restitution curves slightly decreased
towards a BCL of 0.65 s and then increased again. At a BCL of 0.52 s, the
restitution curves bifurcated due to beat-to-beat alternans. Depending on the
number of stimuli, the restitution curves either continuously decreased to
approximately 0.1 s at a BCL of 0.31 s or increased to 0.32 s until a BCL of
0.5 s, afterwards decreased below the APD90 of the control model and ﬁnally
increased again to almost 0.3 s at a BCL of 0.31 s.
The ERP restitution curves shown in Fig. 9.8B looked qualitatively similar
than those of the APD90 restitution curves. However, the ERP of the control
model was 0.315 s at a BCL of 1 s and decreased to 0.27 s or 0.29 s depending
on the number of stimuli. The ERP restitution curves of the mutations were
nearly the same as the control curve at high BCLs. However, the ERP started
to increase at BCLs smaller than 0.65 s as in case of the APD90 restitution
curves of the mutations. Furthermore, the curves bifurcated in the same way
at a BCL of 0.52 s, so that the ERP either decreased to 0.12 s or increased to
0.315 s again at short BCLs.
In Fig. 9.8C, the CV restitution of the control model and the mutations is
depicted. The CV of the control model as well as the mutations started at
750mm/s at a BCL of 1 s slightly increasing towards a BCL of 0.5 s. Then,
the restitution curve of the control model bifurcated at a BCL of 0.45 s and
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the CV rapidly decreased to 560 or 620mm/s at a BCL of 0.3 s. In case of
the mutations, the restitution curves bifurcated already at a BCL of 0.47 s
and either remained constant at around 760mm/s or rapidly decreased to
510mm/s.
The WL of the control model and the mutations was measured at various
BCLs in Fig. 9.8D. All models presented a WL of approximately 240mm at
long BCLs. In case of the control model, the WL slightly decreased towards
short BCLs starting at around 0.6 s. At 0.5 s, the control WL restitution curve
bifurcated and showed small beat-to-beat alternans. The greatest deviations
could be observed at a BCL of 0.3 s, where the WL slightly alternated be-
tween 150mm and 175mm. The mutations presented a prolongation of the
WL up to 250mm at BCLs shorter than 0.65 s. At a BCL of 0.52 s, the bifur-
cation of the WL due to alternans could be seen. The WL either decreased to
60mm or shortly increased, decreased and then increased again to 240mm.
At a BCL of 0.4 s, which was used as the pacing frequency for the initiation
of rotors in the following section, the WL of the control model varied be-
tween 215 and 221mm, as well as between 155 and 230mm in case of the
mutations, depending on the number of stimuli.
9.3.4 Impact of Ion Channel Mutations on Initiation of Rotors
In addition to the previous analyses, the initiation of rotors as described in
section 5.4 was investigated under the inﬂuence of mutations of the KCNA5
gene encoding the channels responsible for the ultra-rapid delayed rectiﬁer
potassium current IKur. For this purpose, a cross-ﬁeld (S1-S2) protocol was
used after the initialization of the models at a BCL of 0.4 s. Three regular line
stimuli were applied to the tissue before the cross-ﬁeld stimulus was placed.
This stimulus was applied 50ms after the end of the ERP of the previous
regular excitation wave measured at the left border of the 2D tissue patch.
In this way, the cross-ﬁeld stimulus could initiate APs in parts of the tissue,
which were already excitable again.
In Fig. 9.9A, the control Courtemanche model is shown. 345ms after the
initiation of the regular excitation wave, the cross-ﬁeld stimulus was applied.
In direction of the previous excitation wave, a conduction block due to the
still refractory tissue could be observed. Therefore, the excitation could only
propagate perpendicularly to the regular excitation wave. 100ms later, the
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Figure 9.9. Initiation of rotors using the control (A), A576V (B), E610K (C) and T527M (D)
models. For the initiation of a reentrant circuit, a cross-ﬁeld (S1-S2) protocol was used. Stimulus
sites are indicated by dashed lines. The TMV distributions of the three mutations and the control
case shown in A–D were obtained at different times to ﬁt the varying simulation times.
excitation had already entered the previously refractory tissue. However, the
front of the excitation wave had propagated along the area of the cross-ﬁeld
stimulus, which was still refractory, and already left the tissue patch after
545ms. Consequently, no reentrant circuit was initiated and the tissue was
completely repolarized 200ms later.
Since all mutations presented pronounced alternans at a BCL of 0.4 s as de-
scribed in the previous section, the number of stimuli played a crucial role
in the initiation of rotors. As in case of the control model, three regular line
stimuli were applied ﬁrst, so that the last regular beat had a long duration
and fast CV. Due to this, the premature cross-ﬁeld stimulus could cause an
excitation wave with shorter WL making a reentrant circuit more probable.
At a BCL of 0.4 s, the ERP of all mutations was 5ms longer than in case of
the control model, so that the cross-ﬁeld stimulus was applied after 350ms.
After 500ms, all mutations caused excitation waves entering the area of
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the cross-ﬁeld stimulus, which was not refractory any more. The excitation
waves showed more than a complete rotation after 700ms. However, differ-
ences between the mutations could be observed already, being more clear at
900ms. In case of the A576V mutation (Fig. 9.9B), the lower left part of
the patch was excited by the rotor, but the previous excitation wave caused
a conduction block, so that the wave front left the tissue patch, which was
completely repolarized after 1100ms. A similar pattern could be observed
in case of the T527M mutation shown in Fig. 9.9D, where the conduction
block was more pronounced. Due to this, a small part at the lower border
of the patch and the upper left corner were still excited after 900ms. Again,
the reentrant circuit terminated and the tissue was completely repolarized
after 1100ms. In contrast, the E610K mutation showed no conduction block
eliminating the excitation wave after 900ms. Instead, a small new excitation
wave could pass through a tunnel of refractory tissue at the upper left corner
and the lower tissue border. However, only the back of the wave remained
after 1100ms causing no reentrant circuit any more, so that the tissue was
completely repolarized after 1300ms.
9.3.5 Discussion
In this study, the impact of the KCNA5 mutations A576V, E610K and
T527M, which are associated with AF [176], on human atrial electro-
physiology was investigated. The effects of the mutations were integrated
into the IKur formulation of the Courtemanche model using patch clamp data
of the mutated channels. The measured current traces could be reproduced
well by the simulations with the adjusted parameters. Furthermore, only rel-
ative changes due to the mutations were integrated into the model of atrial
electrophysiology to eliminate inﬂuences of the measurement conditions.
The resulting increased value of gKur1 in case of the T527M mutation was
probably responsible for the increased peak current amplitude during the
upstroke of the AP. Furthermore, some of the parameter values as e.g. uam2,
uim2 or gKur2 were similar or equal to the control values in case of some of
the mutations, which might be due to the deﬁned parameter ranges. In case
of e.g. gKur2, the lower boundary was determined by the value resulting from
the adjustment to the WT data to prevent negative conductivity values. Due
to this, the parameter value could not get smaller than the deﬁned boundary,
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resulting in almost no relative difference compared to the original control
parameter value.
The resulting APs under the inﬂuence of the mutations presented an ele-
vated TMV during the plateau phase causing a more pronounced spike-and-
dome morphology of the APs. Due to this, the APD50 was signiﬁcantly
increased, whereas the APD90 was slightly shortened due to the faster re-
polarization (stronger activation of IKr and IKs). In general, the underlying
IKur was reduced in case of the mutations, only mutation T527M caused an
increased current peak during the upstroke of the AP. All mutations pre-
sented nearly the same restitution properties. The main difference between
the control model and the mutations was the pronounced alternans of the
APD90, ERP, CV and therefore also the WL. At BCLs shorter than 0.52 s,
the restitution curves bifurcated due to beat-to-beat alternans. Consequently,
the maximal difference in APD90 and ERP was almost 300ms, the difference
in CV 250mm/s and in WL 180mm, depending on the number of stimuli.
Due to this, the WL of the mutations could be in a range similar to the con-
trol Nygren, Maleckar and Koivumäki models as shown in section 9.2.2,
allowing the initiation of reentrant circuits. Using the same cross-ﬁeld (S1-
S2) stimulus protocol for the control model and the mutations, the control
model failed to initiate a reentrant circuit, since the WL was too long com-
pared to the dimensions of the patch. In contrast, a single rotor could be
initiated in case of the mutations. However, the reentrant circuits were not
stable over the time, since the mentioned alternans caused regions in the tis-
sue patch with longer or shorter ERP depending on the previous diastolic
interval. As a consequence, chaotic excitation propagation patterns could be
observed, especially in case of the E610K mutation. In 3D tissue simula-
tions, these chaotic patterns would probably evolve into stable ﬁbrillation,
since the atrial anatomy with obstacles and heterogeneous tissue properties
would allow better pathways for the reentrant circuits than in case of a ho-
mogeneous 2D tissue patch with borders as in this study. Furthermore, the
BCL, at which the patch was initialized could be reduced, so that the WL
would be smaller favoring stable rotors. Although the reentrant circuits ini-
tiated in case of the mutations were not stable, the proarrhythmic properties
mainly due to the alternans could be shown. Due to lack of electrophysiolog-
ical measurement data of the mutations simulated in this work, the observed
effects could not be compared to experimental data on the organ level.
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In previous work, the heterozygous E375X mutation of KCNA5, which is
also associated with AF [205], was modeled in [136] by a reduction of the
maximal conductivity only. In the simulations, the mutation caused early af-
terdepolarizations at high pacing frequencies, which might induce AF. The
effects of pharmacological inhibition of IKur on AF was investigated in mea-
surements or using computational simulations in e.g. [132, 206]. Neverthe-
less, this is the ﬁrst study, in which a biophysically detailed model repro-
ducing the measured currents under the inﬂuence of KCNA5 mutations was
used to investigate the effects of these mutations on multiscale simulations
of human atrial electrophysiology.
In future work, the sensitivity of changes of the parameters on the function
to be minimized in equation (4.9) could be analyzed. In this way, informa-
tion on the origin of the observed large differences between some of the
parameters (e.g. uia4 or gKur1) of the different mutations could be gained.
Perhaps, the adjustment of the biophysically detailed model of IKur with 24
adjustable parameters to the given patch clamp currents is an underdeter-
mined system, i.e. the parameters could possibly not be uniquely identiﬁed.
For this purpose, a different clamp protocol could provide complementary
information. In addition to the 2D patch simulations, the initiation of AF
could also be simulated using accurate anatomical 3D models of the human
atria in future work to investigate the chaotic excitation patterns resulting
from the mutations. The multiscale simulations of the effects of ion channel
mutations presented in this study help to better understand the mechanisms
responsible for the initiation of AF. Furthermore, the pharmacological treat-
ment could be adapted to the mutations based on these simulations, allowing
for patient-speciﬁc therapy of AF in the future.
10
Results: Modeling Effects of Acute Cardiac
Ischemia
This chapter presents the results of multiscale simulations of the effects of
different stages of acute cardiac ischemia in the ventricles as described in
chapter 6 and in [16, 17]. At ﬁrst, the inﬂuence of ischemia on single ven-
tricular myocytes was investigated. Afterwards, the impact of the occlusion
of the distal LAD on the ventricular excitation propagation was investigated
at different ischemia stages and with varying transmural extent of the is-
chemic region. Finally, the corresponding forward calculated BSPMs and
ECGs were analyzed, especially regarding shifts of the ST segment, which is
an important diagnostic marker of ischemia and myocardial infarction [72].
10.1 Single-Cell APs at Different Ischemia Stages
The APs resulting from the parameter changes described in Table 6.1 are
shown in Fig. 10.1A. Only the course of the transmembrane voltage (TMV)
of epicardial myocytes is presented in this ﬁgure, since the changes due to
ischemia are most prominent in this cell type. This was due to the higher sen-
sitivity of IK,ATP compared to endocardial and M cells. Nevertheless, quali-
tatively similar but less pronounced effects could be observed in these cells.
Table 10.1. AP parameters of an epicardial myocyte at different stages of acute cardiac ischemia.
AP parameter control stage 1 stage 2 phase 1b
0 min 5 min 10 min 20–30 min
amplitude (mV) 124.1 108.5 83.1 74.6
Vm,rest (mV) −85.6 −73.6 −64.3 −58.1
APD50 (ms) 279.6 94.3 56.3 42.7
APD90 (ms) 309.1 116.5 72.1 56.3
dVm/dtmax (V/s) 94.7 61.4 39.4 37.2
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Figure 10.1. Action potentials (A) and upstroke phase of APs (B) of an epicardial myocyte at
different stages of acute cardiac ischemia.
The main effects of acute cardiac ischemia on the AP, which are summarized
in Table 10.1, were reduction of the APD, amplitude and maximum upstroke
velocity dVm/dtmax, as well as a rise of the resting membrane voltageVm,rest .
The slowed dVm/dtmax due to ischemia is presented in detail in Fig. 10.1B.
In the control myocyte, the TMV slowly rose until the threshold voltage of
the sodium channels is reached. A fast upstroke of the TMV is visible af-
terwards. In case of ischemia, the membrane continuously depolarized with
a slower upstroke velocity. In general, the impact of acute cardiac ischemia
on the AP gradually increased with increasing time after the onset of the ef-
fects. However, the most signiﬁcant changes of the APs shown in Fig. 10.1
could be observed between the control case and after 5min of ischemia. In
this case, the amplitude was reduced by 12.6%, the APD50 and APD90 were
shortened by 66.3% and 62.3%, respectively. The dVm/dtmax was slowed
by 35.2% and Vm,rest was shifted by 12mV towards more positive values.
In comparison, the changes during the following stage 2 after 10min and
phase 1b after 20− 30min were smaller. Altogether, the amplitude was de-
creased to 60.1%, Vm,rest was increased by 27.5mV, the APD50 and APD90
were shortened by 84.7% and by 81.8%, respectively, and dVm/dtmax was
decreased by 60.7% after 20− 30min of ischemia compared to the control
case.
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Figure 10.2. Ventricular TMV distributions (t = 200ms of cardiac cycle) at different stages of
ischemia (5min, 10min and 20−30min after occlusion of the distal LAD) with varying transmu-
ral extent of the ischemic region. Setup 1 was a subendocardial ischemia, setup 3 an intermediate
ischemic region and setup 10 transmural ischemia. The corresponding ischemic regions are de-
picted in Fig. 6.2.
10.2 Modeling Ischemic Tissue
The impact of different stages of acute cardiac ischemia on ventricular ex-
citation propagation was investigated using the ischemic regions depicted in
Fig. 6.2. In this case, the severity of the occlusion of the distal LAD was
analyzed by varying the transmural extent of the ischemic region ranging
from subendocardial to completely transmural. The excitation propagation
simulated in the ventricles with ischemic regions differed from the control
case. The most prominent changes could be observed, if the entire ventricles
were nearly homogeneously depolarized in the control case, which is illus-
trated in Fig. 10.2. There, distributions of the TMV of the control case and
nine ischemia cases at t = 200ms of the cardiac cycle are presented. In the
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three columns, the different stages (5min, 10min and 20−30min after oc-
clusion of the distal LAD) of ischemia were grouped. The transmural extent
of the ischemic region varied from subendocardial (setup 1) over an exem-
plary intermediate ischemic region (setup 3) to completely transmural (setup
10) in the different rows. During the ﬁrst ten minutes of ischemia, the most
signiﬁcant changes were visible in case of transmural ischemia, since the
epicardial layer was not activated there. However, setups 1 and 3 presented
a slightly reduced TMV in the ischemic regions during phase 1a due to the
lower amplitude and shorter duration of the APs. After 10min of ischemia,
a delayed activation of the endocardial layer resulting in a higher TMV than
after 5min of ischemia could be discovered in setup 10. During phase 1b,
the ischemic regions could easily be identiﬁed, since the TMV was drasti-
cally reduced compared to the healthy tissue. In case of setup 1, only short
APs with low amplitude were responsible for this effect, whereas complete
conduction block occurred in the CIZ in case of setup 3 and setup 10.
10.3 Forward Calculation of ECGs under the Inﬂuence of
Ischemia
The BSPMs shown in Fig. 10.2 resulting from the forward calculation of the
TMV distributions during the ST segment can be found in Fig. 10.3. The
torsos corresponding to different stages of ischemia and transmural extents
of the ischemic regions were arranged in the same way as the corresponding
TMV distributions in Fig. 10.2. In the control case, a nearly homogeneous
BSPM of around 0mV could be observed due to the completely depolar-
ized ventricles depicted in Fig. 10.2 (inset). In general, Wilson chest leads
V3 and V4 were closest to the ischemic region. Therefore, the most promi-
nent changes of the body surface potentials could be found in this area. After
5min of ischemia, only the transmural ischemic region (setup 10) caused a
signiﬁcant change of the BSPM compared to the control case. In setup 10, an
elevation of the body surface potentials around the chest leads could be de-
tected during all stages of ischemia, although the area of elevated potentials
was smaller during phase 1b. In contrast, subendocardial ischemia (setup 1)
resulted in a slight depression of the body surface potentials around the chest
leads after 10min becoming even more pronounced after 20−30min of is-
chemia. The BSPMs of the intermediate ischemic region (setup 3) did not
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Figure 10.3. BSPMs (t = 200ms of cardiac cycle) resulting from ventricular excitation propaga-
tion shown in Fig. 10.2. Shown are different stages of ischemia (5min, 10min and 20− 30min
after occlusion of the distal LAD) and varying transmural extent of the ischemic region.
differ from the control case till 20−30min after the occlusion of the LAD.
After this time, a slight depression of the body surface potentials around the
chest leads could be seen.
As the most prominent changes of the BSPMs due to the occlusion of the dis-
tal LAD were determined in Wilson chest lead V4, the resulting ECGs of all
simulated ischemia stages and transmural extents of the ischemic region are
presented in Fig. 10.4. This ﬁgure gives an overview of the various changes
of the ECG due to acute cardiac ischemia, mainly shifts of the ST segment,
which are used as a diagnostic marker of ischemia and infarction. In addi-
tion, the TQ segment was slightly elevated due to the increased Vm,rest in
the ischemic regions. Moreover, the amplitudes of the QRS complexes and
T waves, as well as the onset of the T waves were altered. In the control
case, the ST segment was nearly a zero baseline, whereas subendocardial
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Figure 10.4. ECGs in the Wilson chest lead V4 showing ST segment shifts resulting from dif-
ferent stages of ischemia (5min, 10min and 20− 30min after occlusion of the distal LAD) and
varying transmural extent of the ischemic region (light tone: subendocardial, dark tone: transmu-
ral).
ischemia (light tone) caused a slight depression of the ST segment. This
effect was more pronounced at later stages of ischemia. However, transmu-
ral ischemia caused a pronounced elevation of the ST segment being most
prominent after 10min and smallest after 20− 30min of ischemia. In be-
tween these shifts of the ST segment, some ischemia setups also caused a
nearly zero baseline as in the control case. The 12-lead ECGs of these so-
called “electrically silent” [1] ischemia cases (setup 3 at different ischemia
stages) are presented in Fig. 10.5. The ECGs of the ﬁrst 10min of setup 3 are
hard to distinguish from the control case. Only at the onset and end of the T
wave, small differences could be noticed. However, the differences between
the control case and setup 3 during phase 1b were more pronounced. There,
even the ST segment was depressed in leads V3 to V5 in addition to changes
of the QRS complex and the T wave.
10.4 Discussion
In this study, the inﬂuence of different stages of acute cardiac ischemia on
a single myocyte, the ventricular excitation propagation and the forward
calculated ECGs was investigated. The effects of acute ischemia on car-
diac electrophysiology worsened in the course of the ﬁrst 30min. In the
affected ventricular myocytes, the APs were shortened, the amplitude and
maximum upstroke velocity reduced and the resting membrane voltage in-
creased. In the ventricles, the transmural extent of the ischemic region and
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Figure 10.5. 12-lead ECG of control case and setup 3 (intermediate ischemic region) at different
stages of ischemia. These ischemia cases were partly electrically silent, i.e. hard to distinguish
from the control case.
the ischemia stage were varied. Subendocardial ischemia caused shorter APs
with reduced amplitude in the endocardial layer with increasing effects to-
wards phase 1b. The resulting injury currents were directed from the healthy
epicardium towards the endocardium causing slight ST segment depression
in leads close to the ischemic region. In case of transmural ischemia, the in-
jury currents ﬂowed from the less affected endocardium towards the more
injured epicardium causing pronounced ST segment elevation. Cellular un-
coupling during phase 1b effected a complete conduction block across the
entire ventricular wall resulting in less pronounced ST segment elevation. In
intermediate ischemic regions, injury currents even compensated each other
producing similar ECGs as the control case.
In previous works, effects of phase 1a (e.g. [148]) or phase 1b (e.g. [141–
143, 145]) on cardiac electrophysiology were investigated. However, the ef-
fects of different stages of ischemia on the ECG were not investigated so far.
In contrast to e.g. [140], metabolic effects of acute cardiac ischemia were
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modeled only indirectly in this work in order to reduce computing time. The
same reason was responsible for the use of the monodomain model, which
in general is sufﬁcient for the computation of cardiac excitation propaga-
tion and body surface ECGs [207]. However, the bidomain model could be
required for the simulation of phase 1b ischemia, since the anisotropy ra-
tio might change in this case. The inﬂuence of the width of the BZ and the
location of the ischemic region were analyzed in a previous work of this au-
thor [208]. A wider BZ facilitated the conduction towards the CIZ. Different
locations of the ischemic region inﬂuenced, which ECG lead presented the
most pronounced ischemia effects.
Although shifts of the ST segment of the 12-lead ECG are used as a diag-
nostic marker of acute cardiac ischemia and myocardial infarction, a signiﬁ-
cant part of the patients showing “electrically silent” ischemia without these
changes are missed [1]. As suggested e.g. in [209], the BSPM could help
to identify these ischemia cases. In the present simulation study, even the
BSPM of setup 3 did not show signiﬁcant differences during the ﬁrst 10min
compared to the control case, although this nearly complete compensation
of injury currents might be due to the symmetrical shape of the ellipsoidal
ischemic region. Since these cases are assumed to be unlikely, a diffusion
model of the coronary blood ﬂow as presented in e.g. [210] should be used
to create more realistic ischemic regions in future simulations. Nevertheless,
the use of BSPMs could improve the diagnosis of ischemia, since posterior
myocardial infarctions or ischemia are hard to diagnose using the 12-lead
ECG [209]. Furthermore, other markers as troponin T or CK-MB also help
to reliably detect ischemia, but with a delay of typically three hours.
11
Results: Modeling the Impact of Pharmacological
Therapy on Cardiac Electrophysiology
The results of multiscale simulations of the effects of pharmacological
agents on cardiac electrophysiology outlined in chapter 7 and in [18] are
presented in this chapter. Initially, the impact of two antiarrhythmic agents,
dronedarone and amiodarone, on control and electrically remodeled human
atrial electrophysiology was investigated. Furthermore, the effects of the gas-
troprokinetic agent cisapride and the antiarrhythmic amiodarone, which both
cause QT prolongation, were analyzed in healthy and ischemic ventricular
tissue.
11.1 Pharmacological Treatment of Control and Remodeled
Atria
In this section, the inﬂuence of dronedarone and amiodarone on control and
electrically remodeled atrial electrophysiology was investigated using the
Courtemanche model. The multiscale simulations ranged from the single
cell up to 2D tissue patches, in which the inﬂuence on reentrant circuits was
analyzed. General differences between control and electrically remodeled
atrial electrophysiology are described in section 9.2.
11.1.1 Atrial Single-Cell APs under the Inﬂuence of Dronedarone and
Amiodarone
The effects of dronedarone and amiodarone on control and electrically re-
modeled human atrial APs are presented in Fig. 11.1. The corresponding
values of the AP properties are summarized in Table 11.1. With increas-
ing concentration of the antiarrhythmics, the AP amplitude was decreased
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Table 11.1. AP properties of control and electrically remodeled atrial myocytes under the inﬂu-
ence of dronedarone and amiodarone (BCL= 1s). drone: dronedarone. amio1: amiodarone setup
1. amio2: amiodarone setup 2. l: low concentration. h: high concentration.
setup amplitude (mV) Vm,rest (mV) APD50 (ms) APD90 (ms) dVm/dtmax (V/s)
control cAF control cAF control cAF control cAF control cAF
no drug 105.6 108.0 −81.0 −84.4 172.4 87.3 298.4 147.9 190.9 194.1
drone l 103.5 106.2 −80.6 −84.3 227.3 117.3 378.2 183.5 185.3 184.3
drone h 99.6 102.6 −80.5 −84.3 248.2 127.7 398.7 191.7 163.0 154.2
amio1 l 92.2 95.1 −81.1 −84.4 230.0 109.3 359.6 165.3 131.8 122.6
amio1 h 80.6 82.7 −81.5 −84.1 218.3 142.6 334.5 187.5 66.2 65.3
amio2 l 92.6 94.9 −81.7 −84.0 114.8 93.8 261.3 147.8 124.7 116.9
amio2 h 80.6 82.7 −81.7 −84.2 122.6 98.2 241.5 143.6 67.1 66.0
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Figure 11.1. Control (A) and cAF (B) APs under the inﬂuence of dronedarone and amiodarone.
drone: dronedarone. amio1: amiodarone setup 1. amio2: amiodarone setup 2. l: low concentra-
tion. h: high concentration.
in control and cAF myocytes in a similar fashion. However, the decrease
was more pronounced in case of amiodarone (−13 to −25mV) compared
to −2 to −6mV in case of dronedarone. Almost no difference in amplitude
could be observed between setups 1 and 2. Linked to the reduced ampli-
tude, the maximum upstroke velocity was also slowed due the administration
of dronedarone and amiodarone, again to a greater extent in case of amio-
darone, but also in case of cAF. The reduction of dVm/dtmax was largest
(−66.3%) in case of cAF-induced remodeling using the high concentra-
tion of amiodarone setup 1. In the control case, dVm/dtmax was slowed by
−65.3% with the same setup and concentration. Setup 2 presented an only
slightly smaller decrease of dVm/dtmax. The resting membrane voltageVm,rest
showed only slight shifts in the range of−0.7 to+0.5mV due to the pharma-
cological agents. Dronedarone and amiodarone setup 1 caused a signiﬁcant
prolongation of the APD. The high concentration of dronedarone prolonged
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the APD50 (control: +43.9%, cAF: +46.3%) and APD90 (control: +33.6%,
cAF: +29.6%) most. In case of amiodarone setup 2, a different effect could
be observed: the APD50 was shortened in the control case, which was more
pronounced using the low concentration, whereas in case of cAF, the APD50
was increased with increasing concentration. However, the APD90 decreased
with increasing concentration of amiodarone setup 2, but in case of cAF, this
shortening was negligibly small (maximally −2.9%).
11.1.2 Effects of Dronedarone and Amiodarone on Restitution
Properties
The impact of dronedarone and amiodarone on the restitution properties of
the control and electrically remodeled 1D tissue strand is shown in Fig. 11.2.
The slope of the APD90 curve dAPD90/dDI, the ERP, the CV and the WL
were varied over DIs between 0 and 1 s. Generally, almost no alternans could
be observed in the different models, therefore, only one trace is shown for
each model.
Fig. 11.2A and B present the dAPD90/dDI, which was around zero at long
DIs in all cases. The slope of the control model slightly increased to 0.3 to-
wards a DI of 0.09 s and then decreased again. However, dronedarone caused
negative values of dAPD90/dDI at DIs shorter than 0.09 s. In contrast, the
low concentrations of amiodarone setups 1 and 2 exhibited an increase of
the slope up to 1.2 at short DIs. The high concentrations of amiodarone pre-
sented similar slopes as the control case at short DIs, but also large peaks
with slopes of 8.8 at a DI of 0.18 s in case of setup 1 and 2.9 at a DI of 0.33 s
in case of setup 2. In case of cAF, oscillations of the slopes of the APD90
restitution curves to slightly negative values could be observed at short DIs.
However, the dAPD90/dDI of the cAF model without the inﬂuence of phar-
macological agents increased towards values between 0.2 and 0.4 at short
DIs. Dronedarone and amiodarone setup 1 presented oscillations in a similar
range, although they started already at a DI of 0.4 s. In contrast, amiodarone
setup 2 caused smaller oscillations close to zero and maximally up to 0.2.
The ERP under the inﬂuence of dronedarone and amiodarone is presented in
Fig. 11.2C and D. The control model caused an ERP of 0.32 s at DIs longer
than 0.4 s. Then, the ERP slightly decreased to approximately 0.27 s at a DI
close to 0 s. Dronedarone caused an increased ERP of around 0.4 s, which
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Figure 11.2. Restitution properties of control (left) and cAF (right) tissue under the inﬂuence
of dronedarone and amiodarone simulated in a 1D ﬁber. Slope of the APD90 restitution (A, B),
ERP (C, D), CV (E, F) and WL (G, H) were varied over the DI. drone: dronedarone. amio1:
amiodarone setup 1. amio2: amiodarone setup 2. l: low concentration. h: high concentration.
rapidly decreased at DIs shorter than 0.2 s. With increasing concentration of
dronedarone, the ERP was slightly increased. Amiodarone setup 1 presented
similar ERPs at long DIs. Only the high concentration resulted in a longer
ERP. The low concentration of setup 1 exhibited a slightly steeper slope than
the control case, but the decrease started at DIs shorter than 0.6 s already.
However, the high concentration of setup 1 caused an increase of the ERP
to 0.46 s at DIs between 0.6 and 0.2 s followed by a rapid decline to 0.24 s
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at DIs shorter than 0.2 s. In case of setup 2, the ERP caused by the low
concentration of amiodarone was around 0.28 s at long DIs and continuously
decreased to a DI of 0.25 s. Towards this DI, the ERP was ﬁrst increased and
then decreased to 0.24 s again towards short DIs. The high concentration of
amiodarone setup 2 caused a similar ERP as the control case at long DIs,
but the ERP started decreasing at a DI of already 0.6 s. Furthermore, a slight
discontinuous shift of the ERP towards smaller values could be observed
at a DI of 0.33 s. In case of cAF, the ERP was 0.164 s at a DI of 1 s and
decreased by 30ms to short DIs. Around DIs of 0.2 s, a short increase of the
ERP could be seen. Dronedarone caused an increased ERP of around 0.2 s
at a DI of 1 s, which decreased to below 0.16 s at short DIs. A shift of the
ERP towards higher values, which was more pronounced than in the control
case, could be observed at a DI of 0.3 s in case of the low concentration and
at a DI of around 0.4 s in case of the high concentration of dronedarone. The
low concentration of amiodarone setup 1 exhibited the highest ERP (0.23 s)
at a DI of 1 s. Towards shorter DIs , the ERP of this setup continuously
decreased to 0.15 s except for a shift to smaller values at a DI of 0.4 s. Setup
2 and the high concentration of setup 1 showed smaller ERPs than the control
case at long DIs, but since the values did not decrease signiﬁcantly towards
short DIs, slightly longer ERP values could be seen there. No signiﬁcant
differences between the low and high concentrations of the ERPs of setup 2
were visible.
In Fig. 11.2E and F, the CVs of the models of dronedarone and amiodarone
in control and electrically remodeled 1D tissue strands are depicted. The
CV of the control model was nearly 750mm/s at a DI of 1 s. Towards a
DI of 0.2 s, the CV slightly increased and afterwards rapidly decreased to
630mm/s at short DIs. In general, the slopes of the CV restitution curves
of the antiarrhythmics were ﬂattened, so that the rate adaptation at short
DIs was negligible. Increased concentration of dronedarone and amiodarone
caused decreasing CVs. The high concentration of dronedarone exhibited
CVs slightly below 700mm/s. The CVs of amiodarone setups 1 and 2 were
nearly the same. The low concentration of amiodarone resulted in CVs be-
low 600mm/s. In case of the high concentration of amiodarone, the CV was
almost 200mm/s slower. In case of cAF under the inﬂuence of antiarrhyth-
mics, qualitatively similar results as in the control case could be obtained.
The CVs of all models were shifted by around 100 to 150mm/s towards
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slower values. However, the cAF-induced remodeling without the inﬂuence
of antiarrhythmics showed no rate adaptation at short DIs similar to the mod-
els of antiarrhythmics.
The WL restitution of the control and electrically remodeled atrial models
under the inﬂuence of dronedarone and amiodarone is given in Fig. 11.2G
and H. Since the WL is the product of the ERP and the CV, the resulting
curves look qualitatively similar. The control atrial model presented a WL of
nearly 240mm between DIs of 0.3 and 1 s. Below 0.3 s, the WL decreased to
around 170mm at short DIs. Independent of the concentration, the WLs were
prolonged by around 50mm in case of dronedarone. Similar WLs as in the
control case could be obtained using the low concentration of amiodarone
setup 1. The WL of the high concentration of amiodarone setup 1 was around
180mm at long DIs, slightly increasing towards a DI of 0.2 s and afterwards
rapidly declining to 100mm at short DIs. Amiodarone setup 2 showed the
shortest WLs, which decreased with increasing concentration. The WL of
the low concentration of setup 2 decreased from more than 160mm at a
DI of 1 s to 140ms at short DIs. The WL was reduced from 130mm at a
DI of 1 s to 100mm at short DIs in case of the high concentration of setup
2. As in case of the ERP, discontinuous shifts of the WLs to higher and
lower values could be observed in case of amiodarone setup 2 at DIs of 0.25
and 0.33 s, respectively. In case of cAF, the WL was slightly shorter than
100mm at a DI of 1 s decreasing to around 80mm at short DIs. The WLs of
dronedarone were around 15mm longer than in the cAF model and similar
for both concentrations, except for the discontinuous shifts at 0.3 and 0.4 s,
respectively. The low concentration of amiodarone setup 1 presented WLs
in a similar range as the cAF model, but with a more pronounced decrease.
Setup 2 and the high concentration of amiodarone setup 1 caused nearly ﬂat
WL restitution curves with values down to less than 50mm.
Since the vulnerable window (VW) was nearly constant at all investigated
DIs, only the values at a BCL of 1 s are listed in Table 11.2. Only at the
shortest DI, which could be analyzed, the VW was slightly higher. In the
control model without pharmacological agent, the VW was increased by in-
creasing concentrations of dronedarone to maximally 115%. In case of low
concentrations, amiodarone setup 1 resulted in a slight increase of the VW,
whereas setup 2 caused a decrease of the WL by −13.8%. In case of high
concentrations of amiodarone, a decrease by a maximum of −75% could be
11.1. PHARMACOLOGICAL TREATMENT OF CONTROL AND REMODELED ATRIA 133
Table 11.2. Vulnerable window (VW) of control and electrically remodeled atrial tissue under
the inﬂuence of dronedarone and amiodarone (BCL = 1s).
setup VW (ms)
control cAF
no drug 2.61 1.56
dronedarone low 2.83 1.63
dronedarone high 3.00 1.72
amiodarone setup 1 low 2.64 1.71
amiodarone setup 1 high 0.96 3.72
amiodarone setup 2 low 2.25 1.69
amiodarone setup 2 high 0.66 3.71
observed. In case of cAF without the inﬂuence of antiarrhythmics, the VW
was reduced to 60% of the value of the control atrial model. All drugs in-
creased the VW in case of cAF, especially the high concentrations of amio-
darone (+138%), whereas dronedarone presented moderate prolongations
by up to +10%.
11.1.3 Impact of Dronedarone and Amiodarone on Termination of
Rotors
As described in section 7.4.2, four reentrant circuits were initiated in a 2D
tissue patch using the model of cAF-induced remodeling. Then, the trajec-
tories of the centers of the reentrant circuits were tracked during 5 s, which
is shown in the upper left corner of Fig. 11.3. The spiral wave tips presented
a stable curved, star-shaped meandering during the 5 s under investigation.
Furthermore, a DF of 8.2Hz was measured. The rotor initiation was repeated
using the model of cAF-induced remodeling without the inﬂuence of antiar-
rhythmics and then, the effects of dronedarone and amiodarone were in-
cluded and observed during a period of 5 s. In case of the low concentration
of dronedarone, the meandering of the reentrant circuits was increased, so
that the upper two rotors moved to the borders of the patch and left it af-
ter 2.25 and 2.4 s, respectively. In this case, the DF was reduced by 0.9Hz.
The high concentration also presented an increased meandering of the reen-
trant circuits. Due to this, the rotor in the upper left corner moved towards
the border of the patch and left it after 1.9 s. However, the rotor, which was
previously in the lower left corner, replaced it and moved to the upper left
corner. In the meantime, a wave break occurred close to the center of the
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Figure 11.3. Effects of low (top row) and high (bottom row) concentrations of dronedarone and
amiodarone on rotor trajectories of 4 rotors initiated in 2D cAF tissue patch. Dominant frequen-
cies are shown in parentheses.
upper border of the patch leading to a small reentrant circuit, which was
quickly eliminated by the other rotors. Finally, three reentrant circuits re-
mained after 5 s. However, the DF was decreased by 1.1Hz compared to the
cAF case without the inﬂuence of antiarrhythmics. The low concentrations
of amiodarone also increased the meandering of the rotor centers. This ef-
fect was more pronounced in setup 1, which also decreased the DF by 1.5Hz
compared to only 0.9Hz in case of setup 2. In case of high concentrations of
amiodarone, all reentrant circuits terminated after less than 100ms. Conse-
quently, no DF was measured in these cases.
11.2 Effects of Pharmacological Treatment on Healthy and
Ischemic Ventricles
The inﬂuence of the gastroprokinetic agent cisapride and the antiarrhythmic
agent amiodarone, which are both known to prolong the QT interval of the
ECG [109, 211], on ventricular electrophysiology was investigated. The ef-
fects on control and stage 1 (5min) ischemic ventricular electrophysiology
were compared in a single cell, as well as in a 1D tissue patch. General differ-
ences between control and ischemic ventricular APs are described in chap-
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Table 11.3. AP properties of control and ischemic (5min after onset of effects) epicardial my-
ocytes under the inﬂuence of cisapride and amiodarone (BCL = 1s). cisa: cisapride. amio1:
amiodarone setup 1. amio2: amiodarone setup 2. l: low concentration. h: high concentration.
setup amplitude (mV) Vm,rest (mV) APD50 (ms) APD90 (ms) dVm/dtmax (V/s)
control 5min control 5min control 5min control 5min control 5min
no drug 145.9 108.4 −85.6 −73.5 267.7 147.2 307.3 169.8 101.9 61.3
cisa l 146.1 108.4 −85.6 −73.5 274.7 154.4 318.4 178.2 102.0 61.2
cisa h 146.1 108.4 −85.6 −73.5 277.8 157.7 323.6 182.1 102.0 61.2
amio1 l 136.7 99.3 −85.7 −73.6 299.7 149.4 344.0 171.9 96.0 56.8
amio1 h 124.8 93.0 −85.9 −73.7 317.8 133.5 362.1 155.8 86.0 50.5
amio2 l 137.0 100.1 −86.0 −73.8 270.3 109.2 326.2 133.6 96.5 57.0
amio2 h 124.6 91.3 −86.1 −73.9 288.4 66.3 337.5 89.1 85.9 51.0
ter 10. Furthermore, the impact of the pharmacological agents on ventricular
excitation propagation and the resulting body surface ECGs was analyzed
using the control ventricular model.
11.2.1 Impact of Cisapride and Amiodarone on Ventricular Single-Cell
APs
The effects of cisapride and amiodarone on control and ischemic (5min) epi-
cardial APs are presented in Fig. 11.4. In epicardial myocytes, the effects of
ischemia were most pronounced (compare section 10.1) due to the increased
sensitivity of IK,ATP to loss of ATP compared to endocardial or M cells. The
effects of cisapride and amiodarone on endocardial and M cells were qual-
itatively similar. The resulting changes of the AP parameters of the epicar-
dial myocytes are listed in Table 11.3. Cisapride did not alter the amplitude,
resting membrane voltage and upstroke velocity of the APs compared to
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the models without the inﬂuence of pharmacological agents, whereas amio-
darone reduced the amplitude and dVm/dtmax with increasing concentrations
and no signiﬁcant differences between setups 1 and 2. The amplitude was
decreased by up to 14.6% in the control case and by 15.7% in the ischemia
case using the high concentration of amiodarone. A maximal reduction of
dVm/dtmax by −15.7% and −17.6%, respectively, could be observed in the
control and ischemia models under the inﬂuence of the high concentration
of amiodarone. Amiodarone slightly shifted Vm,rest towards more negative
values by maximally −0.5mV. The APD was increased by cisapride with
increasing concentration. The prolongation of the APD50 of the control and
ischemia models due to cisapride was 7 or 10ms depending on the concen-
tration. In the control case, amiodarone increased the APD50 with increasing
concentrations. Using the high concentration of setup 1, the effect was most
pronounced resulting in a prolongation by around 50ms. However, the same
pharmacological agent caused a shortening of the APD50 in case of ischemia,
whereas the low concentration presented a slight prolongation. The APD50
was shortened more using amiodarone setup 2. The high concentration of
setup 2 caused a maximal shortening by approximately 80ms in case of is-
chemia. The APD90 of the pharmacological agents presented qualitatively
similar results: Cisapride prolonged the APD with increasing concentration
in the control and ischemia cases, whereas amiodarone presented this effect
only in the control cases. After 5min of ischemia, the low concentration of
setup 1 slightly prolonged the APD90, whereas the high concentration short-
ened it. A more pronounced shortening could be seen in case of amiodarone
setup 2. After 5min of ischemia, the APD90 was decreased by a maximum
of 70ms using the high concentration of setup 2.
11.2.2 Restitution Curves of Ventricular Tissue under the Inﬂuence of
Cisapride and Amiodarone
The restitution properties of the control and ischemia model 5min after the
onset of effects shown in Fig. 11.5 were investigated under the inﬂuence
of cisapride and amiodarone in a 1D epicardial tissue strand. As in case of
the single-cell analyses, the ischemia effects were strongest in this tissue.
Furthermore, the impact of cisapride and amiodarone on endocardial and
midmyocardial tissue was qualitatively similar. Generally, the slope of the
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APD90 restitution curve, the CV and the WL were reduced after 5min of
ischemia, whereas the ERP was increased, which is called postrepolariza-
tion refractoriness. The ERP increased almost linearly with decreasing DI in
case of ischemia. Besides, the restitution properties of the ischemic models
initiated APs at every beat at DIs down to 0.27 s in case of cisapride and to
0.45 s in case of amiodarone, whereas the control models could be investi-
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gated at DIs shorter than 60ms. High concentrations of amiodarone did not
allow excitation propagation in ischemic tissue. Additionally, almost no al-
ternans could be observed in the different models. Therefore, only one trace
is shown for each model.
The slope of the APD90 restitution of the models under the inﬂuence of
cisapride and amiodarone is presented in Fig. 11.5A and B. At long DIs,
dAPD90/dDI was nearly zero in all cases. In the control case, dAPD90/dDI
increased towards shorter DIs. Without the inﬂuence of pharmacological
agents, a maximum of almost 0.7 was reached. Cisapride presented similar
values as the control model, whereas the high concentration of amiodarone
setup 1 caused a slope of 1 at short DIs. In contrast, setup 2 and the low con-
centration of amiodarone setup 1 slightly decreased the slope at short DIs.
In case of ischemia, the slope increased only slightly with decreasing DIs
to around 0.05 and then decreased to zero again at short DIs. Cisapride pre-
sented almost the same slopes, whereas amiodarone caused small negative
values with oscillations at short DIs.
The inﬂuence of cisapride and amiodarone on the ERP is shown in Fig. 11.5C
and D. In the control case, the pharmacological agents did not change the
slope of the ERP curves, which rapidly decreased at DIs smaller than 0.4 s.
The control model exhibited an ERP of 0.33 s at long DIs, which decreased
to less than 0.26 s at short DIs. Cisapride slightly increased the ERP with
increasing concentration. This effect was more pronounced in case of amio-
darone setup 2 and strongest in case of setup 1, which led to a maximal
prolongation of 70ms in the control case and of around 150ms in case of is-
chemia. After 5min of ischemia without the inﬂuence of cisapride or amio-
darone, the ERP started at 0.35 s at a DI of 1 s and increased to more than
0.4 s at short DIs. Amiodarone setup 1 presented a steeper increase of the
ERP towards short DIs than the ischemia model without the inﬂuence of
pharmacological agents.
In Fig. 11.5E and F, the CV restitution of the control and ischemia models is
depicted. In the control case, the CV started at around 900mm/s at long DIs.
At DIs shorter than 0.3 s, the CV declined to nearly 700mm/s. Cisapride
presented the same CV restitution. In contrast, amiodarone decreased the
CV with increasing concentration. In case of the high concentration, the CV
was reduced by around 300mm/s. Compared to setup 2, setup 1 could be
investigated at lower DIs leading to smaller CVs, which was the only differ-
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Table 11.4. VW of control and ischemic epicardial tissue under the inﬂuence of cisapride and
amiodarone (BCL = 1s). The high concentration of amiodarone did not initiate excitation prop-
agation in case of ischemia (marked by ×).
setup VW (ms)
control 5min
no drug 0.34 12.87
cisapride low 0.34 12.77
cisapride high 0.33 12.74
amiodarone setup 1 low 0.41 16.69
amiodarone setup 1 high 0.62 ×
amiodarone setup 2 low 0.31 32.88
amiodarone setup 2 high 0.47 ×
ence between both amiodarone setups. After 5min of ischemia, the CV was
around 500mm/s at a DI of 1 s, which continuously decreased to 250mm/s
at short DIs. Cisapride presented exactly the same CV restitution, whereas
amiodarone reduced the CV by maximally 300mm/s. Furthermore, amio-
darone setup 2 slightly ﬂattened the slope of the CV restitution, so that the
CV reduction was less pronounced at short DIs.
The impact of cisapride and amiodarone on the WL restitution is presented
in Fig. 11.5G and H. The control model presented a WL of almost 300mm at
long DIs, which continuously decreased to 180mm at DIs shorter than 0.4 s.
Cisapride caused a slight prolongation of the WL with increasing concen-
tration, whereas amiodarone reduced it with increasing concentration. The
high concentration of setup 1 caused a decrease by almost 60mm. However,
a reduction by more than 70mm could be observed in case of the high con-
centration of setup 2. After 5min of ischemia, the WL was 180mm at long
DIs and reduced to 110mm at short DIs. Cisapride caused a slight prolonga-
tion of the WL. Amiodarone setup 1 showed an increased WL at long DIs,
but the WL decreased more rapidly to lower values than the model without
the inﬂuence of cisapride or amiodarone resulting in decreased WLs at short
DIs. Amiodarone setup 2 led to a prolongation of the WL, especially at long
DIs.
As in case of the VW of dronedarone and amiodarone in atrial tissue de-
scribed in section 11.1.2, the VW investigated in control and ischemic epi-
cardial tissue under the inﬂuence of cisapride and amiodarone was almost
constant at different DIs. Consequently, the VWs at a BCL of 1 s are listed
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in Table 11.4. Acute cardiac ischemia signiﬁcantly prolonged the VW. With-
out the inﬂuence of pharmacological agents, the VW was almost 38 times
longer after 5min of ischemia. Cisapride on the one hand did not signiﬁ-
cantly alter the VW of the control and ischemic tissue. On the other hand,
amiodarone prolonged the VW with increasing concentration except for the
low concentration of setup 2, which led to a slight decrease of the VW in
control tissue. In the control case, the high concentration of setup 1 showed
the maximal increase by +82%. During ischemia, high concentrations of
amiodarone could not excite the tissue. However, the prolongation of the
VW was highest (+155%) using setup 2 in case of ischemia.
11.2.3 Body Surface ECGs Affected by Cisapride and Amiodarone
In order to investigate the impact of cisapride and amiodarone on the body
surface ECG, the excitation propagation was computed in the control ven-
tricular model presented in section 3.3, ﬁrst. Compared to the control model
without the inﬂuence of pharmacological agents, cisapride affected the ven-
tricular repolarization only, whereas the depolarization and plateau phase
remained the same. Since the APD was prolonged by cisapride, the com-
plete repolarization of the ventricles was delayed. In contrast, amiodarone
also had an impact on the depolarization of the ventricles, since the upstroke
velocity and the amplitude were decreased in this case. Furthermore, the ex-
citation propagation was slowed due to the decreased CV under the inﬂuence
of amiodarone. Due to this, the complete depolarization of the ventricles was
delayed and the transmembrane voltage did not reach the same amplitude as
in case of the control model. Additionally, the APD was prolonged by amio-
darone, so that the repolarization of the ventricles started later.
These underlying effects also caused changes in the corresponding body sur-
face ECGs under the inﬂuence of cisapride and amiodarone. Since the signal
amplitudes were highest in lead V4, the resulting changes could be best ob-
served there. The ECGs of the control ventricular model with and without
the inﬂuence of pharmacological agents is shown in Fig. 11.6. The control
model produced a narrow QRS complex and after the ﬂat ST segment a
narrow T wave ending after 405ms, which equated to the QT interval. In
case of cisapride, the QRS complex was the same as in the control model.
Only the onset and end of the T wave were delayed. Consequently, the low
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Figure 11.6. Body surface ECGs of control ventricles under the inﬂuence of cisapride and amio-
darone. cisa: cisapride. amio1: amiodarone setup 1. amio2: amiodarone setup 2. l: low concen-
tration. h: high concentration.
and high concentrations of cisapride prolonged the QT interval by 17 and
26ms, respectively. Low concentrations of amiodarone presented a similar
QRS complex, which was prolonged, whereas high concentrations also de-
layed it. Additionally, the positive peak of the QRS complex resulting from
high concentrations had an increased amplitude and the negative peak a re-
duced amplitude instead. The onset of the T wave was delayed by amio-
darone setup 1 with increasing concentration. Additionally, the T wave was
broadened in this case. Due to this, the QT interval was prolonged by 47 and
75ms, respectively. In case of the low concentration of amiodarone setup 2,
broadening of the T wave could be observed leading to an increase of the QT
interval by 39ms. In contrast, the onset of the T wave was slightly delayed
and the amplitude of the T wave was smaller due to the high concentration
of setup 2. Therefore, the resulting QT interval was also 47ms longer than
the interval of the control model.
11.3 Discussion
In this study, the effects of three pharmacological agents, dronedarone, amio-
darone and cisapride, were investigated in multiscale simulations of control
atrial or ventricular tissue, as well as in models of cAF or acute cardiac is-
chemia. Dronedarone caused a moderate reduction of the atrial AP amplitude
and upstroke velocity, as well as a prolongation of the APD. Consequently,
the ERP and WL were increased. The CV was decreased in a 1D atrial tissue
strand. Only in the control model, a slight reduction of dAPD90/dDI could
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be observed at short DIs, whereas the slope remained similar in case of cAF.
In addition, dronedarone prolonged the VW in atrial tissue. Nevertheless,
the number of rotors and the DF could be reduced after the administration of
dronedarone in a 2D model of cAF.
Since the reported experimental data on the pharmacological inhibition of
ICaL and IKr due to amiodarone covered large ranges in the literature, two
setups with different reduction of the maximal channel conductivities were
created. As a consequence, also some of the resulting effects of both setups
varied. The effects of amiodarone were investigated in atrial and ventricular
tissue, since it is used for the treatment of both, cAF and acute cardiac is-
chemia [85, 87]. In general, amiodarone decreased the AP amplitude and the
upstroke velocity. The APD90 was increased by setup 1 in case of atrial and
ventricular cells except for the high concentration in case of acute cardiac
ischemia. A shortening of the APD90 could also be observed using setup 2
except for the control ventricular model, which exhibited a prolonged du-
ration. Mainly setup 2 presented a slight ﬂattening of the APD90 restitution
slope, whereas it decreased the ERP in atrial tissue. Setup 1 and both ven-
tricular setups prolonged the ERP. The CV was generally reduced in atrial
and ventricular tissue with increasing concentration and almost no differ-
ences between both setups. As a consequence, amiodarone reduced the WL,
except for ischemic ventricular tissue. The effects of amiodarone on the VW
varied also. In most cases, the VW was prolonged, only the low concentra-
tion of setup 2 caused a slight decrease in control ventricular tissue and the
high concentrations of both setups presented a signiﬁcant shortening in the
control atrial tissue. Nevertheless, the DF was reduced in 2D atrial models of
cAF and all rotors were terminated completely using the high concentration
of amiodarone. The main effect responsible for the termination of the rotors
was probably the blockade of INa, which increased the core size of the reen-
trant circuits as described in [212]. Therefore, the existing rotors could not
excite the surrounding tissue again. Amiodarone also inﬂuenced the cardiac
excitation propagation in the 3D ventricular model leading to pronounced
QT prolongation in the body surface ECGs.
Cisapride affected cardiac repolarization only; therefore, amplitude and up-
stroke velocity of the AP, as well as the CV and VW were nearly unchanged.
However, APD and ERP were prolonged due to cisapride with increasing
concentration, causing a slight prolongation of the WL, too. In the body sur-
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face ECGs, this was reﬂected by a prolongation of the QT interval. Since
cisapride and amiodarone presented similar QT prolongations, this marker
alone seems to be insufﬁcient for the identiﬁcation of drug-induced arrhyth-
mias, as also stated in [213]. Therefore, different markers have to be investi-
gated to effectively identify drug cardiotoxicity [214].
In comparison to experimental data, chronic treatment with dronedarone also
increased APD90 and ERP in rabbit atrial tissue [106]. Furthermore, recent
clinical studies showed that dronedarone was not as effective as amiodarone
in the treatment of cAF. Better results could be obtained in the treatment of
non-permanent AF instead [102]. The simulations shown in this study also
showed that amiodarone effectively terminated all reentrant circuits, whereas
dronedarone only reduced their number. Experimental data of APD under
the inﬂuence of amiodarone was conﬂicting in the literature as well [87],
presenting an increase of the APD, no change or a reduction depending on
the study and the species investigated. The different results for setups 1 and
2 reﬂect the broad range of experimental data. The observed predominant
APD prolongation in the atria compared to the ventricles [96] could not be
shown in the present study. Human ventricular APs were analyzed in a small
study consisting of 4 control human hearts and 5 hearts treated with amio-
darone [215]. This study presented no signiﬁcant change of the APD90, but
a slight increase of the AP amplitude and the upstroke velocity was reduced
to only around 60%. This indicates that the inhibition of INa was overes-
timated by the underlying experimental data used in the present study. A
different study [216] of patients with ventricular tachycardia, who presented
a broadened QRS complex only at high pacing rates, supports this assump-
tion. In [217], ﬂattening of the APD restitution was identiﬁed as a possible
antiarrhythmic mechanism of amiodarone, which could also be observed in
the simulations shown in the present study. Experimental studies using cis-
apride also showed a prolongation of the APD and the QT intervals in guinea
pig and rabbit [112], as well as in dog ventricular wedges [113]. Further-
more, QT prolongation and occurrence of torsades de pointes were observed
in humans, which ﬁnally led to withdrawal from market [109].
In a previous work, transmurally varying effects of amiodarone and d-sotalol
were simulated in a 3D canine ventricular wedge model [153]. A reduced
transmural dispersion of the repolarization was found to decrease the vul-
nerability of this model. However, only inhibition of INaL, ICaL and IKs
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were considered in this study. The effects of dronedarone were simulated
in [155], however, a reduction of ion channel conductivities of only INa,
IKr, IKs and ICaL was considered. Furthermore, only changes in single-cell
APD restitution were determined. The effects of a different antiarrhythmic
agent, dofetilide, on the ECG were simulated in [151]. Instead of an endo-
cardial stimulation proﬁle mimicking the Purkinje network, an apical stim-
ulation was used leading to a non-physiological excitation propagation pat-
tern and ECG. The effects of amiodarone on cAF were investigated in [9]
using the model of cAF-induced remodeling published in [175]. The same
cAF model was used in [10] to analyze the effects of dronedarone in human
atrial tissue. In [94], the impact of amiodarone and cisapride on ventricular
electrophysiology and the ECG was studied. However, the inﬂuence on acute
cardiac ischemia and more recent measurement data were included in the
present study. Further computational studies, as e.g. [132, 150, 156], investi-
gated the impact of pharmacological treatment on cardiac electrophysiology.
The inﬂuence of dronedarone, amiodarone and cisapride was analyzed in
multiscale simulations of cardiac electrophysiology. These simulations re-
vealed the slightly different electrophysiological properties of amiodarone
and dronedarone, which is a derivative compound of amiodarone. Futher-
more, differences at the lower simulation scales could explain the antiar-
rhythmic properties of amiodarone and possible mechanisms responsible for
the occurrence of torsades de pointes in case of cisapride.
Due to a lack of measurement data, experimental values of various species
and temperatures were included in this study. Data obtained at body tem-
perature and from different regions of the heart could better be used for the
integration of transmurally varying effects of pharmacological agents. Fur-
thermore, the biophysics of the ion channels could be adapted to effects of
pharmacological treatment as described in chapter 8. In this way, frequency-
and state-dependency of the effects could also be included in future simula-
tions.
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Conclusion and Outlook
In the course of this thesis, the effects of atrial and ventricular rhythm dis-
orders, as well as pharmacological therapy, were investigated in multiscale
simulations of human cardiac electrophysiology.
Ion Channel Level
A framework for the adaptation of model parameters describing the gat-
ing behavior of cardiac ion channels to measured voltage or patch clamp
recordings was developed and implemented. Current recordings of wild type
(WT) and mutated hERG and KCNA5 channels were preprocessed, so that
the models of IKr and IKur could be adapted in this study. A trust-region-
reﬂective (TRR) algorithm and two derivative-free population-based algo-
rithms, a particle swarm optimization (PSO) and a genetic algorithm (GA),
were evaluated alone and in combination regarding their ability to minimize
the difference between simulated and measured ion currents. The combina-
tion of the PSO and the TRR algorithm achieved the smallest least squares.
However, the GA combined with the TRR algorithm caused smaller me-
dian least squares with less deviations. Both algorithms successfully recon-
structed most of the parameter values of synthetic clamp data with known
parameter values. Only some parameters, which inﬂuenced the time constant
of the gating process, depended on each other and showed larger deviations
from the original values. However, the simulated current traces reproduced
the measured clamp recordings of the WT and mutated channels well. Fur-
thermore, the sensitivity of the function to be minimized to changes of the
parameter values was analyzed around the minimum, which resulted from
adaptation to the hERG WT data. The function to be minimized exhibited
small sensitivity to changes of some of the parameters or even discontinu-
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ities in the deﬁned parameter ranges. Due to this, the results of the single
algorithms often depended on the initial parameter vectors showing the oc-
currence of local minima of this optimization problem. A comparable sensi-
tivity analysis should also be carried out with the other clamp data used in
this study, especially the IKur data. As a consequence of the sensitivity anal-
ysis, parameters with negligible inﬂuence on the result could be discarded in
future parameter adaptations. In addition to IKr and IKur, other ion currents
with mutations of the ion channel proteins or under the inﬂuence of pharma-
cological agents could be investigated in future work. For this purpose, also
more sophisticated models of cardiac ion currents could be used.
Single-Cell Level
Five models of human atrial electrophysiology were benchmarked regarding
general model properties, such as long term stability and alternans, as well
as to their ability to reproduce effects of chronic atrial ﬁbrillation (cAF)-
induced remodeling. For this purpose, certain maximal ion channel conduc-
tivities were modiﬁed according to reported values in the literature.
The Courtemanche model was selected for further simulations of KCNA5
mutations and the effects of pharmacological treatment of AF using drone-
darone and amiodarone.
In ventricular myocytes, the effects of the ﬁrst 30 minutes of acute cardiac
ischemia were integrated into the ten Tusscher model describing dynamic
and heterogeneous changes of model parameters. Furthermore, the effects of
cisapride and amiodarone were included in this model. The changes due to
pharmacological agents were integrated by adaptation of the maximal con-
ductivities of the affected ion channels.
The impact of cAF, acute cardiac ischemia, ion channel mutations and phar-
macological treatment on action potential (AP) properties were analyzed.
cAF reduced the AP duration (APD) and resting membrane voltage and in-
creased the maximal upstroke velocity and amplitude, whereas the investi-
gated IKur mutations mainly increased the transmembrane voltage during the
plateau phase. With increasing duration of acute cardiac ischemia, the APs
were shortened, the amplitudes and maximal upstroke velocities decreased
and the resting membrane voltages elevated. Depending on the pharmaco-
logical agents, the resulting changes varied. Cisapride affected only the re-
polarization causing a prolongation of the APs. However, dronedarone and
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amiodarone inﬂuenced the depolarization and plateau phase as well, result-
ing in decreased amplitudes and maximal upstroke velocities of the APs.
Since the reported values of the inhibition of ion channels due to amiodarone
varied in the literature, two setups causing different results were investigated.
If available, measurement data of the same species recorded at body temper-
ature should be used in future work. Additionally, the impact of other phar-
macological agents, especially on mutations of cardiac ion channels, should
be studied.
1D Tissue Level
The restitution properties of the adapted electrophysiological models were
investigated. For this purpose, restitution curves of the APD90, effective re-
fractory period (ERP), conduction velocity (CV) and wave length (WL) were
computed in a 1D tissue strand. In addition, the slope of the APD90 restitu-
tion and the vulnerable window (VW), which describes the interval, during
which a unidirectional block can be initiated, were determined in case of the
pharmacological agents.
cAF caused a reduction of the APD90, ERP, CV and WL in most models of
human atrial electrophysiology. In case of the IKur mutations, the mainly ob-
served effect was pronounced beat-to-beat alternans of the restitution proper-
ties. Depending on the number of stimuli, the values were either in a similar
range as the control model, or signiﬁcantly reduced.
During acute cardiac ischemia, the ERP was prolonged (postrepolariza-
tion refractoriness), whereas the CV and WL were decreased. Cisapride in-
creased the ERP and did not change the CV and VW resulting in an increased
WL. However, dronedarone and amiodarone reduced the CV. The ERP and
therefore also the WL were prolonged by dronedarone, as well as the VW.
Depending on the amiodarone setup, the ERP was either slightly increased
or decreased resulting in a shortened WL in most cases. Amiodarone re-
duced the VW only in case of the control atrial model, but increased it other-
wise. The WL and VW indicate the probability for the initiation of reentrant
circuits and therefore the arrhythmic potency of models of cardiac electro-
physiology in a simple 1D tissue strand. However, some effects, as e.g. the
initiation of reentrant circuits at heterogeneous ischemic regions, can not
be considered in these simulations. Therefore, the effects of altered electro-
physiology also have to be analyzed at higher simulation levels.
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2D Tissue Level
More detailed information on cardiac excitation propagation can be obtained
from 2D tissue patch simulations, in which the behavior of reentrant cir-
cuits was investigated. The ﬁve different models of human atrial electro-
physiology presented different spiral wave tip trajectories and dominant fre-
quencies (DFs) after the initiation of a single rotor. The control Courte-
manche and Grandi models failed to initiate a reentrant circuits, which is
assumed to be the physiological case. Due to the decreased WL, all mod-
els of cAF-induced remodeling successfully initiated rotors with circular,
elliptical or star-shaped meandering of the rotor centers. In case of the ana-
lyzed IKur mutations, a single rotor, which was not stable over time, could be
initiated. The pronounced APD alternans caused chaotic excitation propa-
gation patterns including wave breaks showing the proarrhythmic properties
of these mutations. Furthermore, the impact of dronedarone and amiodarone
on the termination of cAF was investigated. Four rotors were initiated in
the 2D patch without the inﬂuence of pharmacological agents. After inclu-
sion of the effects of dronedarone and amiodarone, the DFs and rotor center
trajectories were analyzed. Dronedarone reduced the number of rotors and
the DF, whereas amiodarone even terminated all rotors at the high concen-
tration. Nevertheless, the effects of atrial ﬁbrillation should be simulated in
realistic 3D geometries of the human atria in future work. There, anatomi-
cal inﬂuences might also provide new ﬁndings regarding the initiation and
termination of AF.
3D Tissue Level
In 3D simulations of ventricular excitation propagation, the inﬂuence of
acute cardiac ischemia and pharmacological treatment with cisapride and
amiodarone was studied. In the ischemic regions, ischemia effects worsened
with increasing time after the onset resulting in conduction block in the CIZ
at worst. Increasing transmural extent of the ischemic region from subendo-
cardial to transmural increased the impact, too, since the effects were most
pronounced in epicardial tissue. Cisapride slowed the repolarization of the
ventricles, whereas amiodarone also delayed the complete depolarization of
the ventricles due to the reduced CV. Finally, the changes of the ventricular
excitation propagation were forward calculated on the body surface, where
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virtual electrocardiograms (ECGs) were derived from the extracellular po-
tentials. Acute cardiac ischemia led to slight ST segment depression in case
of subendocardial ischemia and to pronounced ST segment elevation in case
of transmural ischemia in leads close to the ischemic region. In between,
“electrically silent” ischemia cases presenting almost no changes in the ECG
could be observed. Therefore, the diagnosis of acute cardiac ischemia should
always be based on more markers, as e.g. the troponin T level.
Cisapride and amiodarone signiﬁcantly prolonged the QT interval. Addi-
tionally, amiodarone broadened the QRS complex due to the reduced CV.
As a consequence, prolongations of the QT interval do not necessarily in-
dicate proarrhythmic properties of a pharmacological compound as in case
of cisapride, since amiodarone is used as an antiarrhythmic agent. In this
case, different markers at the lower simulation scales give information about
the pro- or antiarrhythmic potency of a compound. In future work, more is-
chemic regions should be simulated at different occlusion sites with realistic
shapes derived from diffusion models of blood ﬂow in the coronary arteries.
Furthermore, the simulations of acute cardiac ischemia should be compared
to clinically measured ECGs and ischemic regions, if the data are available.
In addition, transmurally varying effects of pharmacological agents should
be analyzed and possibly compared to measured ECGs.
Summing up, the results presented in this thesis help to understand the un-
derlying mechanisms responsible for the initiation or termination of rhythm
disorders. The multiscale simulations revealed the complex impact of phar-
macological agents, which showed anti- as well as proarrhythmic proper-
ties depending on the analyzed aspect. The patient-speciﬁc pharmacological
therapy might be improved especially by the investigation of genetic defects
of cardiac ion channels as presented in this work.
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The presented simulations are an important step towards the under-
standing and improvement of the diagnosis and pharmacological 
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